Lipid-based depots by Breitsamer, Michaela
 Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
Lipid-based depots: 
manufacturing, administration and 
interactions of protein drugs with 
lipid formulations 
 
 
 
 
 
Michaela Maria Breitsamer 
 
 
aus 
Starnberg, Deutschland 
2019 
 
 
 
 
 
II 
 
 
 
III 
 
ERKLÄRUNG 
Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 
2011 von Herrn Prof. Dr. Gerhard Winter betreut. 
 
 
 
EIDESSTATTLICHE VERSICHERUNG 
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. 
 
Wolfratshausen, den 20.05.2019 
 
 
 
________________________________ 
(Michaela Breitsamer) 
 
 
 
 
 
 
Dissertation eingereicht am:  20.05.2019 
1. Gutachter:     Prof. Dr. Gerhard Winter 
2. Gutachter:     Prof. Dr. Wolfgang Frieß 
Mündliche Prüfung am:   25.06.2019
 
 
 
IV 
  
 
 
 
V 
 
 
 
FOR MY FAMILY 
 
 
 
“The way to get started is to quit talking and begin doing” 
Walt Disney (1901 – 1966) 
 
 
 
VI 
  
 
 
 
VII 
ACKNOWLEDGEMENTS 
The present thesis was prepared between March 2015 and December 2018 at the 
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics at the 
Ludwig-Maximilians Universität (LMU) in Munich under the supervision of Prof. Dr. 
Gerhard Winter. 
First of all, I would like to express my deepest gratitude to my supervisor Prof. Dr. Gerhard 
Winter for giving me the opportunity to join his research group and to work on this 
extremely interesting and interdisciplinary project. I really appreciated his scientific input 
throughout all phases of this work, his elaborate advice and his guidance, which also 
contributed to my personal development over the last years. Furthermore, I would like to 
thank him for the outstanding working and team atmosphere, which he created at the 
chair, for supporting my participation in scientific conferences and for initiating and 
motivating me to the numerous collaborations which contributed to a successful thesis. 
I would also like to thank Prof. Dr. Wolfgang Frieß for all the helpful and interesting 
discussion in the past years, as well as for being the co-referee of this thesis. Thank you 
for creating the pleasant working conditions together with Prof. Dr. Gerhard Winter.  
Many thanks also go to Prof. Dr. Olivia Merkel, Dr. Gerhard Simon and Sabine Kohler. 
This interdisciplinary work would not have been possible without the support of many 
cooperation partners, who contributed enthusiastically to this thesis. I would like to thank 
the group of Prof. Dr. Mathias Ritzmann and especially Dr. Christine Weiß from the Clinic 
for Swine at the LMU (Oberschleißheim) for their continuous support with pigs and pig 
skin throughout the course of this thesis. I highly appreciate the collaboration with Dr. 
Heiko Spilgies and Dr. Karsten Heuser from LTS Lohmann Therapie-Systeme AG. 
Furthermore, I would like to express my gratitude to Prof. Dr. Heiko Heerklotz and Anja 
Stulz from the Albert-Ludwigs-Universität in Freiburg, for the nice discussions and fruitful 
cooperation. I would also like to thank NanoTemper Technologies GmbH and especially 
Dr. Nuska Tschammer for helping me with the MST measurements and interpretation 
thereof. 
The groups of Dr. Mathias Schmidt and Prof. Dr. Felix Hausch at the Max-Planck-Institute 
for Psychiatry in Munich are thanked for the opportunity to collaborate to these successful 
in vivo studies. Particularly I would like to thank Max Pöhlmann, Dr. Georgia Balsevich and 
 
 
 
VIII 
Dr. Karla-Gerlinde Schraut for the great work together. The same thanks go out to Dr. 
Sandrine Geranton and Dr. Maria Maiarù from the University College London (UCL) for 
this fruitful partnership. 
I would also like to thank the group of Prof. Dr. Jörg Breitkreutz and especially Bastian 
Hahn from the Heinrich Heine Universität in Düsseldorf for hosting me for some days and 
helping me with the extrusion experiments. 
Further I would like to express my gratitude Dr. Jilong Wang and Prof. XiaoJiao Du from 
the Institutes for Life Sciences and School of Medicine at South China University of 
Technology for their help with the calculation of PK paramaters. 
Many thanks are expressed to my students Nadine Hasreiter and Anna Fuchs, who did 
their “Wahlpflichtpraktikum” on my project and Natalie Deiringer, who conducted her 
master thesis under my supervision. Thank you, you did a great job! In this context, I would 
also like to thank Katharina Kopp who continues the preparation of VPGs for our 
collaboration partners. 
A big “Thank you” goes to my former colleagues from the LMU from the Winter, Frieß and 
Merkel labs for welcoming me so heartily to the group and creating a comfortable and 
funny atmosphere. All our skiing, hiking and other social events and get togethers were 
great fun and made the time unforgettable for me. 
A special thanks goes to my (extended) lab mates Dr. Moritz Vollrath, Weiwei Liu, Carolin 
Berner, Dennis Krieg, Markus Zang, Dr. Katharina Geh and Dr. Leticia Rodrigues Neibecker 
for welcoming me to the lab and the great time we had together in B1.029/B1.028 with 
all the funny craziness and fruitful discussions.  
As a former head of “Disperse” practical course I would also like to express my deep 
gratitude to the whole Disperse-Team – working with you was always fun and easy!  
I am most grateful to Dr. Randy Wanner, Dr. Matthias Lucke, Dr. Kay Strüver, Dr. Benjamin 
Werner, Dr. Kerstin Hoffmann, Dr. Corinna Dürr and Dr. Ilona Vollrath for welcoming me 
so warmly to the group in my first few months and to Simon Eisele, Ruth Rieser, Ivonne 
Seifert and Andreas Stelzl, who made the last years unforgettable. You were not only great 
colleagues but also became excellent friends and never failed to bring a smile to my face! 
Special thanks further go to my lunch and coffee gang, Alice Hirschmann, Dr. Laura 
Engelke and last but not least Andreas Tosstorff, for your friendship and the welcome 
distraction every day. 
 
 
 
IX 
I would also like to express my gratitude to Paula, Rita, Flo, Luca, Anna, Jasper, Lina, Leon, 
Lucas, Jacob and Mira, for all the fun we had together in the last few years besides my 
work at the university – you are the best friends I could wish for. 
My deepest and immense gratitude goes to my parents, Petra and Michael, as well as to 
my sister, Vroni with Thomas, Flocke and Marini who gave me roots and always supported 
me. Thank you for making things possible for me, for being there when I needed you and 
for your infinite and unconditional love!  
Last but not least I would like to thank Felix for his continuous encouragement, his endless 
support, his patience and his love. Thank you for being who you are. You were my dead 
sea when I was threatened to sink! 
 
 
 
X 
  
 
 
 
XI 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ........................................................................................................ VII 
TABLE OF CONTENTS .............................................................................................................. XI 
CHAPTER I VESICULAR PHOSPHOLIPID GELS AS DRUG DELIVERY SYSTEMS FOR 
SMALL MOLECULAR WEIGHT DRUGS, PEPTIDES AND PROTEINS: STATE OF THE 
ART REVIEW ............................................................................................................................... 1 
I.1 Abstract ............................................................................................................................................... 2 
I.2 Introduction ......................................................................................................................................... 4 
I.2.1 Liposomes for sustained release of protein drugs .............................................................................. 4 
I.2.2 DepoFoam technology ........................................................................................................................ 6 
I.2.3 Phospholipid-based phase separation gel (PPSG) .............................................................................. 7 
I.3 Vesicular phospholipid gels (VPGs) ...................................................................................................... 8 
I.3.1 Definition and structural features ...................................................................................................... 8 
I.3.2 Preparation of VPGs and drug encapsulation techniques .................................................................. 9 
I.3.2.1 High-pressure homogenization (HPH) ...................................................................................... 10 
I.3.2.2 Magnetic stirring ....................................................................................................................... 11 
I.3.2.3 Dual centrifugation (DC) ........................................................................................................... 12 
I.3.2.4 Encapsulation techniques for drugs .......................................................................................... 13 
I.3.2.5 Sterile manufacturing of VPGs .................................................................................................. 14 
I.3.3 Sustained release of encapsulated drugs from VPGs ....................................................................... 15 
I.3.4 Applications of VPGs ......................................................................................................................... 17 
I.3.4.1 Application as storage form of liposomes ................................................................................. 18 
I.3.4.2 Application as drug delivery device for the sustained release of small molecular drugs and 
peptides ............................................................................................................................................... 19 
I.3.4.3 Application as drug delivery devices for the sustained release of proteins.............................. 20 
I.4 Summary ............................................................................................................................................ 22 
I.5 References ......................................................................................................................................... 23 
CHAPTER II OBJECTIVES AND OUTLINE OF THE THESIS ........................................... 29 
 
 
 
XII 
II.1 References ........................................................................................................................................ 31 
CHAPTER III NEEDLE-FREE INJECTION OF VESICULAR PHOSPHOLIPID GELS .. 33 
III.1 Needle-free injection of vesicular phospholipid gels – a novel approach to overcome an 
administration hurdle for semisolid depot systems ................................................................................ 34 
III.1.1 Abstract ........................................................................................................................................... 34 
III.1.2 Introduction .................................................................................................................................... 34 
III.1.3 Materials and Methods ................................................................................................................... 36 
III.1.3.1 Materials ................................................................................................................................. 36 
III.1.3.2 Preparation of VPGs ................................................................................................................ 36 
III.1.3.3 Preparation of gelatin blocks .................................................................................................. 36 
III.1.3.4 Injections into in vitro models ................................................................................................. 37 
III.1.3.5 In vitro release of EPO from VPGs after shearing ................................................................... 37 
III.1.3.6 Quantification of EPO with RP-HPLC ....................................................................................... 38 
III.1.4 Results ............................................................................................................................................. 38 
III.1.4.1 Needle-free injection .............................................................................................................. 38 
III.1.4.2 In vitro release after shearing ................................................................................................. 41 
III.1.5 Discussion ....................................................................................................................................... 42 
III.1.6 Conclusion ....................................................................................................................................... 43 
III.1.7 Supporting information .................................................................................................................. 44 
III.2 Further studies ................................................................................................................................. 46 
III.2.1 Material and Methods .................................................................................................................... 46 
III.2.1.1 Viscosity measurement ........................................................................................................... 46 
III.2.1.2 Determination of the density .................................................................................................. 46 
III.2.1.3 Texture analysis ....................................................................................................................... 46 
III.2.1.4 Determination of injection force with needle and syringe ..................................................... 46 
III.2.1.5 Needle-free injection of VPGs with Biojector 2000 ................................................................ 47 
III.2.1.6 Jet force upon ejection with Biojector 2000 ........................................................................... 48 
III.2.2 Results and Discussion .................................................................................................................... 49 
III.2.2.1 Viscosity and gel strength of VPGs .......................................................................................... 49 
III.2.2.2 Injection force with conventional needles .............................................................................. 50 
III.2.2.3 Further post mortem studies on needle-free injection of VPGs ............................................. 52 
III.2.2.3.1 Comparison of different single use syringes in post mortem studies ............................. 52 
III.2.2.3.2 Injection depth ................................................................................................................ 54 
III.2.2.3.3 Injections with large injection volume ............................................................................ 55 
III.2.2.4 Jet force upon ejection with Biojector 2000 ........................................................................... 56 
III.2.2.4.1 Influence of the phospholipid concentration .................................................................. 58 
 
 
 
XIII 
III.2.2.4.2 Influence of ejection temperature .................................................................................. 60 
III.2.2.4.3 Influence of ejection volume ........................................................................................... 60 
III.3 Conclusion........................................................................................................................................ 62 
III.4 References ....................................................................................................................................... 63 
CHAPTER IV PREPARATION OF VESICULAR PHOSPHOLIPID GELS BY TWIN-
SCREW EXTRUSION ................................................................................................................ 65 
IV.1 Introduction ..................................................................................................................................... 66 
IV.1.1 High pressure homogenization ....................................................................................................... 66 
IV.1.2 Dual asymmetric centrifugation and dual centrifugation .............................................................. 66 
IV.1.3 Magnetic stirring ............................................................................................................................ 67 
IV.1.4 Twin-screw extrusion ..................................................................................................................... 68 
IV.2 Material and Methods ..................................................................................................................... 70 
IV.2.1 Materials ......................................................................................................................................... 70 
IV.2.1.1 Phospholipids .......................................................................................................................... 70 
IV.2.1.2 Proteins for release studies and stability ................................................................................ 70 
IV.2.1.3 Other chemicals and salts ....................................................................................................... 70 
IV.2.2 Preparation of VPGs ....................................................................................................................... 71 
IV.2.2.1 Preparation of VPGs by DAC ................................................................................................... 71 
IV.2.2.2 Preparation of VPGs by magnetic stirring ............................................................................... 72 
IV.2.2.3 Preparation of VPGs by TSC extrusion .................................................................................... 72 
IV.2.2.3.1 ZE-5 Mini-Extruder .......................................................................................................... 72 
IV.2.2.3.2 HAAKE MiniLab® Micro Rheology Compounder ............................................................. 73 
IV.2.2.3.3 Leistritz Micro 27 GL - 28D .............................................................................................. 73 
IV.2.3 Methods for VPG characterization ................................................................................................. 74 
IV.2.3.1 Rheology ................................................................................................................................. 74 
IV.2.3.2 Dynamic light scattering ......................................................................................................... 74 
IV.2.3.3 Microscopy ............................................................................................................................. 75 
IV.2.4 Encapsulation of proteins into VPGs .............................................................................................. 75 
IV.2.5 In vitro release studies .................................................................................................................... 76 
IV.2.5.1 Quantification of FITC-Dextran ............................................................................................... 76 
IV.2.5.2 Quantification of mAb ............................................................................................................ 76 
IV.2.5.3 Phospholipid assay .................................................................................................................. 77 
IV.2.5.4 Optical density ........................................................................................................................ 78 
IV.2.5.5 Dynamic light scattering ......................................................................................................... 78 
 
 
 
XIV 
IV.2.5.6 Thermogravimetric determination of water loss during VPG preparation ............................. 78 
IV.2.5.7 Determination of the product temperature ........................................................................... 79 
IV.2.6 Protein stability during extrusion and storage ............................................................................... 79 
IV.2.6.1 Capillary gel-electrophoresis .................................................................................................. 79 
IV.2.6.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) .............................. 79 
IV.2.6.3 Fourier transform infrared spectroscopy (FTIR) ..................................................................... 80 
IV.3 Results and Discussion ..................................................................................................................... 81 
IV.3.1 Preparation of VPGs by extrusion with repeated circulation ......................................................... 81 
IV.3.2 Preparation of VPGs by a continuous extrusion process ................................................................ 86 
IV.3.2.1 HAAKE MiniLab® Rheology Compounder ................................................................................ 86 
IV.3.2.2 ThreeTec ZE-5 Mini-Extruder .................................................................................................. 90 
IV.3.2.3 Leistritz Micro 27 GL – 28D ..................................................................................................... 93 
IV.3.3 In vitro release of FITC-Dextran from VPG ...................................................................................... 96 
IV.3.4 Stability of proteins in VPG after encapsulation and storage ......................................................... 97 
IV.3.4.1 Determination of structural changes by FTIR spectroscopy ................................................... 97 
IV.3.4.2 Evaluation of capillary gel electrophoresis to characterize protein aggregation and 
fragmentation in VPG ........................................................................................................................... 98 
IV.3.4.3 Characterization of protein aggregation by SDS-PAGE ........................................................... 99 
IV.3.5 In vitro release of a monoclonal antibody from VPG .................................................................... 102 
IV.3.6 Storage stability of VPG prepared by different manufacturing processes ................................... 105 
IV.4 Conclusion ..................................................................................................................................... 113 
IV.5 References ..................................................................................................................................... 115 
CHAPTER V INTERACTIONS BETWEEN PROTEINS AND PHOSPHOLIPIDS ....... 119 
V.1 DO INTERACTIONS BETWEEN PROTEIN AND PHOSPHOLIPIDS INFLUENCE THE RELEASE BEHAVIOR FROM LIPID-BASED 
EXENATIDE DEPOT SYSTEMS? ........................................................................................................................ 120 
V.1.1 Abstract ......................................................................................................................................... 120 
V.1.2 Introduction ................................................................................................................................... 122 
V.1.3 Material and Methods ................................................................................................................... 124 
V.1.3.1 Material.................................................................................................................................. 124 
V.1.3.2 Exenatide characterization .................................................................................................... 124 
V.1.3.3 Preparation of vesicular phospholipid gel ............................................................................. 124 
V.1.3.4 VPG characterization ............................................................................................................. 125 
V.1.3.5 In vitro release of exenatide from VPG .................................................................................. 125 
V.1.3.6 Characterization of VPG erosion during in vitro release ........................................................ 125 
 
 
 
XV 
V.1.3.7 Liposome preparation ............................................................................................................ 126 
V.1.3.8 Microscale Thermophoresis .................................................................................................. 127 
V.1.4 Results ........................................................................................................................................... 128 
V.1.4.1 Exenatide characterization and encapsulation in VPGs ......................................................... 128 
V.1.4.2 In vitro release of exenatide from VPG .................................................................................. 129 
V.1.4.3 Erosion behavior of VPGs during exenatide release .............................................................. 131 
V.1.4.4 Interactions studies ............................................................................................................... 132 
V.1.5 Discussion ...................................................................................................................................... 137 
V.1.5.1 In vitro release behavior of exenatide from VPG ................................................................... 137 
V.1.5.2 Interactions between exenatide and phospholipids ............................................................. 137 
V.1.5.3 Erosion-driven, fast release from POPG containing gels ....................................................... 138 
V.1.5.4 Barrier based retention in gels of POPC ................................................................................ 139 
V.1.6 Conclusions .................................................................................................................................... 141 
V.1.7 Acknowledgements ....................................................................................................................... 142 
V.1.8 Supplement ................................................................................................................................... 142 
V.2 Further studies ................................................................................................................................ 143 
V.2.1 Material and Methods ................................................................................................................... 143 
V.2.1.1 Preparation of liposomes ....................................................................................................... 143 
V.2.1.2 Isothermal titration calorimetry ............................................................................................ 143 
V.2.1.3 Isothermal steady-state Fluorescence ................................................................................... 144 
V.2.1.4 Langmuir trough measurements ........................................................................................... 145 
V.2.1.4.1 Compression isotherms of lipid-monolayers ................................................................. 145 
V.2.1.4.2 Surface activity of exenatide .......................................................................................... 145 
V.2.1.4.3 Intercalation of exenatide into lipid monolayers ........................................................... 145 
V.2.2 Results and Discussion ................................................................................................................... 147 
V.2.2.1 Characterization of interactions by isothermal titration calorimetry .................................... 147 
V.2.2.2 Isothermal steady state fluorescence .................................................................................... 150 
V.2.2.3 Comparison of binding events detected by ITC, fluorescence measurements and MST ...... 153 
V.2.2.4 Insertion of exenatide into phospholipid monolayers ........................................................... 157 
V.3 Conclusion ...................................................................................................................................... 160 
V.4 References ...................................................................................................................................... 162 
CHAPTER VI APPLICATION OF VESICULAR PHOSPHOLIPID GELS AS DEPOT 
SYSTEM FOR SMALL HYDROPHOBIC DRUGS .............................................................. 167 
VI.1 Introduction ................................................................................................................................... 168 
 
 
 
XVI 
VI.1.1 SAFit2 ............................................................................................................................................ 168 
VI.1.2 Novel drug candidate #41 ............................................................................................................. 170 
VI.2 Material and Methods ................................................................................................................... 171 
VI.2.1 Material ........................................................................................................................................ 171 
VI.2.2 Methods........................................................................................................................................ 171 
VI.2.2.1 Preparation of VPG encapsulating SAFit2 or #41 .................................................................. 171 
VI.2.2.2 Preparation of a SAFit2-solution as control for in vivo study ............................................... 172 
VI.2.2.3 In vitro release studies .......................................................................................................... 172 
VI.2.2.3.1 Quantification of SAFit2 by RP-HPLC ............................................................................. 172 
VI.2.2.3.2 Quantification of #41 .................................................................................................... 173 
VI.2.2.3.3 Quantification of phosphatidylcholine .......................................................................... 173 
VI.2.2.4 In vivo release studies ........................................................................................................... 173 
VI.2.2.4.1 SAFit2-VPG .................................................................................................................... 173 
VI.2.2.4.2 #41-VPG ........................................................................................................................ 173 
VI.3 Development of SAFit2-VPG .......................................................................................................... 175 
VI.3.1.1 In vitro release behavior of SAFit2 from VPG ....................................................................... 175 
VI.3.1.2 Pharmacokinetic study of SAFit2-VPG .................................................................................. 176 
VI.4 In vivo applications of SAFit2-VPG ................................................................................................. 179 
VI.4.1 Balsevich et al., Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic 
function, Nature Communications (2017) .............................................................................................. 179 
VI.4.2 Maiarù et al., The stress regulator FKBP51: a novel and promising druggable target for the 
treatment of persistent pain states across sexes, Pain (2018) ............................................................... 180 
VI.4.3 Pöhlmann et al., Pharmacological Modulation of the Psychiatric Risk Factor FKBP51 Alters 
Efficiency of Common Antidepressant Drugs, Frontiers in Behavioral Neurosciences (2018) ............... 182 
VI.5 Development of a VPG formulation for the delivery of #41 ........................................................... 184 
VI.5.1 In vitro release behavior of #41 from VPG ................................................................................... 185 
VI.5.2 In vivo performance of #41-VPG ................................................................................................... 186 
VI.6 Conclusion ..................................................................................................................................... 187 
VI.7 References ..................................................................................................................................... 189 
CHAPTER VII SUMMARY AND OUTLOOK ...................................................................... 191 
CHAPTER VIII APPENDIX ................................................................................................... 197 
 
 
 
XVII 
VIII.1 List of Figures ............................................................................................................................... 197 
VIII.2 List of Tables ................................................................................................................................ 205 
VIII.3 List of Abbreviations .................................................................................................................... 207 
VIII.4 Publications arising from this thesis ............................................................................................. 211 
VIII.5 Patent .......................................................................................................................................... 213 
VIII.6 Poster presentations .................................................................................................................... 214 
 
  
 
 
 
XVIII 
 
 
 
VESICULAR PHOSPHOLIPID GELS AS DRUG DELIVERY SYSTEMS FOR SMALL MOLECULAR WEIGHT DRUGS, PEPTIDES AND 
PROTEINS: STATE OF THE ART REVIEW 
1 
CHAPTER I  
VESICULAR PHOSPHOLIPID GELS AS DRUG 
DELIVERY SYSTEMS FOR SMALL MOLECULAR 
WEIGHT DRUGS, PEPTIDES AND PROTEINS: 
STATE OF THE ART REVIEW 
 
This chapter is published as Mini-Review in the International Journal of Pharmaceutics as 
M. Breitsamer, G. Winter; Vesicular phospholipid gels as drug delivery systems for small 
molecular weight drugs, peptides and proteins: state of the art review; (2018). 
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I.1  Abstract  
Lipid-based drug delivery has been investigated for a long time when it comes to 
liposomes and solid-lipid implants or solid-lipid nanoparticles. The promising, 
characteristic properties of these systems have led to the development of newer lipid-
based drug delivery systems for the sustained release of drugs like liposomes for sustained 
delivery of substances, DepoFoamTM technology, phospholipid-based phase separation 
gels and vesicular phospholipid gels. Vesicular phospholipid gels (VPGs) are highly 
concentrated, viscous dispersions of high amounts of phospholipids in aqueous drug 
solution. The easy, solvent-free manufacturing process, high biocompatibility and various 
applications, as depot formulation for the sustained delivery of drugs and as a storage 
form of small unilamellar vesicles make VPGs highly attractive as drug carriers. Over the 
last years, the solvent free preparation process has advanced from high pressure 
homogenization to dual centrifugation (DC). Thereby a very simple one step process has 
been established for the preparation of VPGs. The semisolid VPG was first described in 
1997 by Brandl et al.. Since then, many formulations have been developed, encapsulating 
small molecular weight drugs like 5-FU (2003), cetrorelix (2005), cytarabine (2012) and 
exenatide (2015). In 2010, the first pharmaceutical protein, erythropoietin, was 
encapsulated in VPGs and sustained release of the substance was shown in vitro. In 2015, 
G-CSF was encapsulated in VPGs and tested in vivo for rotator cuff repair in a rat model 
and for PEGylated IFN-β-1b sustained release from vesicular phospholipid gels was 
demonstrated in vitro. Further, a very elegant administration technique for VPGs via 
needle-free injection was established. However, this promising drug delivery system does 
still leave space for improvement and optimization.  
This review summarizes information about lipid-based depot systems in general and 
focuses on the historical development of VPGs. It emphasizes the advantages and 
drawbacks of VPGs as drug delivery device. Additionally, novel preparation methods and 
applications of VPGs will be discussed. A focus will be set on delivery of pharmaceutical 
proteins and peptides.  
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Figure I-1: Graphical abstract. 
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I.2  Introduction 
Controlled drug delivery systems deliver the drug at a predetermined rate, locally or 
systemically for a specified period of time [1]. Besides, drug delivery devices based on 
synthetic polymers like PLGA and PLA, many lipid-based drug formulations, e.g. solid lipid 
implants and liposomes have been investigated for the sustained release of 
therapeutically relevant substances. 
Lipid-based drug delivery systems are composed of physiologically occurring lipids like 
phospholipids, triglycerides, cholesterol and cholesterolesters [2]. This composition of the 
carrier material offers a great number of advantages over other drug vehicles [2]. 
Naturally occurring lipids like phospholipids are the major component of cell-membranes 
in humans, animals and plants and therefore tolerated well after administration in 
comparison to synthetic polymers [3]. An additional advantage of lipids as matrix material 
of drug carriers is the often simple and cheap manufacturing process of lipid-based 
vehicles as well as the possibilities to adapt the release kinetics by modification of the 
composition. Besides liposome-based carriers, on which we will focus, many other lipid-
based drug delivery devices are available which have been summarized elsewhere [2]–[5]. 
Thus, in the following we will only give a brief overview on liposomal drug delivery systems 
for the sustained release of drugs. After that, the published data on vesicular phospholipid 
gels, a novel and very promising liposomal depot system is summarized.  
Our review includes the historical development of the formulation, description of the 
preparation process, proposed release mechanism for VPGs and the applications for the 
sustained release of proteins and peptides as well as other drugs. Special focus will be on 
the last decade of research in this particular field. 
I.2.1   Liposomes for sustained release of protein drugs 
 Liposomes are the most extensively investigated among drug carriers based on 
phospholipids [1], [6]. First described by Bangham et al. in 1964, the simple phospholipid 
vesicles, made to overcome toxicities or prevent drug degradation in the blood stream, 
developed over the years to an easy to manufacture drug carrier with high 
biocompatibility and the ability for controlled, triggered and sustained release of drugs 
[7].  From 1990 to 2012 thirteen liposomal formulations have been approved by the FDA 
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and many more are in clinical trials [3], [4]. However, most of the approved liposomal drug 
formulations are used for systemic i.v. applications, sometimes protecting the drug from 
elimination and thereby prolonging the plasma half-life. Liposomes composed of the 
classical phospholipids are rapidly removed from the blood by the cells of the reticulo-
endothelial system (RES) after i.v. systemic application which is the biggest drawbacks of 
these systems [6]. Surface modifications, e.g. PEGylation, of liposomes increases 
circulation time of the carriers in the blood by forming a protective layer on the surface, 
but nevertheless availability of the drug was only prolonged up to a few hours to days [8].  
Over the last two decades, especially the incorporation of proteins and peptides into 
liposomal formulations has increased. Liposomally encapsulated proteins and peptides 
display improved therapeutic activity, decreased side effects and modulated immune 
response [6]. Their capability to induce both humoral and cellular immune response at 
the same time may be a disadvantage in some applications but is also the cause for their 
use as immunological adjuvants for protein and peptide vaccines. 
Size, structure and lipid composition of liposomes contribute to the release of drugs, when 
used as depot drug delivery systems [9]. The larger size of e.g. multivesicular liposomes 
(MVL) or multilamellar vesicles (MLV) is preferable for non-vascular routes of 
administration used for depots e.g. subcutaneous, intrathecal, epidural etc. [10].  
Multivesicular liposomes (MVL) have been first described by Kim et al. in 1983 [11]. MVL 
are unordered structures, consisting of numerous discontinuous internal aqueous 
compartments which are separated by lipid bilayers [11], [12]. They have to be 
distinguished from liposome aggregates, where aqueous compartments are separated by 
two bilayers in close contact. MVL are prepared by a two-step, water-in-oil-in-water, 
double emulsification process [13]. Due to the high aqueous-volume-to-lipid ratio, high 
encapsulation efficiencies for water-soluble drugs can be achieved. As a result of the large 
size of these liposomes, they remain at the injection site and degrade slowly over time 
[12], [13]. Additionally, they have a prolonged clearance, giving them the ability for the 
sustained release of drugs and therefore to act as a depot system for few days. To this 
effect, Mu et al. showed sustained release of Bevacizumab from MVL in vitro and in vivo 
over several weeks [12]. 
Crommelin et al. reported that liposomes can be used as a sustained delivery device over 
several days after s.c. or i.m. injection [14]. It has also been shown, that subcutaneously 
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injected stealth liposomes showed prolonged half-lives in comparison to i.v. or i.p. 
administration [15]. 
Another approach to manufacture liposomal depots has just been reported recently. This 
technique uses negatively charged phospholipids in large unilamellar liposomes, which 
are in situ mixed with divalent cations e.g. calcium or magnesium to induce controlled 
aggregation of the liposomes [16]. First characterizations of these liposomes show 
promising results. However, in vitro and in vivo release behavior has not been investigated 
so far. 
I.2.2  DepoFoam technology 
In 2000, a special case of MVL for the controlled delivery of protein and peptide drugs, 
the DepoFoamTM technology, was first described by Ye et al. [17]. DepoFoamTM is 
composed of multiple non-concentric compartments with an aqueous core, bound by a 
continuous network of lipid membranes. This rather structured geometry distinguishes 
them from the unordered MVL described above. Several mechanisms have been proposed 
for the release of drugs from DepoFoamTM. Breakdown of the lipid membrane, 
reorganization of the vesicles e.g. internal coalescence and permeation are possible ways, 
contributing to drug release [18], [19]. Further, lipid phase composition, osmolarity of the 
aqueous phase, interactions between the encapsulated drug and the lipid and the type of 
acid used for manufacturing contribute to the release rate from MVL [18]. 
Ye et al. showed that DepoFoamTM can be an ideal vehicle for controlled drug release [17]. 
It was possible to modulate the release rate of specific therapeutic proteins and peptides 
by changes in the formulation e.g. lipid composition or composition of the aqueous phase 
and to achieve a high encapsulation efficiency and biocompatibility. This new technology 
was marketed as DepoCytTM (cytarabine) and as DepoDurTM (morphine) [18], [19].  
Vyas et al. observed a sustained release profile of IFN-α-2a from DepoFoamTM in vitro over 
a period of one week [20]. A high percentage of protein encapsulation could be achieved 
with this DepoFoamTM technique, but the complex manufacturing process by water-in-oil-
in-water double emulsification with organic solvent involved is a big disadvantage of this 
system. 
 
VESICULAR PHOSPHOLIPID GELS AS DRUG DELIVERY SYSTEMS FOR SMALL MOLECULAR WEIGHT DRUGS, PEPTIDES AND 
PROTEINS: STATE OF THE ART REVIEW 
7 
I.2.3   Phospholipid-based phase separation gel (PPSG) 
In the last years, phospholipid-based phase separation gels (PPSG) have been developed 
and evaluated for the sustained release of proteins and peptides [21]–[23]. PPSG are 
injectable in-situ forming depot formulations containing large quantities of phospholipid 
(up to 70%), oil and ethanol [21]. Phospholipids are solved in ethanol by stirring and a 
formulation with relatively low viscosity and acceptable injectability is produced. After 
administration of the PPSG into the body, solvent exchange leads to a sol to gel transition. 
Ethanol is replaced by surrounding aqueous medium following a concentration gradient 
and as a result phospholipids solidify due to their insolubility in aqueous solutions. Due to 
its composition, the newly formed gel is biodegradable and biocompatible. However, local 
irritation effects of ethanol at the injection site have been reported [21]. 
Wu et al. reported that both hydrophobic and hydrophilic chemotherapeutic agents can 
be easily encapsulated into these PPSG [22]. It was shown, that doxorubicin was released 
from the depot formulation for more than 14 days after one single injection. 
Zhang et al. reported of PPSG for the delivery of octreotide acetate [21]. The addition of 
medium chain triglycerides (MCT) and significant decrease of ethanol content in the 
formulation reduced local irritation after administration. Octreotide acetate was released 
from the PPSG over several weeks and release was found to be slowest for high 
phospholipid concentrations. A similar system was later used for the release of leuprolide 
acetate [24]. 
In 2016 the sustained delivery of antigens and adjuvants from PPSG was shown [23]. It 
was found, that PPSG not only delivers the drug over a prolonged time but also supports 
the humoral immune response in synergy with the adjuvant without causing local 
irritation or systemic toxicity.  
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I.3  Vesicular phospholipid gels (VPGs) 
VPGs are semisolid depot formulations composed of phospholipid vesicles and lamellar 
structures and have shown many desirable properties in recent research. They were first 
described by Brandl et al. in 1997 and ten years later, in 2007, he prepared a 
comprehensive summary of the literature existing on VPGs until then [25], [26].  
Since then, new insights concerning the development of VPGs, like the design of a new 
manufacturing process and novel applications of VPGs have been achieved. In the present 
review the actual state of the art, summarizing the almost 20 years of research and 
development on VPGs, will be presented. 
I.3.1  Definition and structural features 
VPGs are highly concentrated, semisolid dispersions of phospholipids in an aqueous 
medium e.g. buffer or drug solution [25]–[27]. Unlike other lipid-based depot systems, 
VPGs consist of phospholipids as major lipidic component of the system. Other lipids, like 
cholesterol may be added if desired [28]–[30]. The morphology of VPGs has been 
extensively studied by freeze fracture transmission electron microscopy (FF-TEM) and it 
was shown that they are mainly composed of closely packed vesicles with compartments 
containing aqueous medium in the core of the vesicles [25]. Brandl et al. observed that 
VPGs composed of 35 to 45% (m/m) phosphatidylcholine display a very homogenous 
structure based on small and uniform vesicles, while higher concentrations of 
phospholipids result in a more heterogeneous structure with larger vesicles and planar 
lamellar stacks in between the small vesicles. The vesicles are so tightly packed that the 
aqueous areas between the vesicles are reduced to a minimum and steric interactions 
between the hydrophilic head-groups of the phospholipids lead to the rheological 
behavior which is comparable to other hydrogels incorporating macromolecular viscosity 
enhancers [26]. This inner structure does not only facilitate the encapsulation of 
hydrophilic substances in the core of the vesicles but also in between, in the lamellar 
structure of the gel, and therefore high encapsulation efficiency is obtained in comparison 
to liposome dispersions. 
Another big advantage over other lipid-based systems is the fact that no concentration 
gradient exists between the core of the vesicles and the surrounding buffer phase (as 
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there is no such surrounding phase), which is the main cause of low encapsulation 
efficiency and drug loss during storage of classical liposome dispersions [26], [31]. 
Additionally, it has been shown that VPGs release their hydrophilic content in a sustained 
manner [31]. These unique features make VPGs a very promising drug delivery device 
suitable for the sustained release of drugs with high encapsulation efficiency for 
hydrophilic and lipophilic drugs. Their excellent tolerability due to their main components, 
phospholipids, supports their cause essentially.  
Next to their application as depot system VPGs can also be used as storage form for small 
unilamellar liposomes (SUVs). By dilution of VPGs with excess aqueous medium and 
mixing with the help of ceramic beads in a ball mill, the semisolid gel can be transferred 
into a dispersion of SUVs [26], [32]. Massing et al. described the production of small 
liposomes by first preparing VPGs and subsequent dilution of the VPG to liposomal 
dispersions [33]. Additionally, their use as model membranes comparable to or even 
better than PAMPA-model has been described [34]. 
However, one drawback of the system is the rather high viscosity of the formulation, 
which is influenced by the amount of phospholipids incorporated into the formulation and 
further by the encapsulated drug [35]. In some in vivo studies, VPG was administered 
directly during surgery or had to be diluted to liposomes before administration [28], [30], 
[36]–[38]. The high viscosity compromises the administration of the VPGs with thin s.c. 
needles, so low patient compliance and eventually inaccurate dosing have to be 
considered. To overcome this drawback, needle-free injection (NFI) technology was 
investigated for the administration of the highly viscous VPG system [39]. It was shown, 
that by NFI VPG formulations with up to 45% (m/m) phospholipid content were easily 
injectable into pig skin with a Biojector 2000. 
NFI of VPGs is a major breakthrough in the development of VPG which facilitates future 
applications of the depot system. 
I.3.2  Preparation of VPGs and drug encapsulation 
techniques 
In comparison to other phospholipid-based systems like liposomes and DepoFoam™, the 
manufacturing process is very simple, does not involve organic solvents like chloroform, 
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is extremely elegant and cheap and facilitates the preparation of large amounts as well as 
lab-scale size. Aseptic manufacturing is also feasible. 
Next to the preparation of VPGs, consisting only of one phospholipid, in a one-step 
technique, the manufacturing of VPGs from lipid blends is of course also possible. To 
achieve a homogeneous distribution of the lipids over the entire lipid phase, solid lipid 
blends can be prepared by freeze drying from organic solutions [26], [32]. In order to 
prepare the lipid blends, lipids are dissolved in organic solvents e.g. tert-Butanol or 
Chloroform or mixtures of both, before the solution is shock-frozen and organic solvents 
are carefully removed by freeze-drying (e.g. shelf temperature: -55 °C, condenser 
temperature: -70 °C, vacuum: 20 hPa) as described in detail by Brandl [32]. Alternatively, 
lipid mixtures can be achieved by extrusion methods as e.g. described by Haas et al. [40]. 
Further, the film-method, often used for the preparation of liposomes, has also been used 
for the preparation of lipid mixtures but is less suited due to the high amount of lipids 
needed for VPGs [28]. 
Three different preparation techniques for VPGs have been described in the literature. 
I.3.2.1  High-pressure homogenization (HPH) 
The preparation of VPGs was first described by Brandl et al. in 1997 [25]. For the 
preparation of the highly viscous VPGs the dry powdered lipids are mixed with buffer or 
the drug solution respectively. Then the mixture is allowed to swell for a few hours and 
fed into a high-pressure homogenizer e.g. APV Gaulin Micron Lab 40 as used in the work 
of Brandl et al. or Microfluidizer 110. Homogenization can be done with up to 150 MPa, 
usually with 70 MPa in ten cycles to prevent heating of the material  and high 
encapsulation efficiencies are achieved [25], [27], [32]. The described process facilitates 
the preparation of large amounts of VPGs. However, the originally used high pressure 
homogenizer (APV Gaulin Micron Lab 40) is not available anymore and it is questionable 
if similar encapsulation efficiency and homogeneity can be reached with devices by other 
manufacturers.  
HPH is a technology that has been widely studied for food processing and for the 
preparation of emulsions [41]–[43]. It enables the preparation of very fine dispersions by 
application of high shearing forces on the formulation. 
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Freeze fracture microscopy studies revealed that the formulations prepared by HPH could 
be separated into two groups. Low phospholipid contents resulted in high homogeneity 
and small, densely packed vesicles, while a more heterogeneous morphology for the 
higher phospholipid concentrations was observed [25]. 
Although HPH is a commonly used technique, it is responsible for degradation of DNA or 
proteins, therefore only short mixing intervals should be used to prevent degradation of 
the encapsulated substance [2]. HPH is especially useful for the preparation of high 
amounts of VPG. In research and development small batches are needed and HPH has 
limitations regarding downscaling to smaller amounts than 40 ml [33]. 
I.3.2.2  Magnetic stirring 
In the same publication in which Brandl et al. described HPH as preparation method, the 
magnetic stirring method has already been mentioned [25]. VPGs were prepared by first 
adding dry powdered phospholipids to buffer. Afterwards the mixtures were allowed to 
swell for two hours under magnetic stirring. Freeze-fracture microscopic examination of 
the obtained VPGs showed a different size and morphology in comparison to the result 
obtained by high-pressure homogenization. Low mechanical energy input by magnetic 
stirring of the mixtures resulted in heterogeneous vesicles with large diameters and uni- 
to multi-lamellar walls.  
In spite of the questionable quality of the VPGs, in 2013 Zhong et al. described the 
magnetic stirring method for the preparation of VPGs with encapsulated thymopentin 
[44]. He prepared VPGs with phospholipid concentrations of 300 mg/g to 400 mg/g 
encapsulating thymopentin by magnetic stirring of the drug solution with egg 
phosphatidylcholine for 90 minutes. By this method particle sizes of 400 to 500 nm were 
achieved. Further, Zhang et al. used the magnetic stirring method for the preparation of 
VPGs encapsulating exenatide [45]. In this work phospholipid contents were between 200 
to 400 mg/g which resulted in large average vesicle sizes of about 15 µm after dilution. In 
this case the VPGs were prepared by addition of exenatide-solution to the accurately 
weighted phospholipids and subsequent magnetic stirring for 30 minutes at room 
temperature. 
Although magnetic stirring is a very simple and easy to scale up technique, it is 
questionable if reproducible homogeneity and sufficient stability of the VPGs is obtained 
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by this method. It is further questionable whether the dispersion after magnetic stirring 
fulfills the defined criteria for VPGs at all. Zhang et al. reported stratification of 
formulations with low phospholipid amounts [45]. Nevertheless, first release studies 
showed that VPGs with sustained release of small substances could be obtained by this 
preparation method [44], [45]. 
I.3.2.3  Dual centrifugation (DC) 
Massing was the first to describe a new, elegant and straight forward technique for the 
preparation of VPGs, Liposomes and lipid-based Nanoparticles [33], [46]. 
DAC is a special centrifugation technique in which a container is not only rotated around 
the main rotation axis of a conventional centrifuge but also around a second axis in the 
middle of the container [33]. The two counter-rotating, superposed movements result in 
a simultaneous inward and outward movement of the material and therefore high 
shearing forces on the material in the container and an efficient homogenization of the 
mixture. DAC is well suited for the rapid mixing of two viscous components, which makes 
it an excellent candidate for the preparation of VPGs as well as for liposomes and fat-
emulsions [33], [47]–[51]. Homogeneous mixtures of the substances can be reached in a 
short time.  
Massing et al. investigated several parameters with an influence on the obtained 
liposomes and VPG [33]. They found that increasing lipid amounts led to decreasing mean 
liposome size after dilution of the VPG. Further, the homogenization time, choice of beads 
as dispersion aid to improve the quality and mixing speed have great influence on 
liposome size. Still, expectantly, the temperature of the formulation increases in the 
course of longer centrifugations. To this end, a multi-step preparation protocol has to be 
used with cooling steps in between the centrifugation or a cooled DAC system is required 
to prevent degradation of the drug during preparation, especially when mixing aids (e.g. 
glass balls) are used [52]. 
Over the last years, the DAC method has been improved to dual centrifugation (DC) [51]. 
In DC the principles of DAC, i.e. two counter-rotating movements for rapid and 
homogenous mixing of components, are used but the centrifuge has two or more rotating 
baskets, thus not needing a counterweight in the setup of the centrifuge. Further, DC 
systems like the ZentriMix 380R centrifuge by Hettrich AG may be equipped with a cooling 
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system like conventional centrifuges and therefore facilitate also processing of sensitive 
compounds without applying a multi-step protocol which is needed when using a DAC. A 
schematic drawing of a DAC in comparison to the novel DC setup is shown in Figure I-2. 
 
Figure I-2: Schematic drawing of a dual asymmetric centrifuge (left) from the side in comparison to a dual centrifuge 
from the top (middle) and from the side (right). 
The fact that components are mixed in a closed plastic or glass container in a DC makes 
this method simple in comparison to HPH. DC facilitates also lab scale production of VPGs 
and is suited for aseptic manufacturing. In contrast to that, during HPH the VPG has direct 
contact with the metal surface of the instrument, as well as the moving parts needed for 
homogenization. This may result in metal abrasion into the product.  Additionally, if higher 
energy input is needed to achieve a better mixing quality, centrifugation speed and 
duration can be easily adapted in a DC. In a HPH the pressure can be increased within 
certain limits and the material can be recycled several times to achieve better 
homogeneity. However, the need to remove the material from the HPH and re-introduce 
it again for multiple cycles, makes the process more susceptible for contamination and 
other problems. 
I.3.2.4  Encapsulation techniques for drugs 
In literature three loading techniques are described for VPGs [32]. Hydrophilic drugs are 
encapsulated into VPGs by direct loading. Here the drug solution is directly added to the 
phospholipids previous to the preparation via HPH, DC or magnetic stirring and thereby 
substances are truly entrapped within the vesicles of the gel and in the aqueous phases 
between the vesicles. This method has often been used in the past, also  for the 
encapsulation of proteins or peptides into VPGs [29], [37], [48]. 
Further, substances can also be passively loaded into the pre-formed VPG e.g. in a hospital 
pharmacy setting. Therefore, an appropriate, small volume of drug solution is added to 
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the drug-free VPG, pre-mixing is done with a sterile spatula and the mixture is incubated 
until the drug is equally distributed throughout the formulation by diffusion following a 
concentration gradient [32]. In this case, the phase transition temperature Tm of the 
phospholipids plays an important role, regarding the encapsulation efficiency. Moog et al. 
used the described method for the entrapment of gemcitabine into VPGs by diffusion of 
the drug into the VPG supported by elevated temperature [28]. Further, Kaiser et al. 
compared this loading method with direct entrapment of 5-fluorouracil and found that 
the passive loading technique was not suited for encapsulation of the drug [30]. 
Lipophilic or amphiphilic substances can be incorporated in the lipid-phase. Therefor a 
homogeneous lipid-drug mixture is formed, e.g. by freeze drying the phospholipid and the 
drug from organic solutions, which is then hydrated with an appropriate amount of buffer. 
Balsevich et al., Maiarù et al. and Pöhlmann et al. used this method for the preparation of 
VPGs encapsulating the selective FKBP51 antagonist SAFit2 [53]–[55]. 
I.3.2.5  Sterile manufacturing of VPGs 
Steam sterilization in the final container is the preferred method for sterilization of 
parenteral drug formulations. One of the drawbacks of liposomal formulations is a loss of 
encapsulation efficiency following steam sterilization. This is for example caused by 
vesicle fusion, leakage of the drug and chemical degradation of the phospholipids [56]. 
Tardi et al. investigated steam sterilization of VPGs in the terminal container [57]. 
Autoclaving of VPGs under standard conditions (121 °C, 15 minutes) caused fusion of the 
vesicles which did influence the release behavior of the gel in respect to slower erosion of 
the matrix but no hydrolysis of phospholipids was observed. Sterilization stability of 
cytarabine loaded VPGs has been investigated by Qi et al. [58]. It was found that although 
changes in characteristic properties of the VPG e.g. viscosity and slower drug release were 
observed, essential properties of VPGs, like the tightly packed vesicular structure, 
sustained release and the possibility of redispersion were still preserved [58]. Hence, 
steam sterilization is the method of choice for sterilization of the end product if the 
encapsulated drug does allow it. 
If steam sterilization is not applicable e.g. due to the sensitivity of the drug against high 
temperatures, alternatively the VPG can be prepared under aseptic working conditions in 
a closed container or vial. 
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I.3.3  Sustained release of encapsulated drugs from VPGs 
Tardi et al. were the first to investigate the release behavior of encapsulated calcein from 
VPGs [31]. A custom made flow through cell as shown in Figure I-3 was used for the 
examination of the release behavior. For release testing, the VPG was filled in the donor 
compartment on the downside of the flow-through cell and release medium was pumped 
through the acceptor compartment with a flow rate of 10 ml/h which is comparable to a 
clearance time of 180 s.  
 
Figure I-3: Schematic drawing of the flow through release cell described by Tardi et al. (1998). 
The release of hydrophilic markers from VPGs occurred for time periods of hours up to 
days and the encapsulated compound was released by two competing mechanisms 
occurring at the same time: erosion of the phospholipid matrix and diffusion of the drug 
out of the gel following a concentration gradient. It was observed that VPGs with a 
phospholipid amount of up to 30% (m/m) disintegrate spontaneously with rather fast 
release of the encapsulated drug. Release from gels with a phospholipid concentration of 
up to 40% (m/m) is stated to be erosion controlled, while the release from gels with a 
phospholipid amount of up to 50% (m/m) seems to be diffusion controlled [31]. Many 
authors came to the same, not surprising conclusion: a high amount of phospholipids 
leads to a slower release of drugs from the formulation [29], [45]. Neuhofer also observed  
that gels with a low phospholipid concentration are washed out of the release cell very 
fast [35]. He observed that a certain threshold of phospholipids in the formulation is 
needed to provide high enough viscosity of the gel and therefore a slower release by 
erosion of the gel. A correlation between viscosity and protein release was found when 
only the lipid amount of the gel was changed, leaving all other formulation parameters 
the same. 
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But not only does the phospholipid content strongly influence the release behavior of 
drugs from VPGs.  The type of phospholipid (e.g. charged phospholipids) and the 
formulation buffer influence the release kinetics [31], [35], [48], [59]. Additionally, the 
drug load affects the release behavior significantly. To this end, Grohganz et al. observed 
differences in release of cetrorelix acetate when different concentrations of the peptide 
were encapsulated into the VPG [29]. The absolute released amount increased up to a 
certain concentration, above which further increase of the concentration led to a reduced 
absolute release. Tian et al. showed that by adjustment of the lipid charge the release 
behavior of EPO from VPGs could be modulated [48]. She found that lipid charge and lipid 
amount both were the dominant parameters influencing the protein release from VPGs 
which was mainly due to erosion of the gel. Further, Tian was able to show that an increase 
of protein load led to a decreased release rate [59]. Additionally to the choice of a suited 
lipid species and charge, the phase transition temperature (Tm) has to be taken into 
account when VPG formulations are developed. At temperatures near the Tm of a 
phospholipid, the drug uptake into the empty liposomes is superior to other 
temperatures. Thus, higher encapsulation efficiencies may be reached around the Tm of 
the phospholipid especially when passive loading is used. 
Next to the above mentioned factors which influence the release behavior, it is crucial to 
know if the encapsulated drug is actually encapsulated in the vesicles of the VPG. True 
encapsulation into the vesicles results in longer release rates, since in this case the drug 
has to diffuse out of the vesicles, pass one or more membranes and regions with different 
hydrophobicity. Brandl et al. found a encapsulation efficiency of 30 to 70% for the model 
compounds calcein and carboxyfluorecein [27]. Kaiser et al. investigated if 5-fluorouracil 
is encapsulated in the vesicles which were obtained after dilution of a VPG [30]. He could 
show an effect of lipid composition and pH on the encapsulation efficiency. Further, 
Grohganz et al. demonstrated an encapsulation efficiency of cetrorelix acetate into 
vesicles of the VPG above 65% [29]. However, the VPG was diluted before determination 
of the encapsulated drug in the vesicles, thus a leakage of the drug out from the vesicles 
during dilution steps cannot be ruled out and has to be taken into account. 
In recent literature, other methods for the investigation of the release behavior have been 
described. Even et al. used a micro-centrifugation cap release model for the release of 
TRP2, a small peptide [60]. The VPG was filled in the round bottom of a micro-
 
VESICULAR PHOSPHOLIPID GELS AS DRUG DELIVERY SYSTEMS FOR SMALL MOLECULAR WEIGHT DRUGS, PEPTIDES AND 
PROTEINS: STATE OF THE ART REVIEW 
17 
centrifugation cap, buffer was carefully added and samples were taken by complete buffer 
exchange. Advantages of this model are the simplicity, easy handling and low sample 
dilution. Another testing method was used by Zhang et al. for the release of exenatide 
from VPGs [45]. VPGs were filled into dialysis bags with defined molecular weight cut-off 
and placed in release medium. Again, samples were taken by replacing the release 
medium.  
All currently used release models do still have drawbacks like high dilution of the samples, 
turbidity of the released fractions and lack of homogeneity of the exposed surface of the 
depot, therefore further optimization of the release models is needed. Additionally, a 
decent in vitro – in vivo – correlation is still not possible, since only few PK data of VPGs in 
their function as depot system is available. 
I.3.4  Applications of VPGs 
VPGs have been used in the past for different types of applications which are illustrated 
in Figure I-4. 
 
Figure I-4: Overview of applications for VPGs. 
Table I-1 summarizes all investigated VPG formulations with different pharmaceutical 
relevant substances. Especially since 2010, VPGs have been mainly used as depot 
formulations for the sustained release of drugs. 
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Table I-1:Chronologic summary of VPG formulations with encapsulated drugs which were investigated over the last 
years. 
Encapsulated 
drug 
Production procedure Investigated administration type Year References 
Vincristine HPH, passive loading Diluted VPG (i.v. injection) 2002 [38] 
Gemcitabine HPH, passive loading Diluted VPG  (i.v. injection) 2002 [28] 
5-fluorouracil HPH, direct loading Diluted VPG (in vitro) and depot 
system (in vitro) 
2003 [30] 
Cetrorelix HPH , direct loading Depot system (in vitro) 2005 [29] 
Erythropoietin DAC, direct loading Depot system (in vitro) 2010 [48], [59] 
Cytarabine HPH or DAC, direct loading Depot system (implantation during 
surgery) 
2012, 
2014 
[36], [58] 
Thymopentin Magnetic stirring, direct 
loading 
Depot system (s.c. injection) 2013 [44] 
G-CSF DAC, direct loading Depot system (implantation during 
surgery) 
2015 [37] 
IFN-β-1b 
PEG-IFN-β-1b 
DAC, direct loading Depot system (in vitro) 2015 [35] 
TRP2 DAC, direct loading Depot system (in vitro and in vivo) 2015 [60] 
Exenatide Magnetic stirring Depot system (s.c. injection, in vivo) 2015 [45] 
SAFit2 DAC, direct incorporation 
technique 
Depot system (s.c. injection, in vivo) 2017, 
2018 
[53]–[55] 
I.3.4.1  Application as storage form of liposomes 
In the first years, VPGs were mainly used as storage form of liposomes with high 
encapsulation efficiency for hydrophilic drugs. Liposomal formulations do have the 
drawback of a low encapsulation efficiency of substances in the core of the vesicles. To 
remove the free, not liposomal encapsulated drug from the solution an extraction step 
has to be included in the preparation protocol. However, over longer storage time drugs 
diffuse out of the vesicles following a concentration gradient. 
VPGs are well suited concentrated storage forms of liposomes. By one-step or multi-step 
dilution of the gel and vigorous mixing, e.g. by shaking of the dispersions with a ball mill, 
a homogeneous liposome dispersion with small unilamellar liposomes can be obtained 
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[32]. By this technique liposomes with high encapsulation efficiency can be prepared [27]. 
This described method has already been successfully used for the preparation of 
liposomes with encapsulated vincristine, 5-fluorouracil and gemcitabine for anti-cancer 
treatment and encapsulation efficiencies of up to 54% liposomally entrapped drug were 
reached [28], [30], [38]. The technique enables the bedside preparation of liposomal 
dispersions in the oncology clinical setup. 
Just recently, Chen et al. described the preparation of a thermoreversible hydrogel with 
insulin-loaded liposomes [61]. VPG was prepared to encapsulate insulin into the 
liposomes, before the VPG was diluted to liposomes and insulin-loaded liposomes were 
incorporated in the hydrogel. 
I.3.4.2  Application as drug delivery device for the sustained release 
of small molecular drugs and peptides 
Most publications of the last years on the applications of VPGs have dealt with the 
sustained release of small molecular weight drugs (MW < 1000 Da) and peptides (< 100 
amino acids). Grohganz et al. were the first to encapsulate cetrorelix, a small peptide, into 
VPGs and to use this system for the sustained release of the substance [29]. From short-
term release studies (7 days), they predicted that 80% of cetrorelix was released over 3 
months, depending on the lipid amount and the drug content of the VPG. 
In another study thymopentin was incorporated into various VPG formulations with low 
phospholipid content and sustained release was investigated in vivo [44]. Therapeutic 
efficacy of thymopentin entrapped in VPGs and administered s.c. once weekly was shown 
to be comparable to a thymopentin solution injected once daily for 7 days. Not only was 
this result interesting regarding the investigated low phospholipid concentrations, but 
also in terms of the small size of the entrapped drugs and the preparation process by 
magnetic stirring. However, similar results were observed for a second small peptide. 
Exenatide was encapsulated into VPGs by a similar preparation method and showed 
sustained release over three weeks in vitro [45]. In vivo results showed that by a single 
injection of exenatide loaded VPG, a sustained hypoglycemic effect was achieved over 10 
days and was comparable to twice daily injections of a drug solution over the same time. 
However, in both cases VPG encapsulating thymopentin or exenatide were prepared by 
magnetic stirring and Zhang et al. observed stratification of VPGs with low phospholipid 
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amount [44], [45]. It is unknown if the preparation process, resulting in VPG with low 
physical chemical stability, is itself responsible for the sustained release of the drugs. 
Interactions between the drug and the phospholipids could be an explanation for the 
sustained release behavior of the small molecules. However, this has not been shown yet.  
In 2014, Qi et al. described the development of a VPG formulation incorporating 
cytarabine for the treatment of xenografted glioma [36]. VPGs were prepared by DAC and 
cytarabine was directly encapsulated into the VPG during preparation. In vitro cytarabine 
was released over 16 days from the VPG. For in vivo tests cytarabine loaded VPG was 
implanted into the brain of mice and therapeutic concentrations were achieved over 28 
days in up to 5 mm distance of the implantation site. 
Even compared the release of a small peptide, TRP2, from solid lipid implants to the 
release from VPGs [60]. She found that TRP2 release from VPGs was incomplete and slow 
in vitro and suspected interactions between the peptide and the phospholipids behind 
this phenomenon. Further, TRP2 was released significantly slower from VPGs in 
comparison to ovalbumin, a much bigger molecule.  
Balsevich et al. encapsulated SAFit2, a selective FKBP51 antagonist, into VPGs (50%, 
(m/m)) and showed an effect of the drug on metabolic parameters several days after 
injection of the VPG [53]. Maiarù et al. used SAFit2-VPG (50%, (m/m)) to improve 
mechanical pain hypersensitivity [54]. It was shown, that SAFit2 released from VPG 
reduced mechanical hypersensitivity for at least 7 days after application, compared to 24 
hours when injected subcutaneously as a solution. After a second application of SAFit2-
VPG, hypersensitivity was reduced for at least 16 days. Pöhlmann et al. used SAFit2-VPG 
together with a commonly prescribed selective serotonin reuptake inhibitor (SSRI) and 
showed in vivo that co-application of both substances lowered the effect of the SSRI on 
anxiety but improved stress cooping behavior [55]. 
I.3.4.3  Application as drug delivery devices for the sustained 
release of proteins 
In 2010, Tian et al. were the first to report of VPGs as depot systems for the sustained 
release of a therapeutic relevant protein [48]. It was shown that VPGs were suitable as 
sustained release systems for erythropoietin (EPO), since EPO was stable during 
manufacturing and the protein was released over two weeks from VPGs with a 
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phospholipid content of 55% (m/m) based on 100% egg lecithin (Lipoid E80). Release 
occurred in a linear manner without any burst effect. With decreasing lecithin content the 
release rate was increased and by incorporation of charged phospholipids in the 
formulation, release could be further modulated.  
Later it was shown, that the sustained release behavior of EPO was maintained after 
ejection of the EPO-VPG using a needle-free injection device (Biojector 2000) [39]. 
Buchmann et al. published in vitro and in vivo data of the entrapment and sustained 
release of granulocyte-colony stimulating factor (G-CSF) from VPGs [37]. By the use of 
VPGs a continuous G-CSF release following zero-order kinetics was achieved in vitro and 
it was shown that the VPG was tolerated well in vivo and had no negative influence on 
wound healing after administration during surgery. However, systemic concentration of 
G-CSF did not show significant differences between Placebo-group and G-CSF-VPG group 
and therefore no conclusion could be drawn about the actual local release rate in vivo. 
Further, the release of interferon-β-1b (IFN-β-1b) and PEGylated IFN-β-1b was 
investigated in vitro [35]. It was observed that the release of native IFN-β-1b from VPGs 
was not possible and strong protein-lipid interactions were assumed to be responsible for 
this. PEGylation of IFN-β-1b facilitated the release from the depot system with a very low 
release rate which indicates that by PEGylation interactions between the protein and the 
phospholipid were reduced but not completely avoided. However, even after intensive 
investigation of the mechanism behind the interactions by Neuhofer with several 
methods, no prediction regarding the influence of interactions between the encapsulated 
protein and the phospholipids on the release behavior was possible [35]. 
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I.4  Summary  
VPGs are a modern depot system for the sustained release of small molecules, peptides 
and proteins and a stable system for the long-term storage of liposomes, which can be 
diluted directly before usage. The manufacturing process by DAC facilitates fast and 
simple preparation of this system and enables production in a broad range of batch sizes. 
At the same time, DAC is gentle to the encapsulated drug and therefore suitable for the 
entrapment of sensitive compounds like proteins and peptides.  
Over the years, VPGs developed from a storage formulation for liposomes to a lipid-based 
depot system for subcutaneous injection. Next to the work of several groups in Europe, 
especially Chinese groups focus on VPGs and their further development as drug delivery 
system. Several formulations have been developed in the last few years, which are directly 
administered as depot systems. In vitro results show strong evidence that proteins as well 
as small molecules and peptides are released in a sustained manner from the depot 
formulation. First in vivo results support the benefits of this system for the delivery of 
those substances, showing sustained release of different drugs and excellent 
biocompatibility. Still, additional in vivo results especially on protein and peptide release 
from VPGs and a correlation of the PK data to the in vitro situation is needed to further 
develop the depot system and bring it to clinical use. 
The application of needle-free injection technology has been evaluated and proven to be 
suitable for the administration of the depot system, thereby overcoming the challenging 
administration problems caused by the high viscosity of the system. 
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Chapter II  
OBJECTIVES AND OUTLINE OF THE THESIS 
 
This thesis is based on years of successful research and development on vesicular 
phospholipid gels and aimed to further develop this drug delivery system, by designing 
more sophisticated administration and manufacturing techniques for VPGs and 
contributing to a better understanding of the mechanisms behind drug release from lipid-
based depots.  
Consequently, the present work was aimed to address the following objectives: 
 
i. In many studies VPGs were administered either after dilution of the highly viscous 
phospholipid dispersion or during surgery [1]–[4]. Administration with a 
conventional s.c. needle and syringe is only possible with excessive injection force 
due to the high concentration of phospholipids in the formulation and the 
resulting high viscosity.  
As a first objective, a novel administration technique is established. In Chapter 3, 
needle-free injection is used to overcome administration difficulties for VPGs, 
which are caused by the high viscosity of the formulation arising from large 
phospholipid concentrations. The aim is to show the robustness of needle-free 
injection technology against changes in injection volume and phospholipid 
concentration of the formulation. Further different single-use syringes, which can 
be used with the Biojector 2000, are evaluated. 
 
ii. Further the established preparation processes, i.e. high pressure homogenization, 
dual asymmetric centrifugation and magnetic stirring, do have several limitations 
like difficulties in temperature control, high shearing forces, long production 
duration and batch mode production only with restrictions on up- and down-
scaling [5], [6]. 
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In Chapter 4 twin-screw extrusion, a gentle, easily controllable and continuous 
method is investigated for its applicability as manufacturing technique for VPGs. 
Three differently sized extruders were evaluated and extrusion parameters like 
temperature, screw speed and the size of the nozzle are varied to investigate their 
influence on physical-chemical parameters of the VPGs. Long-term in vitro release 
studies with FITC-Dextran and a monoclonal antibody from the produced VPGs are 
conducted to investigate the effect of different preparation processes on release 
behavior and the stability of encapsulated proteins was tested. Moreover, storage 
stability of the VPGs is evaluated. 
 
iii. It is known that phospholipid concentration, the encapsulated protein or peptide 
and the type of phospholipids each contribute to the release behavior from VPGs 
[7]–[10]. However, the exact mechanisms behind the release of drugs from VPGs 
have not been investigated so far. It is assumed that protein-lipid-interactions may 
play an important role regarding the release kinetics.  
Chapter 5 focuses on the effect of interactions between encapsulated proteins 
and peptides and the phospholipids on the release behavior from VPGs. Different 
analytical methods e.g. isothermal titration calorimetry (ITC) and microscale 
thermophoresis (MST) are tested for their applicability to investigate the 
interactions between liposomes and a peptide. The interactions between 
exenatide and different phospholipids are characterized to contribute to a better 
understanding of the release behavior of peptides and proteins from lipid-based 
depots, especially VPGs. The focus is set on the effect of differently charged 
phospholipids and the pH of the formulation on interactions.  
 
iv. In Chapter 6 VPGs are used as novel drug delivery systems for two small molecular 
drugs, SAFit2 and #41, in different applications. A preparation process for the 
encapsulation of the two non-water-soluble drugs into VPGs is developed and the 
release behavior was characterized in vitro and in vivo. In pharmacological studies 
the effects of the two substances after release from VPGs on metabolic function, 
pain sensation and depression are investigated. 
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Chapter III  
NEEDLE-FREE INJECTION OF VESICULAR 
PHOSPHOLIPID GELS 
 
Section III.1  of this chapter has been published in the Journal of Pharmaceutical Sciences 
as: M. Breitsamer, G. Winter; Needle-free injection of vesicular phospholipid gels - a novel 
approach to overcome an administration hurdle for semisolid depot systems; (2017).  
To maintain the train of reading throughout the chapter, references of the published 
manuscript (section III.1  ) and all further studies (section III.2  ) are combined in section 
III.4  . 
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III.1  Needle-free injection of vesicular 
phospholipid gels – a novel approach to 
overcome an administration hurdle for 
semisolid depot systems 
III.1.1  Abstract 
Vesicular phospholipid gels (VPGs) are depot formulations for the sustained release of 
drugs which are characterized by a high amount of phospholipids in the formulation. They 
consist of physiological excipients only and therefore display high biocompatibility. Their 
manufacture is simple, cheap, solvent free and ideal for the processing of proteins and 
peptides because of the low stress on the molecule e.g. by elevated temperatures. One 
major hurdle of VPGs is their high viscosity which makes them hard to almost impossible 
to inject with conventional, thin needles used for subcutaneous administration. However, 
so far no data is published to overcome this administration challenge. In the present 
study, needle-free injection (NFI) was investigated and successfully applied as a 
technology for the easy and elegant administration of VPGs. VPGs with different 
phospholipid content were injected with a Biojector 2000 into gelatin blocks and full 
thickness pig skin post mortem as in vitro models and the injection depth was determined 
after injection. The release behavior was tested after shearing the VPG with the device to 
evaluate the effect of shearing on the drug release from the formulation. No differences 
were observed when compared to an ejection with needle and syringe. 
III.1.2  Introduction 
Vesicular phospholipid gels are semisolid dispersions of large amounts of phospholipids 
in an aqueous phase [1]. The have been used in the past as depot formulations for the 
sustained release of proteins, peptides and other small molecular weight drugs [2]–[4].  
VPGs are prepared by high pressure homogenization (HPH) or dual asymmetric 
centrifugation (DAC) [1], [5]. The preparation of VPGs is easy to scale-up and free of 
organic solvent. Further, gentle manufacturing with low temperatures facilitates the 
processing of proteins and peptides in the formulations. Due to the fact that VPGs are 
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only composed of buffer, the drug itself and phospholipids which are the main component 
of cell-membranes, the system is tolerated well after injection. Furthermore, high 
encapsulation efficiencies can be achieved in comparison to liposomal formulations, since 
hydrophilic drugs are not only encapsulated in the vesicles but localized in-between the 
vesicular structures of the phospholipid matrix. All these advantages taken together, VPGs 
are perfectly suited as a depot formulation for the sustained release of pharmaceutical 
relevant substances.  
Tian et al. showed that the sustained release of substances from VPGs correlates to the 
phospholipid amount of the formulation[4]. High phospholipid content results in slow 
release of the substance from the depot, which makes these formulations highly attractive 
but also causes difficulties in application due to the high viscosity of the formulation. Large 
needle sizes, which facilitate the subcutaneous injection, are not tolerated well by the 
patient as well as very slow injection rates. Reduction of the phospholipid content of the 
formulation decreases the viscosity, but it was shown before that this results in rapid 
release of the drug and therefore in a loss of the desired function of the depot [6]. By 
variation of the manufacturing process like it was described by Zhong et al., a lower 
viscosity and therefore injectability of the formulation could be achieved [7], [8]. 
However, the described preparation method produces rather highly concentrated 
dispersions of crude multi-lamellar liposomes than VPGs. 
The injection force with needle and syringe is highly influenced by the viscosity of the 
formulation [9], [10].   
Therefore, to overcome the administration challenge, needle-free injection (NFI) is a 
promising technique. NFI devices work by forcing a liquid with high velocity through a tiny 
nozzle which is pressed against the skin [11]. The Bernoulli equation is used for the 
description of the injection force with NFI [10]. In this equation the only formulation 
property influencing the injection force is the density of the formulation and therefore 
injection of formulations with a NFI device is largely independent of the viscosity. Several 
review articles summarize the methodology, different injectors and applications of NFI 
technology [11]–[13]. 
To our knowledge, the administration of semisolid depot systems like VPGs by using NFI 
technology has not been demonstrated before.  
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III.1.3  Materials and Methods 
III.1.3.1  Materials 
Egg lecithin (Lipoid E80) was a kind gift of Lipoid GmbH (Ludwigshafen, Germany). 
Methylene blue (MB), Sulforhodamine B (SRB), gelatin (Bloom 175, from procine skin) and 
Trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (Steinheim, Germany). 
Chloroform was obtained from Merck (Darmstadt, Germany). High performance liquid 
chromatography (HPLC) grade acetonitrile was purchased from Fisher Scientific 
(Schwerte, Germany). For preparation of buffers highly purified water (HPW, Purelab Plus, 
USF Elga, Germany) was used. 
Human erythropoietin (EPO) solution in phosphate buffer pH 7.2 was concentrated with 
Vivaspin ® 20 Tubes (MWCO 5 kDa; Sartorius AG, Germany). 
III.1.3.2  Preparation of VPGs  
The preparation of VPGs was based on the preparation method first described by Massing 
et al. [5]. VPGs with a phospholipid amount between 25 and 55% (m/m) were prepared 
by dual asymmetric centrifugation (SpeedmixerTM DAC 150 FVZ, Hauschild GmbH & Co KG, 
Germany). In short, the accurately weighted phospholipids were mixed with either 20 mM 
PBS buffer pH 7.4, MB- or SRB-solution in 20 mM PBS buffer pH 7.4 or EPO solution in 
phosphate buffer pH 7.2. The formulations with EPO contained a total protein load of 
10 mg/g. For homogenization of the mixtures with the SpeedmixerTM a process speed of 
3500 rpm was utilized and centrifugation time was 45 minutes. The used DAC was 
equipped with a custom-made cooling system keeping the temperature below 28 °C to 
avoid potential heat stability problems of the protein. 
III.1.3.3  Preparation of gelatin blocks 
Gelatin blocks were prepared as soft models for in vitro evaluation of injectability of VPGs 
by NFI. They were composed of gelatin (6%), glycerin (16%) and HPW. Each block was 
cylindrical in shape, with a height and diameter of 45mm. Gelatin was used because of its 
transparency, controllable mechanical properties, controllable dimensions and easy and 
cheap preparation. 
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After preparation the bloom value of a random sample of gelatin blocks was determined 
using a Texture Analyzer (TA.XT plus, Stable Micro Systems, UK) and Young’s moduli were 
calculated with (see equation (III-1)) [14]. 
𝐸 =
𝜎(𝜀)
𝜀
=  
𝐹/𝐴0
∆𝐿/𝐿0
 
(III-1) 
E: Young’s modulus (modulus of elasticity) 
ε: strain 
σ(ε): stress 
F: force exerted on object under tension 
A0: cross-sectional area of the probe by which the force is applied 
ΔL: length change 
L0: original length of the object 
III.1.3.4  Injections into in vitro models 
0.25 ml of the formulation was filled in single-use syringes suitable for the Biojector 2000 
(BiojectTM No2 with Biojector 2000, Bioject Inc., USA). For better visualization of the 
injected depot, the used formulations were either dyed with MB or SRB. 
The full thickness skin of a shortly before sacrificed 8 to 9 month old pig (provided by 
Veterinary Clinic for Swine, LMU Munich, Oberschleißheim, Germany) was used. During 
the experiment the skin was unharmed on the cadaver to retain the elasticity and 
consistency of the skin in real life. Injections into the pig skin were accomplished in the 
lower abdominal area of the pig. After injecting into the gelatin blocks or the pig skin, 
penetration depth was measured with a scale after cutting through the injection site. 
III.1.3.5  In vitro release of EPO from VPGs after shearing  
The model for the release of EPO from VPGs was based on the eppendorf cap model 
described by Even [15]. Release of EPO from VPGs was tested after ejection of 0.2 g VPG 
with the Biojector 2000 or with a conventional syringe and cannula (Sterican® Size 1 [Ø 
0.90 mm x 40 mm], B. Braun Melsungen AG, Germany).  
Briefly, 0.2 g VPG were filled into 2 ml eppendorf caps and 1 ml of 20 mM PBS buffer 
pH 7.4 was carefully added to the VPG on the bottom of the tube without causing turbidity 
of the sample. Release experiments were carried out in triplicates by complete buffer 
exchange in a Certomat Incubation Shaker (Sartorius AG, Göttingen, Germany) at 37 °C 
and 30 rpm. 
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For the extraction of EPO from the obtained liposomal released fraction chloroform (1:1) 
was added to the released fraction and the samples were centrifuged for 30 minutes at 
15 °C with 5000 rpm before taking the clear supernatant for quantification of the samples 
with reverse phase high performance liquid chromatography (RP-HPLC) [4].  
III.1.3.6  Quantification of EPO with RP-HPLC 
For quantification of EPO a Dionex Ultimate 3000 (Thermo Fisher Scientific, USA) with a 
FLD3100 fluorescent detector (Excitation: 280 nm; Emission: 343 nm) and a Phenomenex 
Jupiter 5µ C18 column (300 A, 250 x 4.6 mm) was used. Mobile phase A was composed of 
10% acetonitrile, HPW and 0.1% TFA and mobile phase B was composed of acetonitrile 
with 0.1% TFA. A flow of 0.5 ml/min was used and elution was done with a linear ramp. 
Good linearity of the calibration curve was obtained between 0.5 µg and 20 µg EPO which 
was injected into the HPLC system. 50 µl of the sample was injected for each run and the 
retention time of EPO was 22.3 minutes. 
III.1.4  Results  
III.1.4.1  Needle-free injection 
Gelatin blocks 
Baxter et al. reported that the Young’s modulus of human skin is 0.3 MPa ± 0.09 MPa, 
while Young’s moduli for pig skin highly depend on the anatomical location of the skin and 
the age of the pig and ranges between 0.5 MPa and 1.0 MPa [14]. We prepared gelatin 
blocks as soft skin models for the in vitro needle-free injection of VPGs. All prepared 
gelatin blocks had a Young’s modulus of 0.35 MPa ± 0.02 MPa which is comparable to 
human skin. 
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Figure III-1: (A) Visual appearance of the injected depot from the side (MB-VPG 35% (m/m)); (B), (C) and (D) injection 
site from above after the injection of formulations with (B) 25% (m/m), (C) 35% (m/m) and (D) 55% (m/m) 
phospholipid content. 
All formulations up to a phospholipid concentration of 50% (m/m) were easily injectable 
with the Biojector 2000 into gelatin blocks. When VPGs with phospholipid contents of 25% 
(m/m) and 30% (m/m) were injected wet-shots occurred, meaning that residues of the 
VPG were visible on the surface of the gelatin after injection. The injection of VPGs with a 
phospholipid amount of 55% (m/m) caused the formation of large jet channels and 
ruptures in the gelatin blocks from the surface.  
In conclusion, NFI of VPGs into gelatin block was successful for formulations with a 
phospholipid content in the range between 35 and 50% (m/m). 
  
Pig skin post mortem 
Since the gelatin blocks lack the characteristic skin structure with different skin layers, 
elasticity and consistency further injections into pig skin were done, using the cadaver of 
a recently killed pig.  
VPGs with a phospholipid content from 25 to 45% (m/m) could be successfully injected 
into the pig skin. The formulations penetrated into the subcutaneous tissue and in rare 
cases into the muscle tissue below the skin and no residues of the VPG were observed on 
the surface of the skin after injection. A longish appearance of the injected depot, which 
was situated parallel to the skin surface, was observed after cutting out the injected VPG 
without harming the depot. This observation was especially apparent when VPGs with low 
phospholipid amount were injected and penetrated into the muscle layer.  
VPG with a phospholipid content of 50% (m/m) was successfully injected into the dermis 
of the skin and only partially into the fat tissue. Intradermal administered VPG formed a 
palpable bleb at the injection site which was slightly raised and brightly colored. 
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Sometimes wet-shots occurred when these high phospholipid amounts were injected and 
residues of the formulation were observed on the nozzle or the skin after injection.  
 
Figure III-2: NFI into pig skin post mortem. (1A) Injection site from above after injection of a formulation containing 
40% (m/m) phospholipids. (1B) Cut through the injection site for the visualization of the penetration depth. (2A) 
Intradermal injection (SRB-VPG 50% (m/m)) without residues of the VPG on the surface. Pink color of the dyed VPG 
is visible through the upper skin layers. (2B) Cut through the injection site. 
In conclusion, formulations with a phospholipid amount between 25 and 45% (m/m) were 
injectable into pig skin using the Biojector 2000. VPGs with a phospholipid content of 50% 
(m/m) were injectable but results were not reliable due to the variable injection depth 
into different skin layers and the occasional incidence of wet-shots. 
 
Penetration depth  
Injection depth was measured with a scale after cutting through the injection site. For 
each phospholipid concentration at least two measurements were done and the mean 
was calculated. 
The VPGs penetrate about 2.5 fold deeper into the gelatin blocks in comparison to the 
penetration depth into pig skin after NFI. This is due to the different layers of the skin 
which display different texture and resistance to the jet stream of VPG into the tissue. In 
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both models the injection depth decreases with increasing phospholipid content which is 
due to the decrease of fluidity of the samples with increasing phospholipid amount. 
 
Figure III-3: Injection depth of VPG formulations into ( ) gelatin blocks and ( ) pig skin post mortem with increasing 
phospholipid amount. Data is plotted as mean ± SD (n=2 or 3). 
III.1.4.2  In vitro release after shearing 
We successfully injected VPG formulations into gelatin blocks and into pig skin. Still, the 
question if this administration technique with its high shearing forces does influence the 
release behavior of VPGs e.g. by destruction of the gel inner structure, has to be 
answered. Therefore, we tested the release of EPO from VPG with a phospholipid content 
of 45% (m/m) and a final EPO concentration of 10 mg/g. Before release testing the VPG 
was either ejected with a conventional needle and syringe or the Biojector 2000 was used. 
When ejecting with needle and syringe cannulas with large diameter of 0.90mm were 
chosen to facilitate the ejection of the formulation, since ejection with a conventional 
subcutaneous needle with a diameter between 0.45 and 0.30mm was not possible. 
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Figure III-4: Cumulative release of EPO from VPG with a phospholipid content of 45% (m/m). EPO-VPG was either 
filled into the eppendorf tubes with a conventional needle and syringe or ejected with the Biojector 2000 
 previous to release testing. Data is plotted as mean ± SD (n=3). 
Sustained release of EPO was observed over five testing days. The curves of the 
formulations ejected with needle and syringe and with the Biojector 2000 are similar in 
shape and total amount of released drug.  
III.1.5  Discussion 
The present study shows that NFI technology is a promising method to overcome the s.c. 
administration hurdle for VPGs. All formulations up to phospholipid content of 55% (m/m) 
were easily injectable with the Biojector 2000 into gelatin blocks. The wet-shots occurring 
at lower phospholipid contents are due to the limited inner elasticity of the gelatin blocks 
and the relatively low viscosity of the formulations. These factors lead to the back flow of 
the fluid through the injection channel.  
VPGs with phospholipid content up to 45% (m/m) were injectable into pig skin and 
penetrated into the subcutaneous tissue. Previous publications describe a spherical or 
cylindrical shape of the injected liquid after administration with a needle-free injector 
[13], [16]. The shape of the obtained depot in our study highly depended on the 
phospholipid content and penetration depth of the sample. For VPGs with lower 
phospholipid content (≤ 45% (m/m)) the propulsion of the semisolid material is not 
sufficient to infiltrate deeper layers and therefore stagnation pressure leads to the 
distribution of the gel in the subcutaneous tissue and rarely the upper muscle layers into 
two directions following the muscle macro-structure.  A longish shape of the depot which 
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is parallel to the skin surface is the result. A spherical shape in the intradermal and 
subcutaneous layers occurs when higher phospholipid contents (50% (m/m)) are injected. 
However, in our NFI study with pig skin the chosen injection site as well as elasticity and 
consistency of the skin does have great influence on the outcome. Baxter et al. already 
found that the texture of pig skin is highly dependent on the anatomical location of the 
skin [14]. They described that abdominal porcine skin is highly similar to human skin. We 
found that NFI is best feasible when injecting into the lower abdomen of the pig, while 
injections into the hind leg or breast skin often resulted in wet-shots. Further, when VPGs 
with a low phospholipid content of 25% (m/m) were injected, in some cases we observed 
intra muscular injections due to the high propulsion of the material with relatively low 
viscosity. Since these i.m. injections were not the intention of this study, we propose that 
for the administration of these formulations with low viscosity an adjustment of the jet 
force of the injector is needed. Further, we conclude that VPGs with 30 to 45% (m/m) 
ideally combine best suitability for NFI with a Biojector 2000 and superior applicability as 
depot systems because of their slow release rates. 
Another important factor is the quality of the VPG after shearing with the Biojector 2000. 
It has been reported, that VPGs release their contents by diffusion and matrix erosion [4], 
[6], [17]. In our study we could show that shearing of the gel with the Biojector 2000 does 
not influence the release behavior of EPO. 
III.1.6  Conclusion 
NFI is not only beneficial for the administration of semisolid systems but additionally 
prevents needle stick injuries, reduces the risk of infections and overcomes patient 
aversion towards needles [12]. We succeeded in NFI of VPGs with different phospholipid 
content and therefore could show that it is possible to administer this promising depot 
system via a very simple and elegant method. The in vitro release behavior of EPO was 
not affected by shearing of the VPG with the Biojector 2000.  
In conclusion the injection of VPGs with a Biojector 2000 is feasible and this excellent 
depot system is now ready for future applications in clinical trials. 
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III.1.7  Supporting information 
This article contains supplementary material. 
Supplement 1 – Equations for calculation of injection forces 
Rearranged Bernoulli equation for the calculation of the injection force for NFI-devices. 
𝐹 = 2 𝜌 𝐴 (
4 𝑄
𝐶𝑓 𝜋 𝐷2
)
2
 
(III-2) 
F = syringe plunger force 
Q = volumetric flow rate 
ρ = fluid density 
Cf = orifice flow coefficient (0.95 for a practical, round edged orifice) 
D = orifice diameter 
A = cross-sectional area of syringe plunger 
 
Hagen-Poiseuille equation for the calculation of injection force with needle and syringe of Newtonian fluids. 
𝐹 =
8 𝑄 𝜇 𝐿 𝐴
𝜋 𝐷4
 
(III-3) 
F = syringe plunger force 
Q = volumetric flow rate 
µ = dynamic viscosity 
L = needle length 
D = needle inner diameter 
A = cross-sectional area of syringe plunger 
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Supplement 2 – Physical properties of VPGs 
Table III-1: Summary of the physical properties of VPGs. Viscosity was determined with a rotational rheometer (PP25 
with Physica MCR 100, Anton Paar, Ostfildern, Germany) with a plate/plate geometry. Gel strength and injection 
forces were determined with a Texture Analyzer (TA.XT plus, Stable Micro Systems, UK) in compression mode. 
Phospholipid 
amount [%] 
Viscosity 
[Pa*s] 
Gel strength 
[g] 
Injection force [N] 
0.1 ml/sec; 
RT; 27G 
17.5 µl/sec; 
RT; 27G 
0.1 ml/sec; 
45°C; 27G 
0.1 ml/sec; 
RT; 23G 
25 0.13 ± 0.02 0.23 ± 0.05 10.81 ± 0.21 3.22 ± 0.23 7.28 ± 0.14 3.03 ± 0.09 
30 0.28 ± 0.02 0.17 ± 0.09 21.92 ± 1.70 5.85 ± 0.07 14.32 ± 0.07 4.30 ± 0.09 
35 0.81 ± 0.11 0.23 ± 0.05 40.44 ± 1.86 11.02 ± 0.14 32.24 ± 0.41 8.09 ± 0.15 
40 2.28 ± 1.01 0.57 ± 0.05 47.12 ± 3.54 21.91 ± 1.59 > 50 19.40 ± 0.52 
45 8.41 ± 0 45 3.03 ± 0.09 > 50 38.83 ± 4.68 > 50 34.00 ± 0.27 
50 41.74 ± 7.15 22.53 ± 0.25 > 50 48.56 ± 2.42 >50 > 50 
55 84.70 ± 
11.95 
31.57 ± 0.65 > 50 > 50 > 50 > 50 
 
 
  
 
 
CHAPTER III 
46 
III.2  Further studies 
Additionally to the above described study, which was finally published in January 2017 in 
Journal of Pharmaceutical Sciences, deepening research on the topic was conducted, 
which is described in the following. To maintain the train of reading, references of both 
sections are summarized at the end of the chapter. 
III.2.1  Material and Methods 
For detailed information on the used materials see III.1.3.1  . 
VPGs were prepared as described in III.1.3.2  . 
III.2.1.1  Viscosity measurement 
Viscosity of the prepared formulations was determined using a rotational rheometer with 
a plate-plate geometry (MCR 100 with PP25, Anton Paar, Ostfildern, Germany). The 
shearing rate was set to 10 – 100 s-1 and approximately 0.2 g VPG was used for one 
measurement. For comparison the viscosity at a shearing rate of 32.9 s-1 was used.  
III.2.1.2  Determination of the density 
To determine the density of the VPGs a glass pycnometer (volume: 1 ml) was used. For 
each measurement VPG was filled into the pycnometer and the mass of the VPG was 
determined by weighing. Density was calculated (ρ = m/V) from the determined mass (m) 
and volume (V). 
III.2.1.3  Texture analysis 
Gel strength of the VPGs was measured using a Texture Analyzer (TA.XT Plus, Stable Micro 
Systems, UK). For each measurement about 1 g of VPG was carefully filled in a 2 ml 
centrifugation tube. A micro probe with a diameter of 4 mm was pushed into the gel with 
a speed of 0.5 mm/sec to a final penetration depth of 5 mm. The gel strength was 
determined as the maximum force needed. 
III.2.1.4  Determination of injection force with needle and syringe 
Injection forces into air and into the skin of a piglet were measured using the Texture 
Analyzer. 0.5 ml VPGs with different phospholipid concentration (between 25% (m/m) 
and 55% (m/m)) were filled into BD 1 ml syringes with Luer-Lok TM Tip (BD Franklin Lakes, 
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New Jersey, USA). Sterican® Size 20 cannulas with a diameter of 0.4 mm and a length of 
20 mm (27G x 3/4 ”) (B. Braun, Melsungen, Germany) which are often used for the 
subcutaneous injection of liquids were used for measurement of injectability of VPGs into 
air.  
All injections into pig skin were done following the protocol of the National Institutes of 
Health (NIH Clinical Center Patient Education Materials). In short, the skin was pinched up 
with two fingers and the needle was injected into the skin in a 90-degree angle. Injection 
force measurements into pig skin were performed at different conditions: 
• Variation of the injection rate: 0.1 ml/sec and 17.5 μl/sec 
• Variation of the formulation temperature: room temperature (ca. 20 °C) and 45 °C 
• Variation of needle diameter:  
o Sterican®Size 20 cannulas; 27G; diameter 0.4 mm 
o Sterican® Size 16 cannulas; 23G; diameter 0.6 mm 
The average force of at least two measurements was calculated. The experimental setup 
for the measurement of the injection force is shown in Figure III-5. 
 
Figure III-5:  Schematic drawing of the Texture Analyzer for measurement of injection force. 
III.2.1.5  Needle-free injection of VPGs with Biojector 2000 
A detailed description of needle-free injection of VPGs using a Biojector 2000 is given in 
section III.1.3.4  .  
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Two different single use syringes were used for further evaluation of the needle-free 
injection process: No2 (32G; 0.004 inches; Bioject Inc., USA) and No3 (30G, 0.006 inches; 
Bioject Inc., USA). 
III.2.1.6  Jet force upon ejection with Biojector 2000 
The impact force after ejection of a VPG-stream by the Biojector 2000 on a piezo-sensor 
(Kistler 9215) was measured. The generated tension is increased by a charge amplifier 
(Kistler 5011) and visualized with an oscilloscope (FLUKE 123 Scopemeter). Since it was 
not possible to collect digital data, photos of the displayed graphs were taken and the 
data was digitalized using a commercially available plot to data digitalizer 
(WebPlotDigitizer). During the ejection of the jet, the Biojector was set in a custom made 
coupler and fixed with a stand to minimize vibrations of the injector itself and to 
guarantee an exact position of the injector above the sensor. The gap width between the 
orifice and the force plate was 2.5 mm. The experimental setup of the jet force 
measurements is shown in Figure III-6. The sensor is calibrated so the force can be directly 
taken from the oscilloscope (1 V = 1 N). The influence of phospholipid concentration (25%, 
30%, 35%, 40%, 45% and 50% (m/m)), composition of the lipid phase (S100, POPC, 
POPC/POPG, E80+MCT (35% + 5% (m/m)), E80+MCT (40% + 5% (m/m))), injection volume 
(0.25 ml, 0.5 ml, 1.0 ml) and the temperature (25 °C, 30 °C, 35 °C, 40 °C, 45 °C) of the 
formulation on the jet force was investigated with the two single use syringes also used 
for post mortem injections (No2 and No3). For all measurements with increased 
temperature during injection, samples were pre-warmed for at least 30 minutes at the 
respective temperature and ejection onto the pressure sensor was done directly after 
taking the sample out from the incubator. Triplicate measurements were conducted for 
each sample.  
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Figure III-6: Experimental setup of the jet force measurement. 
All pressure calculations were based on the inner area of the nozzle of the syringe. 
Pressures were calculated with the following equation:  
𝑃 =  
𝐹
𝐴
 (III-4) 
with F as the measured force (initial peak force or drop-off force), A as the area calculated 
from the inner diameter of the nozzle and P as the pressure of the ejected jet-stream. 
III.2.2  Results and Discussion 
III.2.2.1  Viscosity and gel strength of VPGs 
As it has already been shown before, the viscosity and gel strength of the formulations 
increase with increasing concentration of phospholipids in the formulation [4]. Viscosity 
of VPGs composed of different contents of Lipoid E80 and 20 mM PBS pH 7.4 was 
compared at a shearing rate of 32.9 s-1. VPG-formulations with a phospholipid content of 
25% (m/m) display a viscosity of only 0.13 Pa∙s ± 0.02 Pa∙s, while VPGs with a phospholipid 
content of 55% (m/m) display a huge viscosity of up to 90 Pa∙s. 
The viscosity and gel strength of VPGs with an increasing concentration of Lipoid E80 are 
shown in Figure III-7. 
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Figure III-7:  Viscosity (at shearing rate 32.9 s-1) and gel strength of VPGs with increasing phospholipid concentration 
in % (m/m). VPGs were composed of Lipoid E80 and 20 mM PBS pH 7.4. (n=3, Mean ± SD) 
III.2.2.2  Injection force with conventional needles 
Injection force during an injection with needle and syringe can be split in three phases. 
First the resistance of the plunger has to be overcome, before kinetic energy is passed on 
to the liquid and the liquid is finally forced through the needle [18]. Additional force is 
needed to overcome the tissue resistance at the needle tip when injecting into 
subcutaneous tissue [19]. The addition of all these processes results in the total injection 
force, used here to characterize syringeability and injectability. 
All formulations (25, 30, 35, 40, 45, 50 and 55% (m/m)) were injected subcutaneously into 
pig skin with an injection rate of 0.1 ml/sec commonly used for testing, which is 
appropriate for the end-user [9], [20]. However, not all formulations could be injected 
with this injection rate due to the exceptional high forces needed. Subsequently all 
formulations were tested with a rather slow injection speed of 17.5 μl/sec. The 
moderation of the injection force by using slower injection rates is a common technique 
to facilitate for example the injection of highly viscous formulations or injection of liquids 
by handicapped patients e.g. rheumatoid arthritis patients [20]. In general, as expected 
the injection force needed increases significantly with increasing phospholipid 
concentration. The complete range of VPG-formulations could be injected into pig skin at 
a very slow injection rate of 17.5 μl/sec. At the higher injection rate of 0.1 ml/sec injection 
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was only possible up to a maximum phospholipid concentration of 40% (m/m) in the 
formulation. There are no generally accepted limits for injection force and injection time 
[21]. Still, several authors give clues on the feasibility of an injection by the patient. 
Rungseevijitprapa et al. stated that liquids can be injected easily up to an injection force 
of 25 N [22]. Sheikhzadeh et al. found that patients with rheumatoid arthritis are able to 
apply average injection forces of 22.5 N with conventional syringes and maximum forces 
of up to 33 N were measured [20]. 
However, not only the injection speed is contributing to the injection force. Many 
parameters, including device components (e.g. syringe size, needle diameter and length) 
and drug formulation properties (e.g. dynamic viscosity), have great influence on the 
injection force [19], [21]. This relationship is described by the Hagen-Poiseuille-Equation: 
𝐹 =  
8 ∙ 𝑄 ∙ 𝜇 ∙ 𝐿 ∙ 𝐴 
 𝜋 ∙ 𝐷4
 (III-5) 
Additionally to these physical parameters, human factors (e.g. strength, flexibility and 
coordination) contribute to the injectability of liquids. The syringe plunger force needed 
for injection (F) directly correlates to the volumetric flow rate (Q), the dynamic viscosity 
(μ), the length of the needle (L) and the cross-sectional area of the syringe plunger (A). An 
indirect correlation exists to the inner diameter of the needle (D). 
There are several parameters according to this equation which can be adapted in certain 
limits to achieve better syringeability and injectability. Next to injection with lower 
injection speed, another method to facilitate the injection of highly viscous formulations 
is the injection at higher temperatures (with certain limitations regarding the drug 
compound). Dynamic viscosity of formulations greatly depends on the temperature of the 
formulation. This aspect was investigated for VPGs by pre-warming of the formulations to 
the desired temperature of 45 °C for at least 45 minutes and direct testing of the injection 
force thereafter. Further, the inner diameter of the needle can be increased to a certain 
limit by using thicker needles or thin wall needle to reach lower injection forces. However, 
this is often associated with higher sensation of pain  
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Figure III-8: Injection force of VPGs with different phospholipid concentration during injection with needle and syringe 
- comparison of different injection conditions. Dashed line shows injection force of 25 N. 
As shown in Figure III-8 the injection force at 45 °C is slightly lower in comparison to the 
injection force at room temperature. However, a higher injection temperature did not 
lead to satisfying results regarding the needed force for injection since VPG formulations 
with a phospholipid concentration above 30 to 35% (m/m) still were not easily injectable.  
Further, a second needle with larger inner diameter was tested. As it was also observed 
for the very slow injection rate of 17.5 μl/sec, the injection force could be lowered 
significantly by using larger needles. In conclusion, it is in theory possible to inject VPG 
formulations with high phospholipid concentration by lowering the injection speed to very 
slow rates or using large needles. Still, the injection forces needed for VPGs with a high 
phospholipid concentration exceed the force which can be managed by humans at far and 
less patient compliance is to be expected for both techniques due to the long and painful 
administration duration. 
III.2.2.3  Further post mortem studies on needle-free injection of 
VPGs 
III.2.2.3.1  Comparison of different single use syringes in post mortem studies 
To complement our already published data on needle-free injection of VPGs using No2 
single use syringes, injections into pig skin post mortem were performed with a second 
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single use syringe, No3 [23]. No3 syringes do have a larger inner diameter of the orifice in 
comparison to No2 syringes. According to the manufacturer information, both, No2 and 
No3, syringes can be used for subcutaneous injections of liquids into skin [24].   
VPGs with a phospholipid concentration from 30 to 50% (m/m) were easily injectable into 
pig skin with a volume of 0.25 ml per injection using a No3 syringe. 
Formulations mainly penetrated into the subcutaneous tissue without leaving residues on 
the surface of the skin. Sometimes partial intradermal injection (see Figure III-9A), which 
could be identified by a bright, easily visible color of the SRB-VPG (Sulforhodamine B-VPG) 
below the skin directly at the injection site, occurred. In other cases, the VPG penetrated 
into muscle tissue of the skin, which is shown in Figure III-9D for a 50% (m/m) VPG. The 
occurrence of intramuscular injections, which was rare in general, was more likely when 
No3 syringes were used in comparison to No2 syringes, leading to the conclusion that the 
propulsion of an ejected stream from a No3 syringes is higher in comparison to No2 
syringes. This was to be expected, since depth of penetration tests for liquids showed 
deeper injections and a higher probability for i.m. injections for the No3 syringes [24]. 
As described before also for liquid injections, the shape of the injected VPG was spherical 
or longish  [13], [16]. 
 
Figure III-9: NFI into pig skin post mortem. Injection site from above after injection of SRB-VPGs containing 40% (m/m) 
(A) or 50% (m/m) (B) phospholipids using a No3 single use syringe for injection. Lower row shows cuts through the 
injection site: 40% (m/m) SRB-VPG (C) and 50% (m/m) SRB-VPG (D). 
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III.2.2.3.2  Injection depth 
In a next step the injection depth of VPG-formulations was determined after cutting 
through the injection site  
Injection depth into pig skin after NFI was between 0.4 and 1.2 cm (Figure III-10). This 
difference is caused by the different layers of the skin, which display different texture and 
resistance to the jet stream of VPG into the tissue. Further, the muscle tissue below the 
subcutaneous tissue acts like a barrier due to the completely different structure and 
prohibits that the jet stream of VPG penetrates deeper. Since the subcutaneous tissue of 
the pigs had a thickness of about 1.0 cm, the shots from No3 syringes sometimes resulted 
in partial intramuscular injections as also observed in trans-sectional cuts through the 
injection site. 
For both single-use syringes the injection depth decreases slightly with increasing 
phospholipid concentration, which is due to the decrease of fluidity of the samples with 
increasing phospholipid concentration. The velocity of the jet stream decreases during its 
path through the outer skin and different skin layers until finally the jet stream is stopped 
in the subcutaneous tissue. This process is faster for VPGs with high viscosity in 
comparison to VPGs with low viscosity, resulting in low injection depth. 
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Figure III-10: Injection depth of VPG formulations composed of E80 as phospholipid and 20mM PBS pH 7.4 as aqueous 
phase. VPGs with phospholipid concentrations between 30 and 50% (m/m) were injected into pig skin post mortem 
with No2 (white squares) and No3 (black dots) single use syringes. 
Additionally, the variability between the injection depths in a triplicate was higher for the 
No3 syringes in comparison to No2 syringes, since standard deviations are significantly 
higher for No3 syringes. This is a result of the i.m. injections which occurred sometimes 
for these syringes, resulting in higher values for the injection depth, while sometimes the 
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same formulations stayed in the subcutaneous tissue resulting in lower values for the 
injection depth. 
Further, it is notable that the amount of phospholipid in the formulation only has a minor 
impact or none at all on the injection depth. 
III.2.2.3.3  Injections with large injection volume 
In all previous studies, a VPG volume of 0.25 ml was used to show injectability with NFI of 
the highly viscous system. Although these small volumes are perfectly suited for the 
application in a study with small animals and drugs which can be encapsulated in VPGs 
with a high drug load, higher administration volumes might be necessary for treatment of 
humans or larger animals and drugs which cannot be encapsulated in highly concentrated 
formulations. To this end, we tested the administration of 0.5 ml and 1.0 ml VPG by 
needle-free injection using No2 and No3 syringes. The Biojector 2000 has the ability to 
deliver a maximum volume of 1.0 ml solution and volumes between 0.5 ml and 1.0 ml are 
commonly used in its application [25]. 
 
Figure III-11: Needle-free injection of 0.25 ml, 0.5 ml and 1.0 ml (from left to right) of VPGs (composed of 45% (m/m) 
Lipoid E80 and Sulforhodamin B solution in 20 mM PBS pH 7.4) using the Biojector 2000 device with No2 syringes. 
Top row shows injection site from above directly after administration. Bottom row shows trans-sectional cuts 
through the injection site. 
Using No2 syringes, all formulations with a phospholipid concentration between 25 and 
45% (m/m) were injectable with larger volumes up to 1.0 ml. When VPGs with 45% (m/m) 
phospholipid were used, sometimes wet shots occurred with a volume of 1.0 ml and tiny 
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residues of the formulation on the skin surface or on the orifice were observed, leading 
to the conclusion that 45% (m/m) phospholipid concentration is the limit of injectability 
for this syringe type. With No3 syringes only injections with 45% (m/m) and 50% (m/m) 
were tested with larger volumes, since it is to expect that lower phospholipid 
concentration results in superior injectability in comparison. 45% (m/m) and 50% (m/m) 
VPGs were easily injectable up to a volume of 1.0 ml using the No3 syringes. When 1.0 ml 
of the 50% (m/m) formulation was injected, tiny residues of the formulation on the skin 
surface were observed sometimes. These wet shots occurred more often when large 
volumes were injected. Again, it is assumed, that the limit of injectability is reached with 
50% (m/m) phospholipid concentration and 1.0 ml injection volume. 
III.2.2.4  Jet force upon ejection with Biojector 2000 
Jet force measurements were performed using an experimental setup comparable to the 
one described by Shergold et al. [26]. The injector was placed above a piezoelectric sensor 
to measure the force of an ejected jet stream. Different parameters like phospholipid 
concentration, VPG temperature, ejected volume and the VPG composition was varied to 
test the robustness of the injector against changes. 
According to Chase et al., there are three stages of injection with a needle-free device 
[27]. During peak pressure phase, the optimal pressure to penetrate the skin is reached, 
followed by delivery phase, during which the formulation is delivered to the injection site 
and pressure decreases slowly. Finally, during drop-off phase at the end of the injection 
the pressure drops instantaneously down to almost zero after the formulation is 
completely delivered. A similar profile with all three phases was observed for the ejection 
of VPG using the Biojector 2000 (see Figure III-12). After a sharp increase of the force on 
the sensor at the beginning of the injection, force slowly decreases during the ejection of 
the VPG and drops down to a minimum when the formulation is completely ejected. It is 
well known, that a drop-off pressure below 1200 psi (~ 8 MPa) can lead to a leak-back of 
the injectant through the injection channel after injection [28].  
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Figure III-12: Exemplary force profiles of VPGs after ejection of 0.25 ml with a Biojector 2000 and No2 syringe. 
Phospholipid concentration was increased from 25% (m/m) to 45% (m/m). 
The two previously used single use syringes were used to investigate the influence of the 
orifice diameter on the injection force. Differences caused by the ratio of calculated jet 
area and measured orifice area, like it was described by Shergold et al., were not taken 
into account by a correction factor [26].  
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Figure III-13: Initial force (A) and injection duration (B) of the ejection of VPGs with increasing phospholipid 
concentration with different single-use syringes (No2 and No3). VPGs were composed of Lipoid E80 (25 -50% (m/m)) 
and 20mM PBS pH 7.4. Graphs show mean (n=3) ± SD. 
The two different orifice sizes resulted in differences in the measured force and ejection 
duration. The initial force of the jet stream ejected from the Biojector 2000 was higher 
when No3 syringes were used, independently of the phospholipid concentration in the 
VPG (see Figure III-13A). However, when the jet stream pressure was calculated from the 
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measured force using equation (III-4), both single-use syringes resulted in similar initial 
pressure values due to the differences in the orifice area (see Figure III-15A). Ejection was 
faster when using the No3 syringes with a larger inner diameter of the orifice (see Figure 
III-13B), since the amount of VPG passing the orifice per time is larger leading to a faster 
emptying of the syringe. 
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Figure III-14: Exemplary force profiles of the ejection of 0.25 ml of 40% (m/m) VPGs composed of Lipoid E80 an 20mM 
PBS pH 7.4 with No2 (black curve) and No3 (red curve) syringe. 
The faster decrease of maintenance pressure during delivery phase is an additional result 
of the larger orifice. Injections with No2 syringe showed a mean injection duration of 
188.23 ms ± 20.62 ms (n=3) for VPG containing 40% (m/m) phospholipids, while injections 
of the same formulation with No3 syringes were significantly faster (83.14 ms ± 11.36 ms; 
n=3). Two exemplary force profiles of these injections are shown in Figure III-14. 
III.2.2.4.1  Influence of the phospholipid concentration 
The viscosity of the VPG increases rapidly with increasing concentration of phospholipid 
in the formulation. This increase is especially pronounced for high phospholipid 
concentrations from 40% (m/m) and above (see Figure III-15B red bars).  Since the 
injection with needle and syringe is strongly influenced by the viscosity of the formulation, 
leading to unacceptable high injection forces, it was to be expected that needle-free 
injection may have limitations regarding formulation viscosity. 
With increasing phospholipid concentration, initial pressure and drop-off pressure 
decrease slightly for injections with a volume of 0.25 ml (see Figure III-15A and Figure 
III-15B). Still, all values were above 30 MPa. Injection duration was similar for all 
 
 
NEEDLE-FREE INJECTION OF VESICULAR PHOSPHOLIPID GELS 
59 
phospholipid concentrations but depended on the syringe type which was used (see 
Figure III-13B).  
During delivery phase, maintenance force decreased faster when VPGs with a higher 
phospholipid concentration were ejected (see Figure III-12). 
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Figure III-15: Initial pressure (A) and drop-off pressure (B) of the jet stream of VPGs with increasing phospholipid 
concentration. Red bars in (B) show viscosity of the formulation. Viscosity was compared at a shearing rate of 32.9 s-
1. VPGs were composed of Lipoid E80 (25 - 50% (m/m)) and 20mM PBS pH 7.4. Graphs show mean (n=3) ± SD. 
Following the Bernoulli equation, injection with a needle-free injector is largely 
independent of the viscosity [10]. It has to be pointed out that the application of the 
Bernoulli equation is limited to cases of steady, laminar flow, which is to a good 
approximation true for single-use syringes which are used for needle-free injection 
devices.  
𝐹 = 2 ∙ 𝜌 ∙ 𝐴 (
4 ∙ 𝑄
𝑐𝑓 ∙ 𝜋 ∙ 𝐷2
)2 (III-6) 
with F as the plunger force, Q as volumetric flow rate, ρ as fluid density, cf as orifice fluid 
coefficient, D as orifice diameter and A as syringe plunger area.  
To this end, viscosity of the formulation should not be a limiting factor in needle-free 
injection technology. The pressure measurements support this assumption. Differences 
in initial pressure and drop-off pressure are small, while viscosity increases massively with 
increasing phospholipid concentration. An explanation for this observation might render 
from changes in density of the formulation. In liquid formulations a density similar to the 
one of water (around 1 g/cm3) is to be expected. However, the density of VPGs is higher 
(i.e. phospholipid concentration of 30% (m/m): 1.1023 ± 0.0005 g/cm3 (n=3)) in 
comparison to water due to the high phospholipid concentration. This results in higher 
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force needed for administration of VPGs according to the Bernoulli equation (equation 
(III-6)). During injection a higher amount of energy from the NFI device is consumed for 
propulsion of the VPG in comparison to liquids, thus the pressure of the VPG jet decreases 
faster while energy is used up and in the following lower drop-off pressure is observed for 
higher phospholipid concentration. 
III.2.2.4.2  Influence of ejection temperature 
Another factor influencing the injectability and syringeability of formulations is the 
temperature of the injected formulation. Higher temperatures facilitate the injection of 
highly viscous formulations with needle and syringe, due to its effect on viscosity of the 
formulation. In this part we investigated the effect of higher temperatures on the viscosity 
and pressures during needle-free injection of VPGs. 
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Figure III-16: Initial pressure (A) and drop-off pressure (B) of 40% (m/m) VPG composed of Lipoid E80 and 20 mM PBS 
pH 7.4 after injection of 0.25 ml. Red bars in (B) show viscosity of the formulation at different temperatures. Viscosity 
was compared at a shearing rate of 32.9 s-1. Graphs show mean (n=3) ± SD. 
Surprisingly, increasing the temperature of VPG formulations to 45 °C does not necessarily 
also influence the viscosity of the formulation. No differences in initial pressure or drop-
off pressure were observed for increasing temperatures for both syringes.  
III.2.2.4.3  Influence of ejection volume 
Three different volumes were tested to show differences between the initial injection 
pressures, injection time and drop-off pressure. No differences were observed between 
the initial injection pressures for all three volumes. Higher injection volumes resulted in 
longer injection durations for both syringe types. A two-fold increase of the volume led to 
a two-fold increase of the injection time (Figure III-17B). As pointed out before, injection 
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duration was shorter for No3 syringes in comparison to the No2 syringes. This is a result 
of the larger orifice, allowing a higher volume per time flow. 
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Figure III-17: Initial pressure (A), injection duration (B) and drop-off pressure (C) of VPG composed of 40% (m/m) 
Lipoid E80 and 20 mM PBS pH 7.4 for different injection volumes (0.25 ml, 0.5 ml and 1.0 ml). Graphs show mean 
(n=3) ± SD. Red line indicates critical drop-off pressure at 8 MPa. 
With increasing volume of the VPG, decreasing drop-off pressure was observed for both 
syringe types. A drop-off pressure of 5.5 MPa for an ejected volume of 1.0 ml was 
measured for the No2 syringe. This value is below the critical limit of 8 MPa, leading to 
the conclusion that these high injection volumes might lead to wet shots more often. 
Limits of injectability are reached for the No2 syringe. These findings are also in 
accordance with the observations for the needle-free injections into pig skin post mortem, 
where wet shots occurred more often for these larger volumes. 
For the No3 syringe, the critical value is not reached for a 40% (m/m) VPG formulation. 
However, the results of the post mortem experiments indicate that the injection of VPGs 
with higher phospholipid concentration also may lead to critical drop-off pressures. 
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III.3  Conclusion 
The administration of VPG, a semisolid drug formulation with high viscosity, is one of the 
challenges, which has to be overcome before clinical studies with the drug delivery system 
can be started.  
In this study, the injectability and syringeabilty of VPGs were investigated and it was 
shown that exceptional high injection forces are reached for VPGs when conventional 
syringes and needles for s.c. injections are used. These difficulties could only to some 
extend be overcome by using needles with larger inner needle diameter or by very slow 
injection rates. However, both of these measures are correlated to low patient 
compliance, due to longer duration and their association with higher sensation of pain. 
Due to these restrictions and difficulties arising from injection of VPGs with conventional 
needles and syringe, a more convenient and patient friendly method is urgently needed. 
Needle-free injection of VPGs with different phospholipid concentration, composition of 
the lipid component, injection volumes and two different single use syringes was 
successfully demonstrated up to 50% (m/m) phospholipid. Injection of VPGs into the 
subcutaneous tissue of pig skin post mortem was possible. Furthermore, the applied 
administration technology shows a high robustness against changes in viscosity and 
temperature, while limitations were visible when larger volumes were injected. Pressure 
measurements confirmed the conclusions gained from post mortem injections, that high 
injection volumes may result in wet shots more often due to the low drop-off pressure 
reached at 1.0 ml injections. Beyond the fact that needle-free injection technology 
facilitates the elegant and simple administration of VPGs, this technique also prevents 
needle-stick injuries, thereby reducing the risk of infections, and overcomes patients 
aversions against needles [12]. 
Additionally, it was ensured that an encapsulated protein (EPO) was still released with the 
favorable sustained release kinetics, which makes VPGs such an interesting depot 
formulation. Shearing of VPGs by the Biojector 2000 does neither destroy the inner 
structure of the VPGs, responsible for the sustained release behavior, nor do shearing 
forces lead to degradation of the encapsulated protein.  
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Chapter IV  
PREPARATION OF VESICULAR PHOSPHOLIPID 
GELS BY TWIN-SCREW EXTRUSION 
 
Parts of this chapter have been submitted as patent to “Deutsches Patent- und 
Markenamt” with the title “Herstellung von VPG mittels Schnecken-Extrusion” 
(application number: DE 10 2018 010 063.5). The publication as a patent application by 
the DPMA is pending. 
Furthermore, parts of this work have been performed by Natalie Deiringer throughout the 
course of her Master Thesis from May 2017 to October 2017 under my supervision. The 
following figures are adapted and partially edited from her work: Figure IV-6, Figure IV-7, 
Figure IV-8, Figure IV-9, Figure IV-10, Figure IV-13, Figure IV-14, Figure IV-15, Figure IV-16. 
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IV.1  Introduction 
One of the advantages of VPGs as drug delivery systems over others is their easy and 
cheap manufacturing. Three different processes have been used in the past for the 
preparation of VPGs. 
IV.1.1  High pressure homogenization 
Originally developed for the preparation of liposomes, to avoid the film method, high 
pressure homogenization (HPH) is the first described method used for the preparation of 
VPGs [1]–[3]. By HPH, small and unique vesicle sizes below 100 nm can be prepared 
without the involvement of organic solvents by forced lecithin hydration [4]. The method 
allows the preparation of batch sizes up to tens to hundreds of grams of VPG and is 
especially suited for large scale production [5]. A pre-dispersion of dry phospholipids or a 
blend of lipids and buffer or drug solution are fed into the high-pressure homogenizer, 
where ultra-fine lipid particles are formed, which then evolve to vesicles after swelling [3]. 
The lipid dispersion is forced through a narrow gap with high pressure, resulting in 
homogenization by cavitation and shearing. In some cases repeated cycles are necessary 
to reach satisfying vesicle sizes [1].  Size distribution of the obtained vesicles depends on 
the applied pressure during the process, the number of cycles as well as lipid type and 
concentration. However, HPH has drawbacks in the production of VPGs in small lab scale, 
the one-step approach is not suited for lipid-mixtures and temperature control may be a 
challenge. Additionally, only short mixing intervals can be used to prevent degradation of 
the encapsulated drug or phospholipids as a result of the high shearing forces and thus 
heat development [6]. 
IV.1.2  Dual asymmetric centrifugation and dual 
centrifugation 
Dual asymmetric centrifugation (DAC) is a technique, suited for the preparation of fat 
emulsions, liposomes, nanoparticles and VPGs [5], [7]–[9]. Massing et al. showed that 
preparation of VPGs by DAC is possible in a broad range of phospholipid concentrations 
and, with the addition of glass beads as homogenization aid, even the preparation of 
liposomes smaller than 100 nm is possible [5]. In a dual asymmetric centrifuge, the 
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container is rotated around a central axis like in a commonly used centrifuge, while a 
counter rotation around the containers center is taking place at the same time. Thereby 
the sample is pushed to the outer side of the container, due to centrifugal forces, and on 
the other hand is pushed in the opposite direction as a result of adhesive forces between 
the sample and the container by the rotation around its own center. By a defined angle of 
the main rotation axis, the content of the vial is forced into the corner between the 
bottom and the vial wall [5]. 
A further development of dual asymmetric centrifugation (DAC) is dual centrifugation (DC) 
[10]. It is based on the same principle as DAC i.e. two counter-rotating movements result 
in rapid and homogenous mixing of components, however in the instrumental setup of a 
DC two rotating baskets are used instead of one. No counterweight as in an asymmetric 
centrifuge is needed. Further, these novel DC systems may be equipped with a cooling 
system as applied with conventional centrifuges, thereby facilitating the encapsulation of 
sensitive compounds into VPGs. 
DAC or DC are fast and easy options to produce VPGs with high encapsulation efficiency 
in small lab scale up to hundreds of grams (depending on the size of the centrifuge). 
Additionally, aseptic production in a closed container is possible. However, the process is 
only possible in batch-to-batch mode production and does not facilitate continuous 
manufacturing.  
IV.1.3  Magnetic stirring 
Next to HPH and DAC, which both apply high shearing forces during manufacturing, 
magnetic stirring has been described for the preparation of VPGs [11], [12]. The dry lipid 
powder is added to buffer and the mixture is allowed to swell, before homogenization is 
conducted by magnetic stirring. However, freeze-fracture microscopic examination 
showed larger vesicle sizes and different morphology for the obtained VPG in comparison 
to VPG prepared by HPH or DAC [2]. Due to significantly lower mechanical energy input 
during the process, dispersity and homogeneity of the VPGs is expected to be lower in 
comparison the HPH or DAC.  
Although magnetic stirring is straight forward and easy to scale up, homogeneity and 
stability of the obtained VPGs is questionable. 
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IV.1.4  Twin-screw extrusion  
The main advantages of extrusion technology over other preparation techniques are a 
continuous operation and manufacturing, high flexibility in batch sizes, high process 
variability by temperature control, screw design and screw speed and excellent mixing 
ability. A twin-screw (TSC) extruder consists of two co- or counter-rotating screws 
embedded in a barrel, which is equipped with temperature control and a feeding system 
(see Figure IV-1). This conveying system transports the material following the action of 
Archimedes’ infinite screws, to the die, which then forms the material [13], [14]. The 
rotation of the two screws leads to homogenization and transportation of the introduced 
material. Heating of the barrel may contribute to this process. Depending on the screw 
design, co- and counter-rotating screws have different mixing abilities. While co-rotating 
screws can be equipped with conveying and kneading elements and result in an excellent 
mixing, counter-rotating screws only convey the material without interchange of the 
material between the screws [15], [16].  
 
Figure IV-1: Schematic drawing of the barrel of a twin-screw extruder with co-rotating screws. 
Extrusion was many years ago introduced to pharmaceutical industry as a novel 
manufacturing technique for polymeric, fat or starch matrices. Especially hot melt 
extrusion (HME) has become a well-established manufacturing method in this field, due 
to its many advantages like the chance to work solvent-free, low costs and the ability for 
fast and continuous manufacturing [13]. Until today, lipid-based implants containing 
sensitive compounds like proteins were developed and sustained release of the protein 
from these depot systems was shown [17]–[20]. Stability of the protein was shown during 
manufacturing and release.  
By using TSC extrusion for the preparation of the semisolid VPGs, several advantages like 
continuous manufacturing and the possibility to encapsulate sensitive compounds, as well 
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as a fast and solvent-free preparation are used to improve the manufacturing process for 
VPGs. Additionally, Haas et al. achieved a homogeneous mixture of two compounds using 
a TSC extruder [21]. This may facilitate the homogenous mixing of two or more 
phospholipids or even the encapsulation of lipophilic drugs by a simple one-step process, 
without the need for preparation of the mixtures, e.g. by freeze-drying, prior to 
homogenization with the aqueous phase. 
In this chapter, we evaluate TSC extrusion as a novel method for the continuous 
manufacturing of VPGs. 
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IV.2  Material and Methods 
IV.2.1  Materials 
IV.2.1.1  Phospholipids 
Egg lecithin (Lipoid E80, Lipoid GmbH, Ludwigshafen am Rhein, Germany) containing 
80 - 85% phosphatidylcholine (PC), 7 – 9.5% phosphatidylethanolamine, a maximum of 
3% lysophosphatidylcholine and 2 – 3% sphingomyelin was used for the preparation of all 
VPG formulations.  
IV.2.1.2  Proteins for release studies and stability 
Erythropoietin (EPO), Interferon β (IFN β) and a monoclonal antibody of IgG-class was 
used for stability and in vitro release studies. 
EPO is a glycoprotein with a single-chain of 165 amino acids and a molecular weight of 
30.4 kDa  [22], [23].  The protein is primarily produced in the kidney and regulates the 
erythropoiesis by inducing proliferation and differentiation of erythroid progenitor cells 
[23]. In therapy EPO was used for the treatment of kidney diseases and hematological 
disorders. EPO is formulated at a concentration of 2.38 mg/ml in 10 mM phosphate 
buffer, containing 100 mM sodium chloride at a pH of 7.5. 
Interferon β (IFN β) is a non-glycosylated cytokine, produced by eukaryotic cells in 
response to viral infections and other biological inducers [24]. In general, IFNs act antiviral, 
antiproliferative and immunomodulatory. IFN β-1b was the first disease-modifying 
therapy, approved for the treatment of multiple sclerosis [25]. The protein was 
formulated at a concentration of 2 mg/ml in acetate buffer, containing 0.1% (m/v) SDS 
and EDTA at a pH of 5 to 6. 
Further, a monoclonal antibody of the IgG-type was used. The antibody was formulated 
in histidine buffer, containing polysorbate 20 and trehalose with a concentration of 
120 mg/ml. 
IV.2.1.3  Other chemicals and salts 
All reagents and chemicals used within this work were of analytical grade and are listed in 
Table IV-1. 
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Table IV-1: List of chemicals and salts, which were used. 
Substance Abbreviation Supplier 
di-Sodium hydrogen phosphate 
dihydrate 
Na2HPO4 *2H2O Bernd Kraft GmbH, Duisburg, 
Germany 
Fluorescein Isothiocyanate-
Dextran (70 kDa) 
FITC-Dextran Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Potassium chloride KCl AppliChem GmbH & Co. KG, 
Darmstadt, Germany 
Potassium dihydrogen 
phosphate 
KH2PO4 Merck KGaA, Darmstadt, 
Germany 
Sodium chloride NaCl Bernd Kraft GmbH, Duisburg, 
Germany 
IV.2.2  Preparation of VPGs 
VPGs with phospholipid concentrations between 35 and 50% (m/m) were prepared by 
different methods. 20 mM PBS pH 7.4 was used as aqueous phase if not stated otherwise. 
Lipoid E80 was accurately weighted and the desired amount of buffer or drug solution was 
added. Then the mixture was homogenized using one of the methods described in the 
following. Batch sizes were 2 g for magnetic stirring (MAG) and DAC, 3 g for the ThreeTec 
extruder (TTE), 5 to 8 g for the HAAKE extruder (HE) and 300 g for the Leistritz extruder 
(LEI). 
IV.2.2.1  Preparation of VPGs by DAC 
VPGs were homogenized following the method, first described by Massing et al. [5]. The 
weighted components were homogenized using a Speedmixer TM DAC 150 FVZ (Hauschild 
GmbH & Co KG, Hamm, Germany) in a 25 ml cylindrical container (PP15-25ml Hauschild 
GmbH & Ca KG, Hamm, Germany)) at a speed of 3500 rpm for 45 minutes. A custom-made 
cooling system, using compressed air, was used to keep the product temperature below 
30 °C. 
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IV.2.2.2  Preparation of VPGs by magnetic stirring 
The mixture of phospholipid and aqueous phase was homogenized using a magnetic 
stirrer (Variomag Telesystem HP 6, VWR International GmbH, Darmstadt, Germany) in 
combination with an agitator (3.0 cm x 0.5 cm) which covered the whole bottom of the 
container (25 ml PP). Speed was set to 300 rpm.  
IV.2.2.3  Preparation of VPGs by TSC extrusion 
Except otherwise stated, phospholipid and aqueous phase were shortly premixed by three 
minutes of magnetic stirring at 300 rpm. These pre-mixtures were then manually 
introduced to the extruder barrel using a syringe. The effect of different extrusion 
parameters, e.g. rotation speed of the screws, die diameter and length, barrel 
temperature, the usage of a cycling function, lipid concentration and preparation method, 
on the product quality was evaluated. 
Three different extruders were used to prepare VPGs by TSC extrusion. 
IV.2.2.3.1  ZE-5 Mini-Extruder 
The ZE-5 Mini-Extruder (ThreeTec GmbH, Seon, Switzerland) was used for the production 
of small quantities of VPGs. The barrel (L/D ratio 15:1) of the extruder is equipped with 
three heating zones which can be controlled separately and an outlet in 180° angle to the 
screws. The parallel, closely intermeshing, conveying screws (length: 75 mm, diameter: 
5 mm) have a pitch of 5 mm. Dies with different diameter (0.4 mm, 0.8 mm, 1.5 mm, 
1.7 mm and 2.0 mm) and length (2 mm or 20 mm) are used with this extruder. 
 
Figure IV-2: A) ZE-5 Mini-Extruder with barrel and drive unit. B) Detailed image of the barrel with three heating 
elements and the die. C) Parallel, conveying screws used during extrusion with the ZE-5 Mini-Extruder. 
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IV.2.2.3.2  HAAKE MiniLab® Micro Rheology Compounder 
The HAAKE MiniLab® Micro Rheology Compounder (ThermoFisher Scientific, Karlsruhe, 
Germany) was used for a minimum amount of 5 g. The barrel of this twin-screw extruder 
can be heated electrically or cooled using air or water and has a bypass function for 
circulation of the material through the barrel several times. It is equipped with conical, 
co-rotating screws (length: 110 mm; diameter: 10 to 4 mm) and different die diameters 
(0.5 mm, 1.0 mm, 1.5 mm and 2.0 mm) were used. The extruder has a rectangular setup 
of the die to the screws. 
 
Figure IV-3: A) MiniLab® Micro Rheology Compounder. B) Detailed view of the open barrel with the two conical, 
conveying screws and the automatic bypass. 
IV.2.2.3.3  Leistritz Micro 27 GL - 28D 
The Leistritz Micro 27GL - 28D (Leistritz Extrusionstechnik GmbH, Nürnberg, Germany) is 
a large-scale extruder suitable for research-scale and small-scale production. A minimum 
amount of 300 g is needed for this extruder.  
 
 
B 
 
 
Figure IV-4: A) Leistritz Micro 27GL extruder. B) Schematic drawing of the screw design used for the mixing screw. 
The extruder is equipped with a heatable barrel (L/D ratio 28:1) with separately 
controllable sections. The parallel, co-rotating screws (length: 1100 mm, diameter: 
A 
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27 mm) are made of sections which can be modulated to the desired design using 
conveying and mixing elements. Two different screw designs were used. Screw A is geared 
to the design often used for hot-melt extrusion (see Figure IV-4B), while screw B is solely 
equipped with conveying elements. A die with an inner diameter of 1.0 mm was used for 
all experiments. 
IV.2.3  Methods for VPG characterization 
All VPGs were characterized with a series of methods including rheological 
measurements, particle size analysis, microscopy, thermogravimetric analysis and visual 
inspection. Each experiment was performed in triplicates. 
IV.2.3.1  Rheology 
Viscosity was determined with a rotational rheometer (Physica MCR 100, Anton Paar 
GmbH, Ostfildern, Germany) using a plate-plate geometry (PP-25, Anton Paar GmbH, 
Ostfildern, Germany). For each measurement approximately 0.2 g of VPG was used. 
Viscosity was measured with a logarithmic ramp of the shearing rate between 10 and 
100 s-1 and a temperature of 25 °C. For comparison of the different formulation viscosity 
at 32.9 s-1was taken. 
Further, oscillatory measurements were conducted to evaluate stability of the VPGs. To 
this end a PP-08 was used and an amplitude sweep test was performed. Frequency was 
kept constant at 1 Hz and storage modulus (G’) and loss modulus (G’’) was determined at 
a shear stress of 5 to 750 Pa (logarithmic ramp) at a constant temperature of 25 °C. 
IV.2.3.2  Dynamic light scattering 
10 mg of VPG was accurately weighted and dispersed in 1 ml HPW. After vigorous mixing 
for 20 s, using a CapMixTM (3M Deutschland GmbH, Neuss, Germany), the solution was 
further diluted (1:10) and mixed again. Z-Average and PDI of the obtained vesicles were 
determined using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) at a 
temperature of 25 °C. 
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IV.2.3.3  Microscopy 
Microscopic images of VPGs were taken, using a Biozero BZ 8100 microscope (Keyence, 
Osaka, Japan) equipped with a Nikon Plan Apo λ (Mag 10x/NA 0.45, Nikon, Tokio, Japan) 
objective. 
IV.2.4  Encapsulation of proteins into VPGs 
EPO and INF β-1b were prepared for encapsulation by dialysis (Spectra/Por Dialysis 
Membrane, Spectrum Laboratories, Rancho Dominguez, USA) for purification. 
Additionally, up-concentration was necessary using 20 ml Vivaspin tubes (Sartorius 
Stedim Biotech GmbH, Goettingen, Germany). For up-concentration, Vivaspins were 
centrifuged at 8000 rpm at 6 °C until the desired concentration was reached. Protein 
concentration was determined by UV-spectroscopy at 280 nm. Protein preparation steps 
for these two proteins are summarized in Table IV-2. 
Table IV-2: Summary of protein preparation prior to encapsulation into VPGs. 
Protein Original formulation Dialysis buffer Vivaspin 
membrane 
MWCO 
Final 
concentration 
EPO 2.38 mg/ml in 
10 mM Phosphate 
buffer, containing 
100 mM sodium 
chloride 
pH 7.5 
5 mM 
phosphate 
buffer 
pH 7.0 
10 kDa 4.8 mg/ml 
IFN β-1b 1.67 mg/ml in 
acetate buffer pH 5-6 
containing 0.1% SDS 
and EDTA 
10 mM sodium 
acetate buffer 
pH 5.3 
5 kDa 4.3 mg/ml 
Further, mAb was used in its original formulation (120 mg/ml), which was composed of a 
histidine buffer, containing polysorbate 20 and trehalose. 
For VPG preparation a direct encapsulation process was chosen. Phospholipids were 
accurately weighted and the desired amount of protein in buffer was added to the lipids 
before homogenization with one of the above described methods. VPGs containing EPO 
(3 mg/g) or IFN β-1b (2 mg/g) were prepared by DAC, magnetic stirring and extrusion, 
using the ZE-5 Mini-Extruder or the MiniLab® Extruder. VPGs containing mAb (10 mg/g) 
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were prepared by DAC, magnetic stirring and extrusion, using the ZE-5 Mini-Extruder or 
the Leistritz Micro 27GL. 
Additionally, Ovalbumin (40mg/ml in 20mM PBS pH 7.4) was encapsulated into VPGs 
(20mg/g) by DAC using the same protocol as described above. 
IV.2.5  In vitro release studies 
For in vitro release studies VPGs (45% (m/m) phospholipids) containing 2 mg/g FITC-
Dextran (70 kDa) were prepared, using the direct encapsulation process described before 
for proteins. Aqueous phase was composed of 20 mM PBS pH 7.4. 
Additionally, mAb-VPGs (45% (m/m) phospholipids) with a protein-load of 10 mg/g were 
used for release studies. 
Custom-made flow through cells (FTC), made of Teflon, were used for release testing 
following previously described release experiments [26]. Approximately 0.5 g VPG was 
accurately weighted into the donor compartment of the release cells, before cells were 
closed tightly. 20 mM PBS pH 7.4 was pumped through the acceptor compartment using 
a multi-syringe pump and a flow-rate of 0.5 ml/h was used. Temperature was kept 
constant at 37 °C using a water bath (JULABO GmbH, Seelbach, Germany). Samples were 
taken at predetermined time points and quantified as follows. 
IV.2.5.1  Quantification of FITC-Dextran 
FITC-Dextran was quantified using a Cary Eclipse Fluorescence Spectrophotometer 50 
(Agilent Technologies, Santa Clara, CA, USA). Released fractions were centrifuged at 
4000 rpm to remove phospholipids. The clear supernatant was used for quantification. 
492 nm was used as excitation wavelength and emission was determined at 518 nm. 
IV.2.5.2  Quantification of mAb 
Released mAb was quantified by RP-HPLC using a Dionex UltiMateTM 3000 (Thermo Fisher 
Scientific, Waltham, USA) equipped with an autosampler (UltiMateTM WPS-3000SL) and a 
fluorescence detector (UltiMateTM FLD 3400RS). Before sample measurement extraction 
had to be performed. Therefore, all samples were diluted with pure ethanol (1:1) and 
mixed accurately. Then phospholipids were removed by centrifugation and the clear 
supernatant was used for quantification.  
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The same extraction protocol was performed with a mAb solution in buffer (100 µg/ml) 
as well as with mAb-VPG with known mAb-concentration in the sample. An extraction 
efficiency of 104.1% ± 7.0% was reached and no effects of the extraction process on the 
mAb was observed. 
Mobile phase A was composed of 10% (m/m) acetonitrile, 0.1% (m/m) trifluoroacetic acid 
(TFA) and highly purified water (HPW) and mobile phase B was composed of 0.1% (m/m) 
TFA in acetonitrile. A Phenomenex Jupiter C4, 5 μm column (Phenomenex Inc. Torrance, 
USA) was used as solid phase and the oven temperature was set to 50°C. In a simple one 
step gradient 100% mobile phase A was changed to 100% mobile phase B in 20 minutes. 
mAb was detected at a retention time of 15.2 minutes using fluorescence (λexc. = 280 nm; 
λem. = 350 nm). The method was qualified with samples containing defined concentrations 
of mAb, phospholipids and mixtures after extraction. The mAb concentration in each 
sample was calculated using a calibration curve (R2 = 0.9998). 
IV.2.5.3  Phospholipid assay 
Further, erosion of the lipid matrix was determined by quantification of PC in the released 
fractions. To this end, a LabAssayTM Phospholipid (FUJIFILM Wako Chemicals Europe 
GmbH, Neuss, Germany) was used as described before by Weiwei Tian [27]. Further 
qualification of the method was performed separately by Weiwei Liu (Pharm. Technology 
and Biopharmaceutics, LMU Munich).  
Samples were prepared following the supplier’s instructions and measured at a 
wavelength of 600 nm using a FLUOstar Omega plate reader (BMG LABTECH, Ortenberg, 
Germany). In this assay, phospholipids are hydrolyzed by phospholipase D and the 
liberated choline is then oxidized by choline oxidase to betaine [28]. Simultaneously 
hydrogen peroxide is produced which initiates the coupling of 4-aminoantipyrine and 
DAOS (N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt) to a blue 
chromophore by oxidation.  
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Figure IV-5: Schematic reaction of the phosphatidylcholine quantification [29]. 
IV.2.5.4  Optical density 
Optical density (OD) of the released fractions was determined to further characterize the 
erosion behavior. The absorbance for each fraction was measured at 600 nm, using a 
microplate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany). 
IV.2.5.5  Dynamic light scattering 
Dynamic light scattering (DLS) was used to determine the vesicle size of VPGs after dilution 
with buffer. 10 mg VPG was accurately weighed and dispersed in 1 ml highly purified 
water by vigorous mixing using a CapMixTM (3M Espe AG, Seefeld, Germany). The obtained 
dispersion was further diluted (1:10) before measurement with a Zetasizer Nano ZS 
(Malvern Instruments, UK). Z-Average and PDI of the lipid dispersion were determined.  
IV.2.5.6  Thermogravimetric determination of water loss during 
VPG preparation 
To determine if water evaporates during preparation, especially at higher temperatures, 
thermogravimetric analysis was carried out on a Hi-Res TGA 2950 (TA Instruments, New 
Castle, USA). Samples of approximately 20 mg were weighed into aluminum pans and 
placed on a microbalance. Then samples were heated from 27 °C to 250 °C, using a linear 
ramp (10 °C/min) under nitrogen atmosphere. Each measurement was performed twice. 
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IV.2.5.7  Determination of the product temperature 
Product temperature was determined directly at the outlet of the extruder with a data 
logger thermometer HH147U (OMEGA, Deckenpfronn, Germany). The sensor was 
inserted directly into the VPG. 
IV.2.6  Protein stability during extrusion and storage 
IV.2.6.1  Capillary gel-electrophoresis 
300 mg VPG containing EPO or IFN-β was diluted in 1 ml formulation buffer and dispersed 
by vigorous mixing with a CapMixTM. Then samples were centrifuged for 10 minutes at 
10 000 min-1 at 6 °C to remove the lipids. The two proteins were analyzed under non-
reducing conditions using a Protein 230 Kit (Agilent, Santa Clara, CA, USA). Following the 
manufacturers protocol, 4 μl of sample and 2 μl of sample buffer were mixed and 
incubated at 95 °C for 5 minutes for protein denaturation. 84 μl HPW were added and 6 μl 
of this mixture were then pipetted into the sample wells of the protein chip. Further, the 
chip was prepared by loading the gel-dye mix, destaining solution and molecular weight 
marker on the chip. Capillary gel electrophoresis was performed applying an Agilent 2100 
Bioanalyzer system (Agilent, Santa Clara, CA, USA). 
IV.2.6.2  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Aggregation and fragmentation of proteins was monitored by non-reducing denaturating 
SDS-PAGE. Protein containing VPGs were therefore diluted to a final protein 
concentration of 0.05 mg/ml with formulation buffer. Tris-buffer pH 6.8 containing 2% 
SDS and 2% glycerin was added to the samples before denaturation at 90 °C for 10 
minutes. 
Different gels were used for separation and resolution of the proteins. EPO and IFN-β were 
analyzed using NuPAGE® 4-12% Bis-Tris Gels (Novex high performance pre-cast gels, 
Invitrogen, Karlsruhe, Germany) with NuPAGE® MES SDS running buffer (Invitrogen, 
Karlsruhe, Germany). Separation was accomplished with a XCell SureLockTM Mini-Cell 
Electrophoresis System (Novex by Life Technologies, Carlsbad, CA, USA) at a constant 
voltage of 200 V for approximately 25 minutes using a BioRad PowerPac 2000 (Bio-Rad 
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Laboratories, Hercules, CA, USA). Mark12TM Unstained Standard (Invitrogen, Karlsruhe, 
Germany) was used as molecular weight marker. 
mAb was analyzed using a NuPAGE ® 3-8% Tris Acetate Gel (Novex high performance pre-
cast gels, Invitrogen, Karlsruhe, Germany) in combination with NuPAGE® Tris-Acetate SDS 
running buffer (Invitrogen, Karlsruhe, Germany). Again, separation was performed at a 
constant voltage of 200 V for approximately 45 minutes. HiMarkTM Pre-stained Protein 
Standard (Invitrogen, Karlsruhe, Germany) was used as molecular weight marker. 
SilverXPress® Silver Staining Kit (Invitrogen, Karlsruhe, Germany) or SimplyBlueTM 
SafeStain (Invitrogen, Karlsruhe, Germany) was used to visualize the results, following the 
manufacturers’ protocols. 
IV.2.6.3  Fourier transform infrared spectroscopy (FTIR) 
Changes in secondary structure of proteins and peptides may be identified by FTIR 
measurements. To evaluate if this method is applicable for characterization of proteins 
extracted from VPGs, ovalbumin was selected as a cheap model protein. FTIR spectra were 
recorder using a Tensor 27 FTIR Spectrometer (Bruker Optics, Ettlingen, Germany) 
equipped with a BioATR II cell. Prior to measurements the detector was cooled down with 
liquid nitrogen for one hour. 
For analysis an ovalbumin solution in HPW (1 mg/ml), VPG with 45% (m/m) Lipoid E80 and 
VPG with 45% (m/m) Lipoid E80, containing 10 mg/g ovalbumin were chosen. Protein was 
extracted from VPGs prior to measurement with chloroform. To this end, 200 mg VPG was 
diluted with 200 μl HPW and mixed properly. Then 500 μl chloroform was added and the 
mixture was centrifuged for 10 minutes at 6 °C and 15 000 rpm. The supernatant was 
taken and the chloroform extraction was repeated two more times before the 
supernatant was clear and could be used for analysis. As control, ovalbumin solution was 
treated similarly. Spectra were collected from 4 000 to 850 cm-1 wavenumbers and were 
processed by buffer spectra subtraction, followed by vector normalization and 
subsequent determination of the second derivative using the Opus software (Version 6.8, 
Bruker Optics, Ettlingen, Germany).  
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IV.3  Results and Discussion 
TSC extruders are often used in pharmaceutical manufacturing due to their excellent 
mixing ability and process variability. The typical setup with two intermeshing screws 
results in a high degree of conveying with short residence times [13], [15], [16]. During 
development of a suitable process for the preparation of pharmaceutical products like 
VPGs, barrel temperature, screw configuration and speed, feeding system and die design 
are the most crucial parameters and all contribute to the residence time of the material 
in the extruder [13], [30]. In this chapter, the different parameters influencing the product 
quality during extrusion of VPGs were addressed, further in vitro release of the obtained 
VPGs was evaluated and protein stability after extrusion and during storage was 
investigated. 
IV.3.1  Preparation of VPGs by extrusion with repeated 
circulation 
VPGs are characterized by a high inner homogeneity and small vesicular structures. To 
achieve this appearance, shearing forces have to be high enough. On the other side, 
shearing forces should not be too high to prevent drug degradation, especially if proteins 
or peptides are encapsulated into the VPGs. 
Method development for preparation of VPGs by extrusion was started with a batch 
process, using the re-cycling function of the MiniLab® Extruder by HAAKE. The MiniLab® 
Micro Rheology Compounder by HAAKE is an extruder for lab scale up to small industrial 
scale production with conically shaped screws. The option to use a bypass for repeated 
re-cycling of the material through the conveying screws facilitates efficient mixing. At the 
same time operating the extruder in this mode allows only batch production of VPGs up 
to several grams. Still, this setup was used for first extrusion runs to gain first basic 
experience. 
Different parameters like the screw rotation speed, the cycling duration using the bypass 
function, the temperature as well as the die diameter were varied to evaluate the effect 
of these parameters on the mixing quality and homogeneity of the VPGs. Additionally, a 
pneumatic feeder was available for this extruder to introduce the material into the barrel. 
Table IV-3 summarizes the different settings which were used.  
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Table IV-3: Overview of settings changed during method development using the re-cycling function. (Varied 
parameters are emphasized for each experiment in bold letters.) 
 Screw 
rotation 
speed [rpm] 
Cycling 
duration 
[min] 
Temp. 
[°C] 
Die 
diameter 
[mm] 
Pre-mixing 
method 
Lipid 
concentration 
[% (m/m)] 
A 40; 100; 200; 
300 
10 30 2.0 3min 
magnetic 
stirring 
45 
B 300 0; 5; 10; 
20 
30 2.0 3min 
magnetic 
stirring 
45 
C 300 10 10; 20; 
30; 60 
2.0 3min 
magnetic 
stirring 
45 
D 300 10 30 0.5; 1.5; 
2.0 
3min 
magnetic 
stirring 
45 
E 300 10 30 2.0 3min 
magnetic 
stirring; 
unstirred, 
feeder 
45 
F 300 10 30 0.5 3min 
magnetic 
stirring 
35; 40; 45; 50 
In vitro drug release from VPGs and homogeneity, satisfying pharmaceutical 
requirements, are the two most important factors, when the depot systems are 
characterized. In this study, homogeneity is evaluated based on viscosity measurements, 
since viscosity is linked to (i) volume fraction and (ii) particle size distribution. High 
viscosity for the same formulation is often related to small particle sizes with a narrow 
particle size distribution and increased packing density of the vesicles [31]. As a 
consequence of the increased packing density the fluidity of the bilayer membranes in the 
VPG decreases and increased viscosity is observed [31], [32]. 
It was shown before, that particle size is influenced by screw speed during hot melt 
extrusion [33]. When the rotation speed of the extruder screws was varied, an increase in 
VPG viscosity was observed with increasing speed (Figure IV-6A). While VPGs prepared 
with a rotation speed of 40 rpm displayed a viscosity comparable to that of VPGs prepared 
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by magnetic stirring, higher viscosity values (10.3 Pa∙s), which are comparable to the VPGs 
prepared by DAC (10.7 Pa∙s), were reached with the fastest rotation speed of 300 rpm. As 
explained above, high viscosity is correlated to smaller vesicles and a higher packing 
density, thus a high rotation speed results in smaller vesicles, which was confirmed by DLS 
measurements. 
Next, different cycling durations were evaluated. Without cycling of the VPG through the 
bypass and thereby only one single shearing process, a rather low viscosity of the VPG 
(4.4 Pa∙s) and thus larger vesicle sizes were achieved (see Figure IV-6B). When the re-
cycling function was used, viscosity increased to 10 to 12 Pa∙s and only a slight increase in 
viscosity was observed with increasing cycling duration. Thus, cycling duration has only a 
minor effect on viscosity and vesicle size, but cycling itself strongly affects the VPG quality.  
It is known, that increasing the temperature from 10 to 30 °C leads to a softening of the 
phospholipids and thus better processability although at the same time, residence time in 
the barrel may decrease slightly [14], [30]. Using the water and compressed air-cooling 
system of the extruder, even low barrel temperatures can be reached. Low temperatures 
of 10 °C result in VPG with rather low viscosity despite of the re-cycling of ten minutes, 
while high temperatures of 60 °C result in exceptional high viscosity (see Figure IV-6C). It 
is important to note that the temperature of the VPG itself only has little or no effect on 
the viscosity of the final formulation (as described in Chapter III). In conclusion, higher 
temperatures influence the manufacturing process by affecting the phospholipids 
consistency. Thus, at rather low temperatures the mixing is not as efficient and VPGs with 
larger vesicles and therefore low viscosity are produced. On the other hand, high 
temperatures e.g. 60 °C may lead to water loss by evaporation especially when the 
material is re-cycled several times through the heated barrel. At 60 °C water evaporation 
led to a liquid loss of 16.1 ± 1.5% (m/m), which resulted in the exceptional high viscosity 
of 41.7 Pa∙s. Further optimization of the process temperature between 30 and 60 °C is 
needed, to reach good VPG quality without significant water evaporation. 
Another factor which should not be neglected is the preparation of the mixture and the 
feeding into the extruder. In this study, lipids and aqueous phase were accurately 
weighted and either injected into the extruder without further preparation, using a 
syringe (manual injection), or samples were stirred after weighing for a few minutes until 
a pre-mixture was achieved which was then injected into the extruder manually or with a 
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pneumatic feeder (feed rate: 25 min-1). Results show a rather high viscosity for the sample 
introduced without any preparation by manual injection (see Figure IV-6D). A pre-swelling 
of the mixture is urgently needed to achieve a homogenous mixture of the phospholipids 
with the aqueous phase. When both components are introduced to the extruder without 
previous stirring, only partial homogenization is achieved by extrusion and a crude VPG-
mixture with separate water is the result. The obtained VPG has a lower water content in 
the gel and thus higher viscosity is the result (water amount in the VPG determined by 
gravimetric analysis: 33.9% (m/m) instead of 55% (m/m)). 
Preparation of the VPG by stirring, gives the lipid time to swell in presence of the buffer. 
Introduction of this pre-mixture by manual injection or the pneumatic feeder results in 
viscosity comparable or slightly higher than the viscosity reached by the sample prepared 
with DAC. In both cases, water loss was below 4% (m/m) which is considered acceptable 
and may also be the case in VPG prepared by other methods (water loss not determined) 
as a result of weighing and other process steps. Manual injection is not the desired 
strategy for introduction of semisolid mixtures into an extruder. Feeders like the 
pneumatic feeder are more accurate in injection speed and less dead volume occurs. The 
slightly increased viscosity of the sample which was introduced with the pneumatic 
feeder, indicates a better mixing quality with smaller vesicles. Two main types of feeders 
are generally used in industrial scale extrusion: Volumetric feeders with an auger or screw 
conveyor, which discharges material from a hopper with constant volume per time and 
gravimetrical feeders using a volumetric feeder associated with a weighing system to 
control the powder supply [13]. Both may be applicable in future scale up. 
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Figure IV-6: Effects of different parameters during extrusion on viscosity (bar plot) and vesicle size (scatter plot) after 
dilution of the VPG. A) Variation of the screw rotation speed. B) Variation of re-cycling duration. C) Variation of the 
barrel temperature. D) Comparison of different preparation methods. E) Variation of the die diameter. White symbols 
or bars represent samples prepared by extrusion, grey symbols or bars represent samples prepared by magnetic 
stirring and black symbols or bars represent samples prepared by dual asymmetric centrifugation. (Mean ± SD; n=3) 
Further, dies with different inner diameters were used. A decrease in die diameter led to 
increasing viscosity (Figure IV-6E). By using smaller dies, the pressure in the barrel and 
residence time of the material in the barrel is increased during the phase when the 
material is flushed from the barrel after re-cycling. Thus, better mixing may be achieved. 
However, due to the high amount of aqueous phase present in the mixture in comparison 
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to e.g. solid lipid implants, the residence time in the barrel could not be prolonged enough 
by the die only to achieve smaller vesicles. 
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Figure IV-7: Effect of increasing phospholipid concentration on viscosity (bar plot) and vesicle size (scatter plot) after 
dilution of the VPG after preparation by different methods. White symbols or bars represent samples prepared by 
extrusion, grey symbols or bars represent samples prepared by magnetic stirring and black symbols or bars represent 
samples prepared by dual asymmetric centrifugation. (Mean ± SD; n=3) 
Increasing phospholipid concentration of the VPG in general results in increasing viscosity. 
The same effect was observed here for different manufacturing techniques (bar plot in 
Figure IV-7). While viscosity increase was less pronounced for VPG prepared by magnetic 
stirring (from 0.3 ± 0.04 Pa∙s for 35% (m/m) VPG to 8.4 ± 1.0 Pas for 50% (m/m) VPG), a 
stronger increase was observed for samples prepared by DAC (from 1.8 ± 0.06 Pa∙s for 
35% (m/m) VPG to 29.7 ± 1.3 Pa∙s for 50% (m/m) VPG) or extrusion (from 0.6 ± 0.1 Pa∙s 
for 35% (m/m) VPG to 30.1 ± 4.2 Pa∙s for 50% (m/m) VPG).  At the same time, smaller 
vesicles were achieved with increasing concentration of phospholipid when samples were 
prepared by extrusion or DAC, while no difference was observed in vesicle size when 
samples were prepared by magnetic stirring (scatter plot in Figure IV-7). 
IV.3.2  Preparation of VPGs by a continuous extrusion 
process 
IV.3.2.1  HAAKE MiniLab® Rheology Compounder 
On the basis of the re-cycling run, a continuous run was developed. For this again, 
different parameters were changed i.e. screw rotation speed, temperature, die diameter 
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and the preparation method. An overview of the different runs which were conducted can 
be found in Table IV-4. 
Table IV-4: Overview of settings changed during method development with the HAAKE MiniLab® extruder. (Varied 
parameters are emphasized for each experiment in bold letters.) 
 Screw 
rotation 
speed [rpm] 
Temp. 
[°C] 
Die diameter 
[mm] 
Pre-mixing 
method 
Lipid 
concentration 
[% (m/m)] 
A 40; 100; 200; 
300 
30 2.0 3min magnetic 
stirring 
45 
B 300 10; 20; 
30; 60 
2.0 3min magnetic 
stirring 
45 
C 300 30 0.5; 1.5; 2.0  3min magnetic 
stirring 
45 
D 300 30 2.0 3min magnetic 
stirring; feeder 
45 
E 300 30 0.5 3min magnetic 
stirring 
35; 40; 45; 50 
In the continuous run, rotation speed does not affect the viscosity of the VPGs (Figure 
IV-8A). Viscosity was for all four tested settings similar to the viscosity of the VPG prepared 
by magnetic stirring and is significantly lower in comparison to the viscosity of the VPG 
prepared by DAC. A trend to smaller vesicles with increasing rotation speed was observed. 
However, the residence time of the mixture in the barrel is not sufficient to achieve small 
vesicles and thus a high viscosity, even when shearing stress is increased by increasing the 
screw speed. 
Table IV-5: Comparison of product temperature of the VPGs after extrusion and the set barrel temperature during 
continuous run. (n = 3; Mean ± SD) 
Set barrel temperature [°C] Product temperature [°C] 
10 13.3 ± 0.2 
20 20.5 ± 0.2 
30 29.7 ± 0.2 
60 54.3 ± 0.2 
Additionally, the effect of different barrel temperatures on viscosity and vesicle size is 
determined. To evaluate if the efficiency of heat transfer from the barrel to the VPG during 
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extrusion, product temperature was determined directly at the die when the VPGs were 
flushed from the system. 
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Figure IV-8: Effects of different parameters during extrusion on viscosity (bar plot) and vesicle size (scatter plot) after 
dilution of the VPG. A) Variation of the screw rotation speed. B) Variation of the barrel temperature. C) Comparison 
of different preparation methods. D) Variation of the die diameter. E) Comparison of different phospholipid 
concentrations. White symbols or bars represent samples prepared by extrusion, grey symbols or bars represent 
samples prepared by magnetic stirring and black symbols or bars represent samples prepared by dual asymmetric 
centrifugation. (Mean ± SD; n=3) 
Only a high temperature of 60 °C affected the viscosity (Figure IV-8B). For this sample 
water loss was determined by gravimetric analysis and only 1.5% (m/m) water was lost 
during extrusion. In this case, the high temperature above the melting temperature of the 
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phospholipid leads to softening of the material and thus better homogenization of the 
buffer phase with the soft phospholipids. However, a product temperature of 54.3 °C is 
too high for sensitive compounds and thus not suitable for the encapsulation of proteins 
and peptides. As already stated before, further optimization of the process temperature 
between 30 °C and 60 °C is needed. 
Feeding the pre-mixed material into the extruder with the pneumatic feeder (feeding rate: 
25 min-1) led to a slight increase in viscosity of the VPGs in comparison to manual feeding 
with a syringe (Figure IV-8C). However, this trend is not significant and the viscosity of the 
DAC sample is not reached.  
Similarly, the effect of the die diameter is minor. Decreasing the die diameter does not 
increase the viscosity statistically significant (Figure IV-8D). However, a trend to higher 
viscosities with decreasing size of the die is observed. Decreasing the size of the die, 
results in longer residence time in the barrel and thus mixing quality is improved. In a 
continuous extrusion run this effect should be even more pronounced in comparison to 
the re-cycling run, since residence time in the barrel can only be increased by smaller dies 
or slower rotation speed of the barrel. However, in the case of VPGs, the effect of the die 
diameter is minor. The buffer-phospholipid mixture shows better flowability in 
comparison to solid lipids or PLGA, used for implant preparation and thus further decrease 
of the die diameter may be needed to observe a stronger effect on residence time and 
mixing quality. The residence time is only prolonged for few seconds and the pressure in 
the barrel does not rise enough to obtain an improvement of homogenization during VPG 
preparation. 
Increasing phospholipid concentration results in increasing viscosity for the samples 
prepared by extrusion and the other methods as well. Viscosity of the sample prepared 
by extrusion is between the viscosity of the samples prepared by magnetic stirring or DAC 
(Figure IV-8E). Determination of the vesicle size of these samples, confirms again, that 
increasing viscosity is correlated to smaller vesicles. In general, higher lipid concentration 
results in smaller vesicles and lower PDI values for samples prepared by extrusion or DAC. 
Thus, DAC and extrusion, both are able to prepare homogeneous mixtures of 
phospholipids with small vesicle sizes and small PDI, especially for high phospholipid 
concentration.  
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IV.3.2.2  ThreeTec ZE-5 Mini-Extruder  
The ThreeTec extruder can be used for small lab scale production. In this study it was used 
as a smaller alternative to the above described HAAKE MiniLab®. In contrast to the 
MiniLab®, which is equipped with conical screws and has a rectangular setup of the screws 
to the die, the ZE-5 extruder is equipped with parallel screws and a linearly arranged die.  
During method development different settings of the extruder like screw speed, 
temperature and die diameter were varied and the obtained product was characterized. 
Table IV-6 summarizes the parameters which were varied in the different experiments. 
Table IV-6: Overview of settings changed during method development with the ThreeTec ZE-5. (Varied parameters 
are emphasized for each experiment in bold letters.) 
 Screw 
rotation 
speed [rpm] 
Temp. 
[°C] 
Die 
diameter 
[mm] 
Die length 
[mm] 
Pre-mixing 
method 
Lipid 
concentration 
[% (m/m)] 
A 40; 100; 
200; 300 
30 2.0 0.2 3min 
magnetic 
stirring 
45 
B 300 30; 60 2.0 0.2 3min 
magnetic 
stirring 
45 
C 300 30 0.4; 0.8; 
1.5; 1.7; 2.0  
0.2 3min 
magnetic 
stirring 
45 
D 300 30 0.4 0.2 3min 
magnetic 
stirring or 
vortexing 
45 
E 300 30 0.4; 0.8; 
1.7; 2.0 
0.2; 2.0 3min 
magnetic 
stirring 
45 
F 300 30 2.0 0.2 3min 
magnetic 
stirring 
35; 40; 45; 50 
An increase of rotation speed does not influence the viscosity significantly (Figure IV-9A). 
The viscosity of the obtained VPGs was comparable to the viscosity of VPGs prepared by 
magnetic stirring. In comparison to VPG prepared by DAC, both, magnetic stirring and 
extrusion, produced VPG with significantly lower values. 
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In contrast to these findings, a higher barrel temperature during extrusion of 60 °C 
(resulting product temperature: 61.1 ± 0.5 °C), results in slightly increased viscosity of the 
VPG (Figure IV-9B). Still, the viscosity values of VPG prepared by DAC are not reached and 
a decrease of the vesicle size is observed with increasing viscosity but still the values 
ranges in the area of the sample prepared by magnetic stirring. Additionally, higher 
temperatures may lead to degradation of the encapsulated drugs, especially when 
sensitive compounds like proteins are used.  Hence, further optimization of the process 
temperature between barrel temperatures of 30 °C (product temperature 29.7 ± 0.2 °C) 
and 60 °C is urgently needed. 
A short pre-mixing step of few minutes was found to be beneficial regarding the mixing 
quality. Different preparation techniques were tested before the material was introduced 
into the extruder. No differences were observed when the sample was vortexed before 
extrusion in comparison to the sample which was introduced into the extruder after 
simple magnetic stirring (Figure IV-9C).  Thus, magnetic stirring was found adequate, since 
high shearing forces during vortexing could potentially result in instabilities of the 
encapsulated drug. 
With decreasing inner diameter of the die, the viscosity increases slightly, however the 
homogeneity of the VPG, i.e. vesicle sizes and PDI, does not improve (Figure IV-9D). Again, 
this may arise from the comparably high flowability of the buffer-phospholipid mixture, 
resulting in less back-pressure from the die and shorter residence time in the barrel in 
comparison to the extrusion of solids, where the effect of the die is more pronounced. 
The length of the die does not affect the viscosity or vesicle size of the VPG significantly 
(Figure IV-9F).  
An increase in phospholipid concentration of the VPG led to an increase of viscosity 
(Figure IV-9E). However, this increase was less pronounced for VPG prepared by magnetic 
stirring or extrusion in comparison to the sample prepared by DAC. Additionally, the 
deviation of the viscosity of the VPG prepared by magnetic stirring or extrusion of the 
viscosity of the VPG prepared by DAC was more explicit for VPGs with higher phospholipid 
concentration (≥ 45% (m/m)).  
 
 
CHAPTER IV 
92 
40 100 200 300 MAG DAC
0
5
10
15
20
25
V
is
c
o
s
it
y
 [
P
a
∙s
]
Rotation speed [min-1]
A
0
100
200
300
400
Z
-A
v
e
ra
g
e
 [
n
m
]
 
30 60 MAG DAC
0
5
10
15
20
25
V
is
c
o
s
it
y
 [
P
a
∙s
]
Barrel temperature [°C]
B
0
100
200
300
400
Z
-A
v
e
ra
g
e
 [
n
m
]
 
stirred vortexer MAG DAC
0
5
10
15
20
25
V
is
c
o
s
it
y
 [
P
a
∙s
]
Preparation method
0
100
200
300
400
Z
-A
v
e
ra
g
e
 [
n
m
]
C
 
0,4 0,8 1,5 1,7 2,0 MAG DAC
0
5
10
15
20
25
V
is
c
o
s
it
y
 [
P
a
∙s
]
Die diameter [mm]
D
0
100
200
300
400
Z
-A
v
e
ra
g
e
 [
n
m
]
 
35 40 45 50
0
10
20
30
V
is
c
o
s
it
y
 [
P
a
∙s
]
Phospholipid concentration [%]
 TTE
 MAG
 DAC
0
100
200
300
400
Z
-A
v
e
ra
g
e
 [
n
m
]
E
 
0,8 1,7 2,0
0
5
10
15
20
25
V
is
c
o
s
it
y
 [
P
a
∙s
]
Die diameter [mm]
 short die
 long die
F
0
100
200
300
400
Z
-A
v
e
ra
g
e
 [
n
m
]
 
Figure IV-9: Effects of different parameters during extrusion on viscosity (bar plot) and vesicle size (scatter plot) after 
dilution of the VPG. A) Variation of the screw rotation speed. B) Variation of the barrel temperature. C) Comparison 
of different preparation methods. D) Variation of the die diameter. E) Comparison of different phospholipid 
concentrations. F) Comparison of the effect of different die lengths (short: 0.2 mm, long: 2.0 mm). White symbols or 
bars represent samples prepared by extrusion, grey symbols or bars represent samples prepared by magnetic stirring 
and black symbols or bars represent samples prepared by dual asymmetric centrifugation. (Mean ± SD; n=3) 
Characterization of the VPG with DLS showed particle sizes of approximately 300 nm for 
all VPGs with low phospholipid concentration (< 45% (m/m)) regardless of the preparation 
method. However, when the phospholipid concentration was increased (≥ 45% (m/m)) 
differences in particle size were observed between the different preparation methods. 
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VPG prepared by DAC showed smaller particles (approx. 200 nm) after dilution with 
corresponding lower PDI values (< 0.4), while VPG prepared by extrusion or magnetic 
stirring showed vesicle sizes of about 300 nm and a PDI value above 0.5. These findings 
are in good accordance with the above discussed assumption that smaller vesicles, result 
in a higher packing density and thus higher viscosity, while large vesicles result in lower 
viscosity.  
By extrusion and magnetic stirring larger vesicles are produced which results in beneficial 
viscosity regarding the injectability of the VPG. Still, the release behavior has to be tested, 
to confirm if this most important feature of the VPG is maintained despite of the 
differences is particle size and viscosity. 
 
Figure IV-10: Macroscopic appearance of the VPG during preparation process by extrusion. A) Untreated 
phospholipids with methylene blue solution. B) Pre-mixture of phospholipids and methylene blue solution after 3 
minutes of magnetic stirring. C) VPG after a single extrusion process of the pre-mixture. 
Macroscopically, the VPG prepared by a single extrusion process using the Mini-Extruder 
ZE-5 was homogenous without any visible phospholipid particles or separation of the 
aqueous phase from the lipids (Figure IV-10). 
IV.3.2.3  Leistritz Micro 27 GL – 28D 
The Leistritz Micro 27 GL-28D extruder is an instrument used for large-scale production. 
A minimum amount of 300 g of material is needed to process it with this extruder. 
Similarly to the ZE-5 extruder, it is equipped with parallel screws and a linearly arranged 
die. The extruder is equipped with a gravimetrical feeder with integrated conveyance 
screws to transport the material to the inlet. The liquid phase is pumped into the extruder 
separately. However, this feeding system could not be used due to poor flowability and 
stickiness of the phospholipid powder at room temperature. An advantage of the extruder 
is the modular construction of the screws, which enables the design of different screws 
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with mixing, kneading and conveying elements as desired. In this study, a conveying 
screw, composed of only conveying elements, and a mixing screw, composed of mixing 
and kneading elements as well as conveying elements, were used to investigate the 
impact of different screws on the product quality.  
Viscosity and vesicle size were investigated to compare the two screws with each other. 
Additionally, the overall performance of the extruder in comparison to DAC and magnetic 
stirring was evaluated in terms of viscosity and vesicle size.  
By the incorporation of mixing and kneading blocks in the screw design, superior mixing 
quality can be reached [13]. In the present study, the usage of a screw equipped with 
mixing and kneading elements affected the VPG characteristics. Viscosity is higher when 
the mixing screws are used, in contrast to the conveying screws. However, this effect is 
only statistically significant for a phospholipid concentration of 45% (m/m) and no 
differences were observed for a phospholipid concentration of 40% (m/m) (Figure 
IV-11A). Just changing the screws from a conveying only design to a mixing design, does 
not affect size of the vesicles after dilution (Figure IV-11B) and the PDI (Figure IV-11C), 
regardless of the phospholipid concentration. The rotation speed of the screws has two 
effects. First, the residence time of the material in the barrel is affected i.e. short 
residence times for fast rotation speed and second, the high shearing forces can be 
achieved by fast rotation of the screws. The effect of the rotation speed on the VPG 
properties was evaluated with the mixing screws, since these were expected to affect the 
material properties more effectively. When the rotation speed of the screws was 
decreased, no significant changes in viscosity were observed in comparison to the fast 
mixing. However, viscosity was significantly increased for both rotation speeds in 
comparison to the conveying screw. This effect was only statistically significant for a 
phospholipid concentration of 45% (m/m), not for 40% (m/m). Size of the vesicles 
obtained after dilution of the VPG significantly increased with decreasing rotation speed 
when the mixing screws were used. No significant differences regarding PDI were 
observed for all setups and formulations. 
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Figure IV-11: Effect of screw design and speed on A) viscosity, B) Size and C) PDI of VPGs after dilution. VPGs with a 
phospholipid concentration of 40% (m/m) and 45% (m/m) were prepared. 
Independent of the differences which could be shown in viscosity and size measurement 
when using a mixing screw or different rotation speed of the screw, the VPG prepared 
with the large extruder shows extremely low viscosity in comparison to VPG prepared by 
DAC or the two other extruders at a phospholipid concentration of 45% (m/m) (see Figure 
IV-12). The extremely low viscosity is advantageous regarding the injectability of the 
depot system. However, it is questionable if the viscosity and differences in vesicle size 
also influences the release behavior of drug substances from VPG and if the dispersion 
quality and stability meet pharmaceutical standards. 
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Figure IV-12: Comparison of viscosity of VPGs prepared by different methods, with increasing phospholipid 
concentration. 
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IV.3.3  In vitro release of FITC-Dextran from VPG  
VPG with a phospholipid concentration of 45% (m/m), containing 2 mg/g FITC-dextran 
(70 kDa) was prepared with the above described manufacturing methods. For preparation 
by extrusion, the following settings were used: screw rotation speed 300 rpm, barrel 
temperature 30 °C, die diameter depending on the extruder (0.4 mm ThreeTec ZE-5; 
0.5 mm HAAKE MiniLab®). All samples were prepared by a single continuous run. 
Release from VPG is mainly dominated by erosion and matrix-controlled diffusion [34]. 
When looking at the physical parameters of VPGs, release rates depend on viscosity, since 
a high viscosity results in higher resistance of the material to the flow. Thus, a slow release 
was expected for VPGs with high viscosity i.e. the samples prepared by DAC. The viscosity 
of all 45% (m/m) VPG formulations used for FITC-dextran release is shown in Figure 
IV-13A. 
Surprisingly, all samples showed sustained release of FITC-Dextran over 52 days with a 
zero-order like release behavior, independently of the manufacturing method (see Figure 
IV-13B). Still, slight differences were observed for the differently prepared samples. VPG 
prepared by DAC showed the fastest FITC-dextran release, followed by the VPG prepared 
with the ThreeTec ZE-5 and the VPG prepared by magnetic stirring. Slowest release was 
observed for the VPG prepared with the HAAKE MiniLab® extruder. 
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Figure IV-13: Characterization of in vitro release behavior of the model compound FITC-Dextran (70 kDa) from 45% 
(m/m) VPG. VPG were prepared by dual asymmetric centrifugation (DAC), magnetic stirring (MAG) or extrusion using 
the ThreeTec ZE-5 Mini-Extruder (TTE) or the HAAKE MiniLab® Rheology Compounder (HE). A) Viscosity at shearing 
rate of 32.9 s-1. B) Cumulative release of FITC-Dextran (70 kDa). C) Cumulative release of phosphatidylcholine for 
characterization of the erosion process. (Mean ± SD, n=3) 
To characterize the erosion behavior of the differently prepared VPGs, 
phosphatidylcholine concentration was determined in the released fractions and optical 
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density was measured. The released amount of PC is shown in Figure IV-13C. Both release 
profiles together indicate a mixture of diffusion and erosion as the dominating release 
mechanisms. This impression is supported by optical density measurements (data not 
shown). The smaller vesicles sizes obtained in the VPG prepared by DAC may result in 
higher viscosity, however, it also leads to a faster erosion of the VPG matrix and thus faster 
FITC-dextran release. At the same time the larger vesicles obtained after preparation of 
the VPG by extrusion or magnetic stirring, results in slower release rates and thus slower 
FITC-dextran release.  
Further, released fractions were characterized by measuring the vesicle size in the sample 
by DLS. Results show the smallest vesicles for the sample prepared by DAC (≤ 500 nm), 
while larger vesicles (≥ 500 nm) were found in the released fractions of all other samples 
(Figure IV-14A). Additionally, PDI was comparably low for the released fractions from the 
sample prepared by DAC (Figure IV-14B). 
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Figure IV-14: Characterization of the released fractions. A) Vesicle sizes determined in the released fractions. B) PDI 
of the released fractions. Black lines show mean, boxes show 25-75% range and error bars show standard deviation. 
All values were calculated from measured data of all released fractions (n = 25 in triplicates). 
IV.3.4  Stability of proteins in VPG after encapsulation and 
storage 
IV.3.4.1  Determination of structural changes by FTIR spectroscopy 
Conformational changes of the protein are commonly determined by FTIR spectroscopy. 
In general, FTIR spectroscopy is a commonly used technique for the characterization of 
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proteins directly in the matrix in which they are embedded e.g. in PLGA microspheres 
[35]–[37]. The applicability of the system was evaluated using ovalbumin (OVA) as high 
amounts of protein are needed in the VPG to obtain FTIR spectra from the diluted samples 
and OVA is cheap and easily acquired in large quantities. 
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Figure IV-15: FTIR spectra of OVA. A) OVA-solution; B) OVA-VPG (red) and placebo VPG (blue) directly on the ATR-
crystal; C) OVA-VPG after dilution and chloroform extraction (red) and OVA-solution after extraction treatment 
(green). 
The spectrum of a native OVA solution is illustrated in Figure IV-15A and shows two 
defined amid bands (amid I ≈ 1650 cm-1 and amid II ≈ 1550 cm-1) as it was expected. As 
already described by Weiwei Tian for G-CSF, it was not possible to detect OVA in the VPG 
itself (Figure IV-15B), after dilution of the OVA-VPG or extraction of the protein from the 
VPG (Figure IV-15C) [27]. The baseline in the range of the two amid bands is not flat when 
OVA is encapsulated into VPG or extracted from VPG and thus background subtraction is 
not possible [35]. Hence, it is not possible to investigate the secondary structure of the 
protein in the VPG without a suitable extraction method which does not interfere with 
the spectrum of the protein solution. The development of such an extraction method is 
beyond the scope of this thesis and thus not further investigated. 
IV.3.4.2  Evaluation of capillary gel electrophoresis to characterize 
protein aggregation and fragmentation in VPG 
On-chip capillary gel electrophoresis, using an Agilent 2100 Bioanalyzer is a method to 
characterize aggregates or fragments in protein samples. Since the system offers fast and 
reliable separation, as well as sizing and quantification of proteins of a molecular weight 
between 14 kDa and 230 kDa, it is a convenient and preferred analysis method in 
comparison to others. Capillary gel electrophoresis has been successfully used before to 
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investigate protein integrity after encapsulation and during release from solid lipid 
implants [18]. However, in the case of VPGs a complete extraction of the protein from the 
phospholipids is not possible.  
First, EPO-VPG was used for analysis. However, the glycosylated protein did not show any 
signal on the chip. Thus, non-glycosylated IFN β-1b was used to test the system for its 
applicability. IFN β-1b showed reproducible signals in the stock solution and a heat-stress 
control revealed protein aggregation linked to a decrease in the monomeric peak. 
However, when samples from VPGs were analyzed (Figure IV-16), the signal of the internal 
standard protein ladder was disturbed and a broadly tailing peak was found in the area of 
the expected molecular weight of the protein (ca. 20 kDa). To remove some of the lipid 
from the sample, samples were centrifuged and the clear supernatant was reanalyzed. 
However, this procedure resulted in massive protein loss and insufficient lipid removal. 
Still, the signal of the on-chip gel electrophoresis was disturbed by the remaining 
phospholipids (dashed line in Figure IV-16). Thus, it was concluded that on-chip gel 
electrophoresis is not suited for samples from VPGs until a method for complete 
extraction of the phospholipids from the samples is found.  
Additionally, the method is not applicable for large molecules like monoclonal antibodies 
and therefore could not be used to investigate the stability of mAb, since aggregates of 
the antibodies (ca. 150 kDa) are already outside of the detectable range. 
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Figure IV-16: Chromatograph of IFN β-1b incorporated in VPG directly after dilution (solid line) or after centrifugation 
(dotted line). 
IV.3.4.3  Characterization of protein aggregation by SDS-PAGE 
In order to determine if the extrusion process induces protein destabilization e.g. 
aggregation, the VPG was diluted to a final protein concentration of 0.05 mg/ml with 
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buffer directly after preparation and used as sample for SDS-PAGE. VPG containing EPO 
or mAb as model proteins were analyzed by non-reducing SDS-PAGE with subsequent 
silver staining.  
EPO-stock solution showed only a single band arising from monomeric EPO (line 2 in 
Figure IV-17A). Lines 3 to 6 in Figure IV-17A show the signal of EPO encapsulated in VPG 
prepared by the different methods: DAC, magnetic stirring and extrusion with either the 
ThreeTec extruder or HAAKE-extruder. All samples show primarily the single band from 
monomeric EPO, leading to the conclusion that EPO is encapsulated into VPGs mainly in 
its monomeric form. After one month (Figure IV-17B) or three months (Figure IV-17C) of 
storage of the EPO-VPG at 2 to 4 °C, again primarily monomeric EPO was found after 
analyzing the samples by SDS-PAGE. 
 
Figure IV-17: Investigation of EPO stability in VPG evaluated by SDS-PAGE. A) Directly after preparation of the VPG by 
the different techniques. B) After one month storage of the VPG prepared by different techniques. C) After three 
months storage of the VPG. Line 1: Molecular weight standard; Line 2: EPO-stock solution; Line 3: EPO-VPG prepared 
by DAC; Line 4: EPO-VPG prepared by magnetic stirring; Line 5: EPO-VPG prepared with ThreeTec extruder; Line 6: 
EPO-VPG prepared by HAAKE-extruder. 
VPGs prepared with different manufacturing techniques, containing a monoclonal 
antibody of the IgG-type were investigated. As described above, samples were used for 
SDS-PAGE directly after dilution from the VPG with buffer (final protein concentration 
0.05 mg/ml) without further extraction of the phospholipids.  
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Figure IV-18: Investigation of mAb stability in VPG evaluated by SDS-PAGE. A) Directly after preparation of the VPG 
by the different techniques. B) After one month storage of the VPG prepared by different techniques. C) After three 
months storage of the VPG. Line 1: Molecular weight standard; Line 2: mAb-VPG prepared by DAC; Line 3: mAb- VPG 
prepared by magnetic stirring; Line 4: mAb-VPG prepared with ThreeTec extruder; Line 5: mAb-VPG prepared by 
Leistritz-extruder; Line 6: mAb-stock solution. 
Next to the band arising from monomeric mAb at approximately 145 kDa, a few, paler 
bands with lower molecular weight, i.e. representing fragments of the antibody, are 
visible (Figure IV-18A). These fragments are already present in the mAb-bulk material (line 
6) and no further aggregates were found. After all the antibody is stable over one (Figure 
IV-18B) and three months (Figure IV-18C) of storage in the VPG and no new bands for 
aggregates or fragments are found. 
TSC extrusion has been used before to manufacture protein or peptide loaded depot 
formulations e.g. solid lipid implants and its applicability for these sensitive compounds 
has been shown [18], [38]. In 2009, Schulze et al. showed that the manufacturing process 
by TSC extrusion does not induce protein destabilization for interferon α (IFN-α) [17]. In 
the present study the applicability of TSC extrusion for sensitive compound like proteins 
is confirmed. SDS-PAGE shows that encapsulation of EPO or a monoclonal antibody into 
VPG does not lead to significant protein aggregation or fragmentation and the protein is 
stable in the VPG for up to three months after preparation at a storage temperature of 2 
to 4 °C. However, in the present study SDS-PAGE was not qualified with a sample showing 
aggregation or degradation of the two proteins. Thus, even though the method has been 
a standard method for determining protein aggregation and fragmentation over many 
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years, results have to be seen critically and further experiments are needed for a definite 
statement about stability of the two proteins in VPGs. 
IV.3.5  In vitro release of a monoclonal antibody from VPG  
In order to support the data obtained from the in vitro release of FITC-dextran, which was 
used as a cheap and easy to quantify model compound for proteins, the release behavior 
of a monoclonal antibody of the IgG-type was determined. Furthermore, simultaneously 
the release behavior of phosphatidylcholine (PC), which is the major component of Lipoid 
E80, is investigated to characterize the erosion process of the VPG. VPG was either 
prepared with the ZE-5 extruder (TTE) or with the Leistritz extruder (LEI) and compared 
with a sample prepared by the standard method DAC. All three VPG show sustained 
release of mAb and PC (Figure IV-19).  
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Figure IV-19: Characterization of in vitro release behavior of mAb from VPG (large symbols, solid lines, left axis) in 
comparison to cumulative release of phosphatidylcholine (small symbols, dashed lines, right axis). mAb-VPG 
(10 mg/g) was prepared by dual asymmetric centrifugation (DAC) or extrusion using the ThreeTec ZE-5 Mini-Extruder 
(TTE) or the Leistritz Micro 27 GL (LEI). (n=3, Mean ± SD). 
However, differences between the release profiles of mAb are obvious. An almost linear 
release behavior with a release rate of 0.2 to 1.6% per day was observed for mAb released 
from VPG prepared by DAC. In contrast to that, the VPG prepared with the Leistritz 
extruder showed a fast release of mAb (ca. 5% per day) in the first 5 days of the release 
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period, which then slows down (0.1% per day). The VPG prepared with the ZE-5 extruder, 
shows similar release behavior to the sample prepare by DAC in the first 20 days of the 
release period, after which the release rate of the TTE sample decreases and slower 
release is observed (0.1% per day).  
As observed for the mAb release, differences in PC release were observed as well. Almost 
linear PC release is observed for all three VPG. However, PC is released faster from VPG 
prepared by DAC. In this case, mAb release and PC release can be linearly correlated and 
differences between the two curves may be explained by diffusion-controlled release of 
the antibody next to the erosion process and release of the antibody which is adsorbed to 
the surface of the VPG and is released faster and easier. In contrast to that, the correlation 
between erosion of the PC matrix and mAb release is not as obvious for the two samples 
prepared by extrusion. Especially in the beginning of the release test, the LEI sample 
shows fast release of the mAb. This may derive from the loosely attached mAb on the 
surface of the VPG. This fraction is larger in comparison to the TTE and DAC sample. In the 
second phase of the release experiment, mAb release from the LEI and TTE sample is 
slower again and can now be correlated to the slow PC release and thus the erosion of the 
phospholipid matrix.  
In general, in vitro release tests with FITC-dextran and mAb both show slower erosion 
when VPG is prepared by extrusion in comparison to VPG prepared by DAC. This effect 
may derive from the above described differences in vesicle size and homogeneity of the 
VPG. VPG with larger vesicles disintegrate slower despite of the lower viscosity of the VPG 
which may falsely be taken as an indicator for release behavior. Larger vesicles result in a 
higher packing density of the VPG matrix, which may result in slower erosion of the VPG. 
A certain rate of polydispersity of the system may contribute to the increase in packing 
density to some extent and thus reinforce this effect. A similar phenomenon has been 
described before by Tardi et al., who observed a slower release of the hydrophilic marker 
carboxyfluorescein from VPGs which were previously sterilized by autoclaving [39]. The 
steam sterilization process led to an increase in vesicle size e.g. by fusion of the primarily 
small vesicles and as a result of that slower release rates were achieved. Both, the VPG 
prepared by the ZE-5 extruder and by the Leistritz extruder show slower release of the 
phospholipids.  
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In the light of these findings it is still surprising that VPG prepared with the Leistritz 
extruder, with a tendency to even larger vesicles and increased polydispersity, releases its 
content faster in the first few days in comparison to the VPG prepared with the ZE-5 
extruder. This difference can be explained by differences in the encapsulation of the 
antibody. True encapsulation of the antibody into the vesicles of the VPG results in longer 
release times (VPG prepared by ZE-5 extruder and DAC), while loosely adsorbed antibody 
to the outer surface of the VPG is released faster. A mixture of both encapsulation types 
may be present in VPG independently of the preparation method. However, the fraction 
of loosely adsorbed mAb in comparison to truly encapsulated mAb may change, 
depending on the homogenization quality. VPG prepared by the Leistritz extruder releases 
the mAb faster in the first few days since it is not truly encapsulated and thus is released 
with a faster off-rate. This theory is also supported by the data obtained from the 
phospholipid assay. The difference in encapsulation may be influenced by slight 
differences in setup of the extruders. Due to its large size, the Leistritz extruder has larger 
slits between the two intermeshing screws, which may result in lower mixing quality and 
thus less true mAb encapsulation into the vesicles.  
After all, in the context of erosion driven release, one should also take into account the 
release model which was used. Flow-through cells (which are used here) are the standard 
release systems for VPG. Their shape and setup allow their application with comparable 
volumes as they might be used for depot systems like VPG in vivo. The defined exposed 
surface of the VPG to the acceptor medium maintains the same throughout the release 
test, allowing a good comparability between data. A constant flow models the situation 
in vivo to some extent. Additionally, no membrane is needed to separate the VPG from 
the acceptor medium, thus membrane influence on the release behavior is out of the 
question. However, the absence of a membrane also facilitates the erosion of larger VPG 
fragments and particles which might be restricted in the subcutaneous tissue in vivo. This 
has to be considered when looking at the in vitro release. Vollrath et al. showed a 
sustained release of a mAb over more than 100 days in vitro from solid lipid implants (SLI) 
[18]. Similar in vitro release time for another mAb from SLI was observed by Sax [20]. Thus, 
a sustained release of mAb of more than 50 days but below 100 days from VPG as semi-
solid depot system, is within expectations, showing that the release model itself produces 
data in a realistic range. 
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IV.3.6  Storage stability of VPG prepared by different 
manufacturing processes 
In order to assess the physical stability of the VPG over three months, VPG with a 
phospholipid concentration of 40% (m/m) prepared by DAC, magnetic stirring and TSC 
extrusion with the different extruders were stored at 2 to 4 °C and 25 °C for three months. 
The process parameters used for preparation of the VPGs by TSC extrusion are 
summarized in Table IV-7.  
Samples were characterized by oscillatory rheologic measurements, DLS, microscopy and 
macroscopic appearance directly after preparation. Subsequently, samples were taken at 
predetermined time points and analyzed. 
Table IV-7: Overview on process parameters during preparation by extrusion. 
Extruder Rotation 
speed [rpm] 
Temperature 
[°C] 
Screw Die diameter 
[mm] 
ThreeTec Mini-
Extruder ZE-5 
300 30 Conveying, 
parallel 
0.4 
HAAKE MiniLab® 
Micro Rheology 
Compounder 
300 30 Conveying, 
conical 
0.5 
Leistritz Micro 27 GL 300 30 Mixing, 
parallel 
1.0 
Oscillatory rheologic measurements can not only be used to characterize multiphase 
viscoelastic systems and their internal structure, but also to predict the stability of these 
systems [40]. Typically, storage modulus (G’) and loss modulus (G’’) are determined 
directly by the rheometer. While G’’ represents the viscous behavior of a sample, G’ is a 
measure for the elastic behavior of the material. At the flow point or cross over point (G’ 
= G’’) the gel character of a systems turns into liquid character [41]. The flow point 
correlates to the strength of inter-particle interaction in the three-dimensional network 
of a semisolid formulation [40]. A high value indicates a higher amount of contact surfaces 
and more dense packing between the particles. Further, the difference between G’ and 
G’’ at the linear viscoelastic (LVE) region can be correlated to stability [42]. In the course 
of this study, an amplitude sweep was conducted for each sample and the difference 
between G’ and G’’ as well as the flow point were determined. Figure IV-20 shows 
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representative amplitude sweeps for each VPG (40% (m/m) Lipoid E80 in 20mM PBS pH 
7.4) prepared by different manufacturing methods. 
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Figure IV-20: Amplitude sweep for VPGs (40% (m/m) Lipoid E80, 20mM PBS pH 7.4) prepared by A) DAC, B) HAAKE 
MiniLab® extruder (HE), C) Leistritz extruder (LEI), D) ThreeTec ZE-5 Mini-Extruder (TTE) or E) magnetic stirring (MAG). 
LVE-region is marked in grey. 
The samples prepared by DAC, magnetic stirring, the ThreeTec ZE-5 Mini-Extruder or the 
HAAKE MiniLab® extruder show a larger storage modulus than loss modulus in the 
 
 
PREPARATION OF VESICULAR PHOSPHOLIPID GELS BY TWIN-SCREW EXTRUSION 
107 
beginning of the measurement. The elastic portion of the viscoelastic behavior is larger in 
this case. This is caused by a tight inner structure of the gel. Links inside the material, e.g. 
chemical bonds or physical-chemical interactions lead to inter-particle interactions and a 
highly ordered structure. Only the sample prepared by the Leistritz extruder shows a 
larger loss modulus than storage modulus from the beginning. In this case the sample 
shows the behavior of a liquid rather than a gel. Additionally, the VPG prepared by DAC 
shows the highest rigidity (high G’) from the beginning, thus it has the thickest consistency 
in comparison to all other samples. 
Table IV-8 summarizes the rheologic parameters. The linearity limit of the LVE-region, 
described by the yield point, indicates the maximum deformation tolerated by the sample 
[40], [43]. The yield point was estimated based on the graphs in Figure IV-20 as the last τ-
value of the LVE-region at which G’ is beginning to show a noticeable deviation from the 
previously constant values. As expected, the sample prepared by DAC exhibits the highest 
yield point.  
Table IV-8: Parameters derived from rheologic measurements. 
Sample Yield point 
τy [Pa] 
Flow point 
τf [Pa] 
G’-G’’ in LVE-region [Pa] Viscosity at γ = 
32.9 s-1 [Pa∙s] 
DAC 167.4 ± 28.9 179.2 ± 22.9 459.8 ± 196.2 1.9 ± 0.1 
HE 100.1 ± 16.1 111.4 ± 21.1 155.4 ± 108.7 1.2 ± 0.2 
LEI 76.0 ± 11.1 - -15.1 ± 13.5 0.8 ± 0.1 
TTE 106.2 ± 14.5 113.3 ± 14.8 261.9 ± 156.8 0.9 ± 0.1 
MAG 93.9 ± 24.1 105.1 ± 25.6 119.2 ± 18.2  0.9 ± 0.1 
Mechanical stability of the DAC sample is higher in comparison to the others. The LEI 
sample is characterized by the lowest limit value for the LVE-region. Furthermore, for this 
sample no flow point could be determined since G’ is below G’’ from the beginning. For 
all other samples the flow transition index (τf/ τy) approaches the value 1, indicating a 
higher tendency of the samples for brittle fracturing [41], [43]. VPGs produced by the 
ThreeTec ZE-5 and HAAKE MiniLab® show increased stability in comparison to the sample 
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prepared with the Leistritz extruder. The difference between magnitude of storage 
modulus and loss modulus in the LVE-region is another stability indicating factor. This 
difference is the highest for samples prepared by DAC, while the samples prepared either 
by magnetic stirring or by extrusion using the ThreeTec ZE-5 or HAAKE MiniLab® extruder 
showed significantly lower values. Thus, the sample prepared by DAC is the most stable 
system, followed by the samples prepared by the two smaller extruders (TTE and HE) and 
the sample prepared by magnetic stirring. Preparation of VPG with the Leistritz extruder 
results in a product with rather liquid properties in comparison. In this case, the mixture 
of phospholipid and buffer is unstable and phase separation may occur.  
In the light of the in vitro release study presented above, where sustained release of a 
mAb was shown from samples prepared with the Leistritz extruder, the phospholipid 
concentration has to be taken into account. In the release study VPG with 45% (m/m) 
phospholipids was tested, while storage stability was determined with VPG with a 
phospholipid concentration of 40% (m/m). A higher concentration of phospholipid may 
lead to a better mixing quality, VPG with more viscous character and an increased rate of 
true encapsulation. Additionally, the encapsulation of a protein e.g. a monoclonal 
antibody may affect the viscoelastic behavior of the VPG. In this context, Neuhofer 
observed an increase in VPG viscosity when proteins like IFN-β were encapsulated [44]. 
He observed a change in viscoelastic behavior from plastic to rheopectic behavior after 
incorporation of the protein. However, the effect of mAb encapsulation on VPG properties 
and stability of the VPG was not within the scope of this work and should be investigated 
in the future. 
Next to the oscillatory tests performed directly after preparation, rotational experiments 
were conducted at each predetermined time point. Viscosity of the sample prepared by 
DAC is the highest followed by the HE, TTE and MAG, while the sample prepared with the 
Leistritz extruder shows the lowest viscosity (Figure IV-21A and Figure IV-21B). 
Furthermore, viscosity of the samples increases slightly during storage. This trend is 
observable for both storage temperatures. 
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Figure IV-21: Characterization of VPG composed of 40% (m/m) Lipoid E80 and 20mM PBS pH 7.4 over storage time of 
three months. VPGs are prepared by dual asymmetric centrifugation (DAC), magnetic stirring (MAG), or extrusion 
with the ThreeTec ZE-5 (TTE), HAAKE MiniLab® (HE) or Leistritz extruder (LEI). Viscosity of the samples stored at A) 
4°C or B) 25 °C is compared at 32.9 s-1. Z-Average of the vesicles obtained after dilution of the VPG after storage at C) 
4°C or D) 25 °C. 
DLS-measurements reveal that neither size (Figure IV-21C and Figure IV-21D) nor PDI (data 
not shown) of the vesicles obtained after dilution, change significantly over a storage 
period of three months independently of the storage temperature. Slight differences 
between the samples prepared by different methods were observed i.e. smaller vesicles 
for VPG prepared by DAC and large vesicle in the LEI sample.  
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Macroscopically, the overall appearance of a homogenous VPG structure was maintained 
over three months, with the exception of the LEI sample which showed starting phase 
separation (Figure IV-22). Additionally, after the complete storage time some samples 
(especially when stored at 25 °C) were slightly darker in color and smelled 
characteristically. Long-term storage of lipid-based systems may lead to chemical 
degradation of the phospholipids, resulting in characteristic odor and color.  
 
Figure IV-22: Macroscopic appearance of VPG 40% (m/m) prepared with Leistritz extruder. A) VPG directly after 
preparation is homogenous in appearance without visible phase separation. B) VPG after three months of storage at 
25 °C shows phase separation. Red arrow indicates separated aqueous phase in the VPG. 
When looking at the microscopic appearance of the VPG, differences between the sample 
prepared by DAC and the other methods were more pronounced after storage. All 
samples show a homogeneous appearance with finely dispersed vesicles directly after 
preparation of the VPG. After three months of storage the sample prepared by DAC still 
shows small vesicles and a homogenous structure, while in all other samples larger 
vesicles and inhomogeneity is observed with different extent depending on the 
preparation method. The sample prepared with the ThreeTec ZE-5 Mini-Extruder and the 
sample prepared with the HAAKE MiniLab®, as well as the sample prepared by magnetic 
stirring show slightly larger vesicles and a minor increase of polydispersity.  The sample 
prepared with the Leistritz extruder shows larger vesicles and a very polydisperse 
appearance after three months of storage. 
  
A B 
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Figure IV-23: Representative microscopic images of the differently prepared VPGs directly after preparation (left) and 
after three months of storage at 2-4 °C (right). Pictures are taken with 100-fold magnification. 
Above described and explained data, shows that VPG prepared with the large Leistritz 
extruder is not stable enough for long-term storage. So far, this preparation method 
results in a VPG with a rather liquid appearance, low viscosity and large vesicles. Phase 
separation of the VPG occurs after storage for few months.  
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At the same time, both of the smaller extruders produce VPG with smaller vesicle sizes, 
which are more stable over a longer storage period even if the physical stability of the 
VPG prepared by DAC cannot be reached. After all, there are different optimization 
strategies how to address the challenge to achieve a more stable VPG by extrusion even 
with large extruders. By smaller dies, pressure in the barrel is increased and additionally 
a slower screw speed results in prolonged residence time of the material in the barrel, 
thus potentially resulting in an improved mixing quality. Other options would be to 
optimize the extrusion temperature. By softening the phospholipids at moderate but 
higher temperatures (30 – 50 °C), homogenization may be improved and the ratio of true 
encapsulation may be increased. Further, optimization of the screw design may lead to 
the desired effect. VPG used for stability testing was prepared by screws with conveying 
elements only. As already seen before (see Figure IV-11A), the incorporation of mixing 
and kneading elements into the screw design can increase viscosity and thus seems to 
have an effect on the viscoelastic behavior of the VPG. 
As already mentioned above chemical instabilities have to be considered, additional to 
physical instabilities, which were investigated here. Phospholipids are mainly sensitive to 
hydrolysis and peroxidation which may both result e.g. in differences in membrane 
permeability and thus may affect the release from lipid-based drug carriers [45]. Especially 
the moving metal parts in a TSC extruder i.e. the screws, may cause metal abrasion, which 
may catalyze chemical reactions. Again, there are different options to overcome these 
difficulties. For once, antioxidants or metal chelators can be added to the formulation to 
prevent lipid oxidation. Further, extruders made from ceramic parts or coated surfaces 
could be used to prevent metal abrasion itself. However, the investigation of metal 
abrasion during the process and chemical instabilities was not within the scope of the 
present study. 
After all, preparation of VPG by extrusion is a promising new manufacturing technique 
with many advantages, resulting in VPG with superior sustained release properties but 
lower viscosity than DAC. Still, the process has to be further optimized and challenges as 
up-scaling and metal abrasion have to be overcome. 
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IV.4  Conclusion 
The established manufacturing techniques for VPG do have several disadvantages like 
long manufacturing durations and high and uncontrollable shearing forces. Additionally, 
DAC and HPH, as well as magnetic stirring, can only be used in batch to batch production 
and have limitations in up- and down-scaling.  
In this chapter a novel manufacturing technique, TSC extrusion of VPGs, was successfully 
developed and evaluated.  Homogenization of phospholipids and aqueous solution by 
extrusion, resulted in macroscopically homogenous VPGs with low viscosity but larger 
vesicles compared to VPG prepared by DAC. Low viscosity, resulting in easier injectability, 
is beneficial for later in vivo applications. However, the effect of larger vesicles in vivo is 
difficult to predict but differences in circulation half-life of the vesicles are to be expected 
[46]. 
Within our study, the effect of different extruders, screw speed and design, die diameter 
and length, as well as barrel temperature were evaluated. Die design, screw speed and 
screw design affect the product quality majorly. Fast rotation speed, results in a better 
mixing quality with smaller vesicles. Additionally, a screw equipped with kneading 
elements improved product quality in comparison to a screw with conveying elements 
only. When a die with smaller diameter was used, smaller vesicle sizes were achieved, 
whereas the die length did not influence the product quality significantly. 
Release experiments showed sustained release of FITC-dextran and a monoclonal 
antibody from VPG after preparation by extrusion. Despite the low viscosity, release rates 
of the VPG prepared by extrusion were surprisingly slower in comparison to those of the 
VPGs prepared by DAC. It was hypothesized that rather vesicle size than viscosity is an 
indicator for the release behavior of VPG by erosion processes. 
Furthermore, it was shown that proteins (mAb and EPO) show similar stability during 
preparation by extrusion compared to DAC. After 3 months of storage, no aggregation or 
fragmentation of the protein was observed in SDS-PAGE. 
Finally, the physical stability of the VPG itself was evaluated over a storage period of 3 
months. Oscillatory rheologic measurements were conducted to predict the gel stability. 
Amplitude sweeps yielded superior stability of the VPG prepared by DAC, followed by the 
VPG prepared with the ThreeTec ZE-5 Mini-Extruder and the HAAKE MiniLab® Rheology 
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Compounder. Despite the lower viscosity and larger vesicles in VPGs prepared by 
extrusion, the VPG was macroscopically and microscopically stable when prepared with 
the ThreeTec ZE-5 Mini-Extruder or the HAAKE MiniLab® Rheology Compounder. Vesicles 
size and viscosity did not change significantly during storage. However, VPG prepared with 
the large Leistritz Micro 27 GL showed a rather liquid appearance in rheologic 
measurements and low stability in macroscopic and microscopic analysis. 
In conclusion, extrusion is a process which is well suited for the preparation of VPG 
encapsulating sensible compounds like proteins. However, further optimization of the 
method is needed. First, up-scalability has to be improved. By applying higher pressure, 
longer residence times in the barrel and using different screw design, VPG quality may be 
improved in larger extruders, resulting in a more stable VPG. After all, a compromise 
between easiness of the method and good up-scalability, quality and storage stability of 
the VPG, as well as sustained release behavior has to be found. 
Furthermore, the method may also be applicable to the direct encapsulation of lipophilic 
compounds into VPG without the use of organic solvents.  It is known that co-extrusion of 
two lipophilic substances results in a homogenous mixture [21]. The transfer of this 
technique to the preparation of VPGs encapsulating lipophilic drugs is thinkable and has 
to be investigated further. 
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Chapter V  
INTERACTIONS BETWEEN PROTEINS AND 
PHOSPHOLIPIDS 
 
Parts of this chapter have been submitted or are intended for publication: 
• Section V.1  : M. Breitsamer, A. Stulz, H. Heerklotz, G. Winter; Do interactions 
between Protein and Phospholipids influence the release behavior from lipid-based 
exenatide depot systems?  
Submitted for publication to European Journal of Pharmaceutics and 
Biopharmaceutics in January 2019. 
• Parts of section V.2  : A. Stulz, M. Breitsamer, G. Winter, H. Heerklotz; Different 
aspects of a complex protein-lipid binding equilibrium as seen by ITC, Fluorescence, 
and MST. 
Manuscript in preparation. 
To maintain the train of reading throughout the chapter, references of the published 
manuscript and further studies are combined in section V.4   . 
This work was conducted in close cooperation with Albert-Ludwigs-Universität Freiburg. 
The personal contribution covers the preparation and characterization of exenatide-VPG, 
including in vitro release behavior, as well as the implementation and evaluation of steady 
state fluorescence and microscale thermophoresis measurements, including written parts 
of these experiments. Isothermal titration calorimetric measurements were conducted 
together with Anja Stulz. Prof. Dr. Heiko Heerklotz and Anja Stulz evaluated and 
interpreted the ITC data. 
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V.1  DO INTERACTIONS BETWEEN PROTEIN AND 
PHOSPHOLIPIDS INFLUENCE THE RELEASE BEHAVIOR FROM 
LIPID-BASED EXENATIDE DEPOT SYSTEMS? 
V.1.1  Abstract 
The release mechanism for proteins and peptides from vesicular phospholipid gels (VPGs) 
is very complex. Drug release proceeds via a combination of erosion of the gel and 
diffusion of the drug out of it. This diffusion can be retarded by a slow permeation of the 
drug across the lipid bilayers in the gel as well as by its direct binding or adsorption to the 
lipid bilayers. Finally, the viscosity and homogeneity of the formulation may affect the 
release behavior. So far, a direct correlation between one of these parameters and the 
release kinetics is not possible. 
In the present study, we aimed to investigate the contribution of drug-membrane 
interactions to the release kinetics of exenatide from differently composed VPGs (POPC, 
POPG and mixtures of both). To this end, in vitro release of exenatide as well as in vitro 
release of the phospholipids was monitored. Binding affinities were determined by 
microscale thermophoresis (MST). 
The sustained release behavior of exenatide could not simply be correlated to high 
viscosity of the VPG formulation. Release of exenatide from VPGs of anionic membranes 
containing POPG proceeded with a half-life of the order of 5 days and it seems to be 
controlled by the erosion of the gel. Its rate is unaffected by the initial pH inside the gel, 
independently of the strong impact of pH on exenatide binding to the membrane. At 
pH 4.5, exenatide is cationic and binds to membranes containing anionic POPG with a high 
affinity (Kd  10-30 µM).  
No high affinity membrane binding of exenatide is detected in this at pH 7.4, where 
exenatide is anionic, and to zwitterionic membranes composed of POPC. Exenatide 
release from the latter has a significantly longer half-life of 30 to 55 days. That means, 
these VPGs are much more resistant to erosion and show a very slow diffusional release. 
In this case, diffusion should be slowed down by the barrier function of the membranes 
rather than membrane affinity.  
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Figure V-1: Graphical abstract. 
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V.1.2  Introduction  
Vesicular phospholipid gels (VPGs) are semisolid drug formulations which are composed 
of phospholipids and a simple aqueous phase only [1], [2]. They are prepared by elegant 
one step manufacturing techniques like high pressure homogenization (HPH) or dual 
asymmetric centrifugation (DAC). Their capability to release drugs and especially proteins 
and peptides with a slow release rate, combined with their easy and cheap manufacturing 
and their high biocompatibility makes them very promising drug delivery systems [3]–[6]. 
Next to their application for large molecules like proteins, they have also been used for 
the sustained delivery of small molecules [7]–[12]. The administration via needle-free 
injection facilitates the versatile application of VPGs [13]. 
The release behavior of VPG is dominated by a combination of an erosion controlled and 
an diffusion controlled process [5]. Tardi et al. found that these two processes occur at 
the same time. VPGs with up to 30% (m/m) phospholipids disintegrate fast. VPGs with 35 
to 40% (m/m) phospholipids show erosion controlled release behavior and VPGs with a 
phospholipid concentration above 45% (m/m) show rather diffusion controlled release 
kinetics. However, there seems to be more behind this release process. Depending on the 
encapsulated drug substance and the phospholipid composition, changes in release 
behavior have been observed [14]–[16]. Possible interactions between the encapsulated 
protein or peptide and the phospholipids may be responsible for the different sustained 
release profiles.  
In this context, Neuhofer et al. addressed the interactions between interferon β-1b and 
the triglycerides H12 and D118, but also different phospholipids [14]. Additionally, he 
found that the extraction of native interferon β-1b from VPG was not possible and 
concluded that interactions were responsible for this phenomenon. PEGylation reduced 
the interaction effects but could not completely avoid it. He also found that the presence 
of a protein drug affected the mechanical properties of the VPG matrix and concluded 
that interactions may be responsible. To this end, he used a Langmuir film balance and a 
quartz crystal microbalance (QCM) to investigate different models like liposomes or 
monolayers. But no consistent correlation between the different methods and no 
prediction of the release behavior could be established. 
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Even et al. investigated the interactions of peptides with different charge and 
hydrophobicity with lipids including D114, soy lecithin, and cholesterol by adsorption 
studies [16]. It was shown that the size, hydrophobicity, or charge of encapsulated 
proteins or peptides are not alone responsible for the sustained release from VPGs. The 
release of a small peptide from VPGs was, against all expectations, slow and incomplete, 
whereas a much bigger protein was released fast in comparison. Additionally, no direct 
relationship between hydrophobicity of the molecule and release rate could be identified.  
Further, it was shown that the high dispersity of VPG produced by DAC or HPH, including 
small vesicles and multi-lamellar structures,  is not necessarily needed to obtain a 
sustained release behavior [17]. Zhang et al. showed in vitro and in vivo sustained release 
of exenatide from VPGs after preparation by magnetic stirring. 
These indications in literature brought us to the hypothesis that sustained release of 
proteins or peptides from lipid-based depots could be controlled by interactions between 
the molecules, more specifically by a binding of the peptides to the phospholipid layers. 
The possibility to tune the release behavior by using these interactions motivated us to 
further investigate and characterize the interactions between proteins and phospholipids 
in this context.  
Interactions between proteins and phospholipids have been studied extensively in the 
past with various methods (SPR, MST, ITC, Flotation assays etc.) [18]. However in such 
studies, the focus was mainly on interactions of proteins with cellular membranes [18]–
[21]. Only few studies on the release behavior of lipid-based depots have been conducted 
so far and in many cases, the focus was on solid lipid implants (SLI) as drug delivery system 
and triglycerides as their main components [14], [16], [22]. 
In this study, we aimed to investigate the interactions between exenatide, a 
pharmaceutically highly relevant, relatively small peptide with a defined secondary 
structure and phospholipids with microscale thermophoresis (MST) measurements and 
correlate our findings to the release behavior from VPGs.  
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V.1.3  Material and Methods 
V.1.3.1  Material  
Exenatide acetate was purchased from Chemos GmbH&Co.KG (Regenstauf, Germany) and 
purified by dialysis (MWCO 5 kDa) into highly purified water (HPW, Purelab Plus, USF Elga, 
Germany) before freeze-drying of the solution for storage. An exenatide stock solution 
was freshly prepared in 50 mM sodium acetate buffer pH 4.5 or 20 mM phosphate 
buffered saline (PBS) pH 7.4 with a concentration of 200 μM. Dilutions thereof were used 
for interaction measurements. 
All phospholipids (POPC, POPG) were purchased from Lipoid GmbH (Ludwigshafen am 
Rhein, Germany). 
V.1.3.2  Exenatide characterization  
A Zetasizer nano ZS (Malvern Instruments, UK) was used for determination of the 
zetapotential of exenatide. Zetapotential of an exenatide solution with a concentration of 
5 mg/ml was measured in HPW after adjustment of the pH value with 1 M hydrochloric 
acid or 1 M sodium hydroxide.  
FTIR measurements were used to investigate the secondary structure of exenatide with 
changing pH value. A Tensor 27 spectrometer (Bruker Optics, Ettlingen, Germany) using a 
BioATR cell II (Harrick, New York, USA) was used to record FTIR spectra. For each 
measurement, 30 µl sample with an exenatide concentration of 5 mg/ml was pipetted 
into the cell. Measurements were controlled using OPUS 7.5 and transmission spectra 
were truncated from 1350 cm-1 to 1750 cm-1. Further spectra were edited by vector 
normalization and second derivatives were calculated using a 17-point smoothing 
function. 
V.1.3.3  Preparation of vesicular phospholipid gel  
VPGs with a phospholipid concentration of 40% (m/m) were prepared by dual asymmetric 
centrifugation (SpeedmixerTM DAC 150 FVZ, Hauschild GmbH & Co KG, Hamm, Germany) 
as described previously [3], [6], [13]. Four different phospholipid combinations were 
prepared: POPC and POPG were used as sole phospholipids; additionally, mixtures of 
POPC and POPG in a ratio of 7:3 and 1:1 were prepared. Phospholipids were accurately 
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weighed in the required amounts before exenatide solution was added until a final 
exenatide concentration of 0.5 mg/g was reached in the VPG. 
V.1.3.4  VPG characterization  
Rheology measurements were performed to characterize the VPG formulations [3]. The 
viscosity of the VPG at a shearing rate of 32.9 s-1 was determined by a rotational 
rheometer (Physica MCR 100, Anton Paar GmbH, Ostfildern, Germany) with a plate-plate 
geometry. All measurements were performed at 25 °C and the shear rate was set to 10-
100 s-1. Approximately 0.2 g VPG was used per measurement. 
V.1.3.5  In vitro release of exenatide from VPG 
For the in vitro release studies, 200 mg of VPG were carefully overlaid with 1 ml 20 mM 
PBS buffer pH 7.4 in 2 ml centrifugation tubes. Then, all samples were incubated at 37 °C 
and 30 rpm in a vertical incubation shaker (Certomat incubation Shaker, Sartorius AG, 
Germany) in upright position. Release experiments were carried out by complete buffer 
exchange [13], [16].  
The concentration of exenatide was determined using a reverse phase high pressure liquid 
chromatography (RP-HPLC). A Jupiter 5 µm C18 300A column (Phenomenex, USA) was 
used for quantification of the peptide. Mobile phase A was composed of 10% (m/m) 
acetonitrile, HPW and 0.1% (m/m) TFA and mobile phase B was composed of acetonitrile 
and 0.1% (m/m) TFA. Table V-3 shows the multi-step-gradient which was used for the 
quantification of exenatide with a flow of 0.5 ml/min. Column temperature was set to 55 
°C and the retention time of exenatide was 12 minutes. Exenatide was extracted by 1:1 
dilution with ethanol, heating for five minutes at 60 °C, followed by 20 minutes of cooling 
at 2-4 °C and five minutes centrifugation. The resulting supernatant was taken for 
quantification. 
V.1.3.6  Characterization of VPG erosion during in vitro release 
The erosion behavior of the differently composed VPGs was characterized in parallel to 
the in vitro release of exenatide. One way of quantifying erosion was in terms of sample 
turbidity which, in turn, was expressed on the basis of optical density.  
All samples were diluted as needed (1:4 or 1:10) with highly purified water and the 
absorbance at a wavelength of 600 nm was determined using a FLUOstar Omega plate 
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reader (BMG LABTECH, Ortenberg, Germany). 300 μl of diluted sample were pipetted into 
U-bottom 96-well-plates (MICROLON® 200, greiner bio-one, Frickenhausen, Germany). 
Absorbance values after dilution were between 0.1 and 1.5 and optical densities of the 
undiluted samples were calculated. 
Alternatively, erosion of the lipid matrix was determined by quantification of PC in the 
released fractions. A LabAssayTM Phospholipid (FUJIFILM Wako Chemicals Europe GmbH, 
Neuss, Germany) was used for this purpose. Samples were prepared following the 
supplier’s instructions and measured at a wavelength of 600 nm using a FLUOstar Omega 
plate reader (BMG LABTECH, Ortenberg, Germany). In this assay, phospholipids are 
hydrolyzed by phospholipase D and the liberated choline is then oxidized by choline 
oxidase to betaine [23]. Thereby, hydrogen peroxide is produced which, in turn, initiates 
the coupling of 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-
dimethoxyaniline sodium salt (DAOS) to a blue chromophore by oxidation, catalyzed by 
peroxidase.  
V.1.3.7  Liposome preparation  
Liposomes were prepared by thin film hydration method. The respective phospholipid 
was solved in chloroform (25 mg/ml), the accurate amount of phospholipid solution was 
mixed as needed using a vortexer and the solvent was removed under a constant stream 
of nitrogen while the glass vial was turned producing a thin phospholipid film on the wall 
of the glass vial. After that, the film was hydrated with 50 mM sodium acetate buffer 
pH 4.5, 10 mM Tris buffer pH 7.4 (containing 110 mM NaCl and 0.5 mM EDTA), or 20 mM 
PBS pH 7.4. Liposomes were extruded by a Lipex (Burnaby, Canada) extruder. Five 
extrusion cycles through a 200 nm polycarbonate membrane were followed by several 
extrusions through a 100 nm polycarbonate membrane to achieve homogeneous 
liposome dispersions. Size, PDI, and zeta potential were determined by dynamic light 
scattering (DLS) using a Zetasizer nano ZS (Malvern Instruments, UK). 
The lipid concentration in the liposome dispersion was determined using a gravimetric 
determination [24].  
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V.1.3.8  Microscale Thermophoresis  
Microscale thermophoresis (MST) measurements were performed using a Monolith 
NT.LabelFree (NanoTemper Technologies GmbH, Germany) with MO.Control v1.5.3.. 
Dilution series were prepared for each of the liposome dispersions (1.0 mM to 3.05E-
05 mM or 0.5 mM to 1.53E-05 mM) following the instrument’s instructions. Then 
exenatide stock solution was added. During the assay, the exenatide concentration was 
kept constant at 2.5 or 5 μM, respectively. All samples were either prepared in 50 mM 
sodium acetate buffer pH 4.5 containing 0.1% (m/v) Pluronic F-127 or in 20 mM PBS 
pH 7.4 containing 0.1% (m/v) Pluronic F-127. 
Samples were loaded into coated glass capillaries (Monolith NT.LabelFree Capillaries, Zero 
Background, MST Premium Coated). Then, capillaries were placed on a tray and inserted 
into the instrument before fluorescent scans were performed to determine the position 
of the capillaries. After that, 16 subsequent thermophoresis measurements (LED 20%, IR 
laser: Medium-Power) were performed. Ambient temperature of the instrument was set 
to 23 °C. For each ligand, a pre-test (with buffer, liposome-dispersion, and exenatide) was 
performed to qualify the sample for measurement before the binding affinity test, using 
the parameters determined in the pre-test. Dissociation constants were calculated after 
the measurement using NanoTemper MO.Affinitiy Analysis v2.2.7 software. 
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V.1.4  Results  
V.1.4.1  Exenatide characterization and encapsulation in VPGs  
Determination of the zeta potential of exenatide over a broad range of pH values showed 
that exenatide turns from positive to negative between pH 4.5 and pH 5.0 (see Figure V-2). 
This is in good accordance with the literature value for the isoelectric point of exenatide 
of 4.86 [25]. 
 
Figure V-2: Zeta potential of exenatide with increasing pH value. (Mean ± SD, n=3) 
With FTIR spectroscopy, the secondary structure of proteins and peptides can be 
analyzed. In order to get further information about the folding behavior of exenatide at 
different pH-values, FTIR measurements were conducted.  
 
Figure V-3: FTIR spectra of exenatide solution with increasing pH value. 
The measurements confirm the alpha-helical structure of exenatide, which is described in 
literature [26]. This alpha-helical structure is preserved over the complete pH range from 
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3.5 to 7.5 (see Figure V-3). No changes or shifts in amid I or amid II band were observed, 
indicating structural integrity of the protein over the complete pH range. 
Exenatide was successfully encapsulated into VPG by direct encapsulation process using 
a DAC as described [6]. In comparison to other preparation methods, this technique is 
very gentle and has been used for the preparation of protein loaded VPG before [3]. 
Exenatide loaded VPG were prepared containing 40% (m/m) of phospholipid and 
characterized by visual inspection and viscosity measurements. 
Visual inspection exhibited a homogeneous appearance of the VPG without lipid 
agglomerates. Rheological behavior of the VPG was studied by rotational rheometry. The 
viscosity of the VPG was compared at a shearing rate of 32.9 s1.  
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Figure V-4: Viscosity of VPG with a total phospholipid concentration of 40% (m/m) loaded with exenatide (0.5 mg/g). 
VPG was prepared with different phospholipid compositions. For comparison the viscosity at a shearing rate of 32.9 s-
1 was taken. (Mean ± SD, n=3) 
All formulations containing POPG showed a high viscosity (above 15 Pa∙s) (see Figure V-4). 
VPG formulations of POPC displayed lower viscosity (below 5 Pa∙s). The viscosity of the 
VPG was not influenced by the encapsulation of the peptide, i.e., placebo VPG showed 
similar values. 
V.1.4.2  In vitro release of exenatide from VPG  
The in vitro release of exenatide from VPGs was determined using formulations with 
pH 4.5 and with pH 7.4. In both cases, exenatide is released very slowly from VPG 
composed of POPC only, while a faster release is observed from formulations composed 
of POPC/POPG mixtures or the single POPG formulation. Complete exenatide release 
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within 16 days was observed for the formulations composed of a mixture of POPC and 
POPG or the POPG only formulation, while VPG composed of POPC only released a 
maximum of 40% of the encapsulated drug within this period. No burst effect was 
observed for all tested formulations and encapsulation pH values. 
At the same time, only slight differences between the two encapsulation pH values were 
observed. At an encapsulation pH 7.4 (see Figure V-5B), exenatide is released faster from 
the formulation containing POPC only in comparison to encapsulation at pH 4.5 (see 
Figure V-5A). Otherwise, the previously observed trend, a faster release from 
formulations containing POPG, was confirmed. 
The release kinetics were fitted by a model taking into account the possibility of two 
fractions A1 and 1 – A1, with different release rates k1 and k2: 
( )1 2max 1 11 1k t k treleasedc c A e A e =  −  − −    
(V-1) 
The half-life of the drug fraction in its retained state, t1/2, is then given by: 
1/2
ln 2
t
k
=
 
(V-2) 
analogously for k1 and k2. The dashed lines in Figure V-5A and Figure V-5B show the fit 
lines. 
A biphasic release behaviour was identified for the formulations containing POPG. One 
fraction (5 to 20%) being released with a half-life of less than 20 minutes and a second 
fraction (80 to 95%) being released with a half-life of 5 days. In contrast to that, 
formulations composed of POPC have a significantly longer half-life of 30 to 50 days 
(approximately 80%) with a small fraction (20%) being released with a half-life of 1 to 10 
days. 
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V.1.4.3  Erosion behavior of VPGs during exenatide release 
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Figure V-5: In vitro release of exenatide from VPG and erosion behavior of VPG during release. A) Cumulative 
exenatide release from VPG. Exenatide was encapsulated at pH 4.5 in all formulations. (Release medium: 20 mM PBS 
pH 7.4). Dashed lines show fit with equation (V-1). B) Cumulative exenatide release from VPG. Exenatide was 
encapsulated at pH 7.4 in all formulations. (Release medium: 20 mM PBS pH 7.4). C) Cumulative optical density of 
the released fractions obtained from in vitro release of exenatide. D) Cumulative PC concentration obtained from 
phospholipid assay for all formulations containing POPC is shown in percentage of total PC in the VPG formulation. 
(Mean ± SD; n = 3) 
One possible mechanism of drug release from VPGs is the erosion of the lipid matrix. 
Optical density (OD) of the release fractions correlates to the erosion of the lipid matrix. 
When optical density is plotted cumulatively, erosion profiles for phospholipids are 
obtained, which are shown in Figure V-5C. Erosion of the VPG composed of POPC is rather 
slow in comparison to the three formulations containing POPG.  
Figure V-5D shows the PC release profiles for the three formulations containing POPC. 
Slow PC release is observed for POPC-VPG while fast release is observed for the two 
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mixtures with POPG. These results do correlate rather well with the release profiles found 
for exenatide. For formulations containing POPG, release of exenatide can be correlated 
linearly to the erosion of the VPG from the beginning. In contrast to that, for formulations 
composed of POPC a linear correlation between exenatide release and erosion can be 
found after a lag-phase of few days. This lag-phase may be a result of the release of loosely 
bound exenatide in the VPG which is released faster. After the lag-phase, erosion of the 
VPG composed of POPC sets in and controls the release behavior. 
V.1.4.4  Interactions studies  
When testing the in vitro release behavior of exenatide from VPG, a correlation between 
viscosity and release kinetics was expected in a way that highly viscous systems should 
release slowly and vice versa. However, since this expectation was not fulfilled, 
interactions between the encapsulated peptide and the phospholipids were investigated 
to see if these are responsible for the slow sustained release from VPG composed of POPC 
only. 
Interaction studies were performed by MST measurements. Since MST has to be 
performed in free “solution”, unilamellar vesicles were prepared for the interaction 
studies by thin film hydration. Z-average size and zeta potential (see Table V-1) of the 
liposomes were determined directly after homogenization of the liposomes by extrusion 
in the respective buffers. Z-average of all liposomes was ≤ 130 nm and PDI ≤ 0.15. 
Table V-1: Zeta potential of the liposomes used for interaction studies. (Mean ± SD, n = 3)  
Liposome 
composition 
Zeta potential [mV] 
pH 4.5 pH 7.4 
POPC -0.6 ± 0.6 -5.6 ± 2.2 
POPC/POPG 7:3 -6.2 ± 1.2 -17.6 ± 0.8 
POPC/POPG 1:1 -6.5 ± 1.7 -20.5 ± 0.8 
POPG -7.2 ± 1.7 -25.4 ± 1.7 
 
Microscale thermophoresis 
Microscale thermophoresis allows the quantitative investigation of interactions of 
proteins or peptides in free solution with other molecules e.g. phospholipids at low 
sample volumes [27], [28]. Label-free measurements have the additional advantages that 
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no sample preparation is required, that the site of interaction on a molecule is not 
disturbed or hindered by the attachment of a fluorescent label to the protein or peptide 
and that mobility is not restricted [28]. Native binding behavior is measured with label-
free MST. It has been demonstrated before that even liposomes with a size of several 
100 nm can be analyzed with MST [29]. 
Since label-free MST is not possible if both binding partners show similar tryptophan 
fluorescence or if background fluorescence by the buffer components leads to increased 
noise, control experiments have to be performed before measuring. Further, optimal 
buffer conditions have to be determined before the experiments [30]. To prevent 
unspecific adsorption to the capillary walls, Pluronic F127 was added to the buffer before 
measurement.  At low liposome concentrations, the unbound exenatide displays a 
migration towards higher temperatures, corresponding to a negative thermophoretic 
signal. Upon binding of exenatide to the liposomes, increasing positive thermophoresis 
was observed (see Figure V-6). Similar behavior has been reported before for RNA-ligand 
interactions [31]. 
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Figure V-6: Raw MST-traces of the titration of exenatide (5 μM) with liposomes composed of a mixture of POPC and 
POPG 7:3 at pH 4.5. Liposome concentration increases from dark green (30.5 nM) over yellow (7.8 – 31.25 μM) to 
dark red (1.0 mM) as arrow indicates. 
Different parts of an MST signal can be analyzed [29]. Before the sample is heated, initial 
intrinsic fluorescence is determined. Usually, the initial fluorescence should be constant 
for all samples; changes in initial fluorescence occur only if the ligand binds closely to the 
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fluorophore. Artifacts or adsorption of the peptide to the reaction tubes have to be ruled 
out to account for this phenomenon.  
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Figure V-7: A) Raw fluorescence spectra: Initial Fluorescence change with increasing amount of POPC/POPG 1:1 
liposomes in exenatide solution (pH 4.5). Liposome concentration decreases from capillary position 1 (0.5 mM) to 
capillary position 16 (15.3 μM). B) Fitting function of the initial fluorescence signal of POPC/POPG 1:1 liposomes to 
exenatide at pH 4.5. (Mean ± Kd Confidence, n = 3) 
In the present study, initial fluorescence changes occurred, indicating a screening of the 
tryptophan residue in exenatide from water upon binding to liposomes. In this case, the 
binding constant Kd may already be calculated from the initial fluorescence changes. Raw 
fluorescence scans of each capillary for the titration of exenatide with POPC/POPG 1:1 
liposomes are illustrated in Figure V-7A. These initial fluorescence changes where not 
observed for any of the formulations at pH 7.4 or for the pure POPC liposomes at pH 4.5. 
For POPC/POPG mixtures and pure POPG liposomes, binding constants could be derived 
from a fit of the normalized, initial fluorescence data to the law of mass action. An 
exemplary fit for the titration of exenatide with liposomes composed of POPC/POPG 1:1 
is shown in Figure V-7B. Primarily, MST-signals describe the fluorescence change at a given 
position in the sample as a function of time after heating by an IR-laser [27], [29]. The 
following thermophoretic movement lasts several seconds until the laser is turned off 
again. Changes in thermophoresis indicate a change in size, charge and the hydration shell 
of a molecule and are therefore highly specific for binding events. 
In our case, initial fluorescence and the MST-signal by 5 seconds was used for data 
evaluation. Kd-values were determined by a fitting function using the law of mass action 
[28]. 
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Kd =  
cLcP
cLP
=  
(cL0 − cLP)(cP0 −  cLP)
cLP
 (V-3) 
A change of thermophoretic movement was observed for liposomes containing POPG at 
pH 4.5 (see Figure V-8A), but neither for liposomes of pure POPC nor for formulations at 
pH 7.4 (see Figure V-8B). 
The dissociation constants Kd for all liposomal formulations as obtained by MST are 
summarized in Table V-2. The fits, derived from the software intern fit-function, resulted 
in binding constants of Kd ≈ 10-30 μM for the initial fluorescence analysis and analysis of 
the MST-signal. We may conclude that all POPG containing formulations investigated here 
show a high affinity binding of exenatide, while no such binding was detectable for pure, 
zwitterionic POPC membranes. 
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Figure V-8: Comparison of Dose Response determined by MST-Signals of the titration of exenatide (5 μM) with 
liposomes at A) pH 4.5 and B) pH 7.4 (n=3). Fit functions for the two POPC/POPG mixtures and the pure POPG 
liposomes are shown for pH 4.5. 
Significance and meaning of the apparent differences between the dissociation constants 
are not important for the current study and would need considerable, additional efforts 
and methods to be elucidated. In particular, the apparently higher Kd for POPG as obtained 
repeatedly from the MST signal but not from initial tryptophan fluorescence should not 
be claimed significant without further validation. Potential sources of enhanced error or 
biases might be an oversimplification of the binding model, incomplete equilibration, 
aggregation phenomena, etc.  
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Table V-2: Summary of Kd-values [μM] derived from the MST measurements. All experiments were performed at 
pH 4.5 in 50 mM sodium acetate buffer. 
Lipid composition Initial Fluorescence 
Kd [μM] 
MST-Signal 
Kd [μM] 
POPC - - 
POPC/POPG 7:3 27.3 (± 3.2) 13.8 (± 2.5) 
POPC/POPG 1:1 10.4 (± 2.0) 13.9 (± 2.0) 
POPG 13.7 (± 4.0) 128.4 (± 35.2) 
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V.1.5  Discussion  
V.1.5.1  In vitro release behavior of exenatide from VPG 
As discussed above, several previous studies suggested faster, erosion controlled release 
from low-viscosity gels and slower, diffusion controlled release from more viscous ones 
[3], [32]. Exenatide release from the formulations studied here showed the opposite 
behavior. The formulations composed of POPC showed significantly lower viscosity than 
those containing POPG but, nevertheless, substantially slower release than those with 
POPG. Obviously, viscosity alone is not always sufficient to understand or predict release 
characteristics. Instead, a complex combination of release mechanisms with their 
individual kinetics has to be considered for a more detailed understanding. 
There are two principal mechanisms of drug release from VPGs, diffusion of the drug out 
of the gel and erosion of the gel releasing the embedded drug. According to the Einstein-
Stokes equation, a peptide of 5 kDa should have a diffusion coefficient in water of the 
order of D = 130 µm2/s. Taking into account that the mean square distance of diffusion, 
MSD = 2Dt, this D implies that within a time of t = 1 h, the peptide spreads out over a root 
mean square distance of RMSD  1 mm. Depending on the dimensions, tortuosity, and 
micro-viscosity of the gel, this should be the order of magnitude of releasing non-
entrapped drug from the gel. Our experimental setup was designed to record long-term 
release and not suited to precisely quantify release on this time scale, but practically all 
release curves showed a release of the order of 10 – 20% of the drug with a half-life of up 
to 1 hour.   
We found a substantial retardation of release for the majority of the drug in all 
formulations tested here, by about 2.5 days for POPG containing gels and by several weeks 
by purely zwitterionic gels of POPC. In the following, we will attempt to interpret this 
behavior on the basis of additional data.   
V.1.5.2  Interactions between exenatide and phospholipids  
In order to assess the contributions of exenatide binding to the lipid gel to the retardation 
of drug release, we have studied exenatide-liposome interactions in dilute systems by 
microscale thermophoresis. The binding of exenatide to phospholipid membranes 
strongly depends on the charge of the peptide and phospholipid. Given that strong 
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binding was observed only for cationic peptide (pH 4.5) to anionic, POPG containing, 
membranes supports the idea of a largely electrostatic, superficial adsorption with little 
or no intrusion of hydrophobic side chains into the membrane.  
Binding was detected based on changes in tryptophan fluorescence and thermophoretic 
mobility with MST measurements. Except for one apparent outlier of unclear significance 
as discussed above, dissociation constants for all liposomes containing POPG are, within 
error, of the order 10-30 µM.  A detailed and rigorous discussion of the subtle differences 
between the Kd-values is, however, not warranted and outside the scope of this study. 
Binding to zwitterionic POPC is significantly weaker and was not measurable in the 
investigated concentration range. Such a high Kd may still suffice for binding all peptide in 
a lipid gel with its far higher concentration but the weaker binding energy would still allow 
for a faster off rate and, hence, release kinetics from the surface to the bulk solution.    
V.1.5.3  Erosion-driven, fast release from POPG containing gels  
Let us recapitulate the insights obtained for exenatide in POPG containing gels. The 
retarded release of  80% of the drug showed half-lifes of 2.5 – 8 days and showed a good, 
linear correlation with lipid erosion into the supernatant (r > 0.98, not shown explicitly). 
At pH 4.5, exenatide binds to POPG-containing liposomes with a high affinity (Kd  10-
30 µM). As one should expect, binding to the anionic membrane was not detectable at 
pH 7.4, where the peptide is negatively charged, too. Nevertheless, release kinetics were 
virtually unaffected by the initial pH within the gel.   
Taken all these points together, we can conclude that the kinetics of exenatide release 
from POPG containing gels studied here is governed by the kinetics of gel erosion. 
However, it has to be taken into account that exenatide released in vesicles may 
contribute significantly to in vitro release data, but not necessarily be fully bioavailable in 
vivo.  
Note that in contrast to zwitterionic lipids swelling spontaneously, only up to a certain 
level of hydration, anionic lipids may swell infinitely due to their electrostatic repulsion 
[33]. An excess of bound peptide at pH 4.5 would overcompensate the charge of the lipid 
and render the overall charge of the peptide-lipid-particles or layers positive. Again, this 
might promote erosion of the gel. Interestingly, both the strongly bound exenatide in the 
pH 4.5 VPGs as well as the non-membrane-interacting exenatide in the pH 7.4 VPGs show 
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no substantial diffusional release that would detectably add to that by erosion. Of course, 
a change in diffusion due to binding will not matter to overall release kinetics as long as 
erosion remains rate limiting. Second, the pH in the VPGs (4.5 or 7.4) approaches the pH 
of the surrounding buffer (20 mM PBS pH 7.4) during the first days of release by diffusion. 
Alignment of the pH of the buffer inside of the VPG to the pH of the surrounding release 
buffer may explain the strong similarities between the release curves at encapsulation 
pH 4.5 and 7.4. Third, as discussed in the next section, both very strong binding and 
repulsion will prevent diffusional release from a multilamellar gel, either by attraction or 
by barrier function, respectively. 
V.1.5.4  Barrier based retention in gels of POPC  
Gels of the zwitterionic lipid POPC retarded the release of  80% of the loaded exenatide 
to rates that suggest half-lifes of several weeks and the correlation with lipid erosion was 
less compelling. An affinity of the peptide to these membranes could not be observed at 
least in dilute liposomal systems implying that interactions in the gel are repulsive or only 
weakly attractive.  
No matter what finally controls release, both erosion and diffusion of these gels are 
retarded to half-lifes of at least weeks. The lack of high affinity binding of exenatide to 
these VPGs suggests that it is primarily the barrier function of membranes in the gel that 
allows for this very slow diffusional release. Note that at least a low affinity of the drug to 
the phospholipid is vital for the molecule to penetrate into and across the phospholipid 
bilayer. The partitioning-diffusion model defines membrane permeability P on the basis 
of partition (here: K) and diffusion coefficient (D):  
𝑃 =  
𝐾 ∙ 𝐷
𝑑
 (V-4) 
for a given membrane thickness of d. That means, membrane binding/partitioning is a 
prerequisite for permeation. For sink conditions, the resulting time dependence of the 
retained concentration becomes: 
𝑐𝑑𝑜𝑛𝑜𝑟(𝑡) =  𝑐0 ∙ 𝑒𝑥𝑝 {−
𝑃 ∙ 𝐴
𝑉𝑑𝑜𝑛𝑜𝑟
∙ 𝑡} (V-5) 
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with the initial drug concentration on the donor side of c0, the membrane area A, and the 
volume of the donor compartment of Vdonor. That means, the rate of drug release across 
a membrane is expected directly proportional to P and hence, to K. The exenatide-
liposome system might not obey the partitioning-diffusion model to a good 
approximation, for example because the peptide might adsorb on the surface rather than 
partitioning into the membrane. Nevertheless, a higher concentration at the membrane 
should facilitate permeation compared to the case of a membrane that is not approached 
by the peptide. In this context, it is also instructive to recall Lipinski‘s rules that, in the end 
of the day, describe prerequisites for passive absorption of a drug across a membrane. 
For fast permeation, it needs intermediate polarity and hydrophobicity values. Too 
hydrophobic molecules (log P > 5) are little soluble and get stuck in the membrane; too 
polar molecules (too many H-bond donors and acceptors) prevent the drug from entering 
the membrane in the first place. Hence, it is very plausible that barrier-controlled release 
from a lipid membrane based drug delivery system does not increase or decrease 
monotonically with a certain parameter, such as hydrophobicity. 
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V.1.6  Conclusions  
Release from VPGs is an extremely complex process, resulting of different mechanisms 
like erosion, interactions, diffusion and permeability of the lipid bilayers, all occurring at 
the same time and complementing each other. Additional factors influencing drug release 
may be the inner structure e.g. vesicle size and homogeneity as well as the viscosity of the 
VPG.  
A high viscosity of the VPG was previously connected to slow release and erosion rates of 
the system. This correlation was not confirmed in the present study. For POPG containing 
VPGs, the release of exenatide showed half-lifes of several days that were, obviously, 
governed by the erosion of the gel. In spite of the fact that these lipid mixtures bound 
exenatide with high affinity (Kd   10-30 µM) at pH 4.5 but not detectably at pH 7.4, gels 
produced at these two pH values shared similar release rates. This can be explained by 
diffusion not being rate limiting and relatively fast pH matching between VPG and release 
medium due to diffusion of protons or hydroxide.  
VPG of POPC showed much slower release of exenatide, with a half-life of several weeks. 
The fact that this lipid did not show high affinity binding of exenatide suggests that their 
very strong retardation of the diffusional release of exenatide is primarily based on its 
very weak permeability across the lipid membranes in the gel.  
Notably, both very high and lacking affinity of the drug to the gel retard diffusion, by 
attraction or barrier function, respectively. 
Thus, a mathematical description of the release from VPGs resulting from this complex 
mixture of mechanisms, contributing to or influencing the release behavior is not possible 
at the moment. A rational design of the depot formulation based on mathematical 
predictions of the release behavior for novel drug candidates is still impossible. 
Further investigations on the release behavior and characterization of the fluidity and 
barrier functionality of the multiple lipid bilayers of the VPG are necessary to resolve all 
mechanisms behind the release kinetics completely, to be finally able to describe release 
behavior from VPG mathematically. 
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V.1.8  Supplement 
Table V-3: Multi-step-gradient elution used during RP-HPLC quantification of exenatide. 
Time [min] Mobile phase A [%] Mobile phase B [%] 
0 100 0 
2 70 30 
10 20 80 
15 20 80 
20 70 30 
32 100 0 
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V.2  Further studies 
In order to support the data in section V.1  on interactions between exenatide and 
phospholipids, isothermal titration calorimetry and isothermal steady state fluorescence 
measurements were additionally conducted. Furthermore, the permeability of the 
differently composed lipid-membranes for exenatide was tested in monolayer 
measurements at the air/water interface. 
Part of the work in this chapter has been conducted in close cooperation with the Albert-
Ludwigs-Universität in Freiburg. ITC measurements were performed together with Anja 
Stulz or by Anja Stulz alone. Prof. Dr. Heiko Heerklotz and Anja Stulz evaluated and 
interpreted the results of these measurements as described in section V.2.2.1  . All other 
data was evaluated and interpreted in intensive collaboration. Parts of this section are 
intended for publication. A manuscript with the working title “Different aspects of a 
complex protein-ligand binding equilibrium as seen by ITC, Fluorescence and MST.” is in 
preparation. 
V.2.1  Material and Methods 
V.2.1.1  Preparation of liposomes  
Liposomes were prepared using the thin-film method described in section V.1.3.7  . 
Alternatively, to the described method a SpeedVac system (Christ RVC 2-18, Martin Christ 
Gefriertrocknungsanlagen GmbH, Germany) was used to produce a thin lipid-film on the 
wall of the glass vial. Subsequently, films were hydrated with 50 mM sodium acetate 
buffer pH 4.5, 10 mM Tris buffer pH 7.4 (containing 110 mM NaCl and 0.5 mM EDTA), or 
20 mM PBS pH 7.4. Liposomes were extruded by a Lipex (Burnaby, Canada) or LiposoFast 
(Avestin Inc., Canada) extruder. 
The lipid concentration in the liposome dispersion was either determined using a Bartlett 
Assay or by gravimetric determination [24], [34]. 
V.2.1.2  Isothermal titration calorimetry  
Isothermal titration calorimetry (ITC) measurements were carried out on a MicroCal VP-
ITC instrument (Malvern Instruments, UK). All runs were performed at 25 °C with a stirring 
speed of 394 rpm. Typically, 8 µL injections were made every 5-10 minutes. As usual, the 
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heat of an initial injection of 1 µL was excluded from the analysis to eliminate its higher 
error. All samples were degassed prior to loading into the calorimeter. In exenatide-into-
lipid titrations, aliquots from the syringe containing an exenatide solution (100 µM) were 
injected to the calorimeter cell (Vcell = 1.4288 mL) which contained a dispersion of vesicles 
(typically, 80 µM lipid). In lipid-into-exenatide titrations, the cell was filled with an 
exenatide solution (typically, 3 µM) and the syringe was loaded with lipid vesicles (800 μM 
lipid). In parallel to some runs, DLS measurements were conducted to check vesicle size 
and size distribution during the ITC experiment. To imitate the exenatide-into-lipid ITC 
run, 8 μL aliquots of an exenatide solution (100 μM) were titrated into a cuvette 
containing 1.4 mL POPC/POPG 1:1 vesicles (80 μM lipid) every 5 minutes. Vice versa, 8 μL 
aliquots of POPC/POPG 1:1 vesicles (800 μM lipid) were titrated into 1.4 mL exenatide 
solution (3 μM) imitating the lipid-into-exenatide ITC. Five minutes after each injection, Z-
average size and PDI were measured with a Zetasizer nano ZS (Malvern Instruments, UK). 
MicroCal PEAQ-ITC analysis software (Malvern Instruments, UK) was used for data 
evaluation and curve fitting according to the law of mass action. 
V.2.1.3  Isothermal steady-state Fluorescence  
Steady-state fluorescence was measured using a Cary Eclipse fluorescence spectrometer 
(Agilent Technologies, USA) and an Optim 1000 instrument (Avacta, USA). Dilution series 
were prepared with a constant amount of exenatide in the solution (typically, 5 μM) and 
increasing amount of liposomes. The two components were incubated for 10 minutes 
before measurement. Samples were prepared either in 50 mM sodium acetate buffer pH 
4.5 or in 20 mM PBS pH 7.4. Interactions were assessed by steady-state fluorescence using 
a Cary Eclipse spectrometer with an excitation wavelength of 280 nm while emission was 
measured in a range between 300 and 450 nm. Fluorescence was measured using a 
cuvette at a defined temperature of 20 °C and spectra were corrected for background 
intensities and scattering of liposomes by background subtraction [35]. Excitation and 
emission slits with 5 nm bandpass were used for all measurements. 
At the Optim 1000 instrument, intrinsic fluorescence mode was used for all 
measurements (λexc = 266 nm, λem = 250-720 nm). Experiments were performed in 
isothermal mode, at a fixed temperature of 20 °C. MCAs with a capillary volume of 9 μl 
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were used for the measurements. Each MCA was measured five times and background 
subtraction of the respective blanks was performed for spectra correction. 
V.2.1.4  Langmuir trough measurements 
Experimental measurements were conducted with a Langmuir-Blodgett Trough 
(Microtrough XS, Kibron Inc., Helsinki, Finland). The rectangular (59 x 397 mm2) PTFE 
trough was equipped with a metal alloy dyne probe for surface pressure (π) 
measurements. The surface area can be adjusted by two mobile PTFE barriers with a 
maximum area of 234 cm2. Prior to each measurement the trough was rinsed with ethanol 
and then highly purified water. All experiments were conducted at 20 °C. 
V.2.1.4.1  Compression isotherms of lipid-monolayers 
Separate stock solutions of the individual lipids (POPC, POPG) or lipid mixtures 
(POPC/POPG 7:3 or POPC/POPG 1:1) were prepared by solving the respective lipids in 
chloroform (1 mg/ml). Monolayers of the phospholipids were obtained by carefully 
spreading 20 µl of the solution on the surface of the 20 mM PBS buffer subphase (pH 7.4) 
using a Hamilton microsyringe (Hamilton Co., Reno, NV, USA). The film was allowed to 
equilibrate for at least 15 minutes, before the film was compressed with a compression 
speed of 56,1 mm/min. Measurements were done in triplicates for each lipid. 
V.2.1.4.2  Surface activity of exenatide 
Further, the surface activity of exenatide was studied in order to determine the 
equilibrium spreading pressure of the peptide on buffer surface. To this end, exenatide 
solutions with different concentrations (0.39063 µM to 200 µM) in 20 mM PBS pH 7.4 
were prepared and the surface pressure of each solution was determined.  
V.2.1.4.3  Intercalation of exenatide into lipid monolayers 
The kinetics of peptide insertion into the monolayers (POPC, POPG, POPC/POPG 7:3 and 
POPC/POPG 1:1) were determined using the same setup as for the compression 
isotherms. Lipid-solutions were added drop wise to the surface of the subphase (20 mM 
PBS pH 7.4) and the film was allowed to equilibrate for 5 minutes to ensure complete 
chloroform evaporation. Then the film was compressed very slowly to a surface pressure 
of 30 mN/m, which is the monolayer-bilayer equivalence pressure, at which the molecular 
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area of lipids in a bilayer and in a monolayer are the same or at least similar and thus the 
lipid packing density of a normal bilayer is mimicked [36]–[38]. Next, 1 ml exenatide 
solution (375 µM) (or buffer for controls) was carefully injected in the subphase and 
surface pressure was recorded for 60 minutes. Since, the monolayer was kept at a 
constant area without further movement of the barriers, increase in surface pressure was 
taken as measure for interactions of exenatide with the phospholipid monolayer. 
Measurements were performed in triplicates for each phospholipid solution. 
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V.2.2  Results and Discussion 
V.2.2.1  Characterization of interactions by isothermal titration 
calorimetry 
Figure V-9 shows the heats produced by the dilution of aliquots of 100 µM exenatide at 
pH 4.5 injected into the cell filled with matching buffer. The experiment shows small but 
significant heats that decrease quasi-exponentially with increasing concentration of 
titrant in the cell. This is the typical behaviour if the molecules of the titrant show 
substantial interactions in the syringe [39]–[42]. Such interactions include the formation 
of dimers or oligomers, but may also be very transient and short-lived. For simplicity, it is 
referred to these interacting molecules as “oligomers” without restriction regarding their 
size, lifetime, or stability. After an injection of an aliquot of oligomers into the cell, these 
oligomers are diluted and dissociate. For subsequent interactions, the cell is “filling up” 
with monomers and the degree of dissociation of the injectant decreases. Integration of 
the curve yields a value of 60 kJ/mol, representing the product of the maximal mole 
number of monomers forming in the cell and their enthalpy of dissociation. Such ITC 
signals have, for example, been used to describe the oligomerization behaviour of 
doxorubicin in quite some detail [40]. 
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Figure V-9: A dilution experiment (“blank”, black crosses) performed by diluting aliquots of exenatide (100 μM) into 
matching acetate buffer at pH 4.5 indicates that exenatide assembles at high concentrations. Titration of exenatide 
aliquots (100 μM) into the cell filled with POPC vesicles (red triangles) (80 μM lipid) yields practically identical heats. 
Data are shown as a function of exenatide concentration. 
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Repeating the peptide titration schedule now with liposomes of 80 µM POPC filled into 
the cell, the heats are practically identical with those in the absence of lipid (orange 
symbols in Figure V-10A, C). This can be explained with (1) exenatide showing no 
significant interaction with POPC liposomes at 80 µM or, (2), the interaction being 
exclusively entropic in nature and hence, isocaloric (ΔH = 0).  
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Figure V-10: A) ITC of POPC (red triangles) and POPC/POPG 1:1 (blue dots) vesicles (80 μM lipid) titrated with 
exenatide (100 μM) at pH 4.5. Data is shown as a function of exenatide/lipid ratio. The solid line represents a 
simulation with the same fitting parameters found by the fit in panel C. B) DLS measurements of exenatide-into-lipid 
titration. 8 μL aliquots of an exenatide solution (100 μM) were titrated into a cuvette containing 1.4 mL POPC/POPG 
1:1 vesicles (80 μM lipid) every 5 minutes. C) ITC curve of exenatide (3 μM) titrated with lipid vesicles (800 μM) 
composed of POPC (red triangles) and POPC/POPG 1:1 (blue dots). Data is shown as a function of lipid/exenatide 
ratio. As in panel A, no interaction of exenatide with pure POPC could be observed under the chosen conditions. The 
model ‘one set of sites’ was used to fit POPC/POPG 1:1 data (solid line). Injections at the beginning of the titration at 
low lipid/exenatide ratio were excluded. D) DLS measurements of lipid-into-exenatide titration. 8 μL aliquots of 
POPC/POPG 1:1 vesicles (800 μM lipid) were titrated into a cuvette containing 1.4 mL exenatide solution (3 μM) every 
5 minutes.  
The latter option seems very unlikely in the light of data on similar systems, but cannot be 
ruled out formally. The lack of any detectable interaction would imply that, if there was a 
binding of exenatide to POPC, its product of dissociation constant Kd and stoichiometry n 
(lipids per binding site) would need to be larger than nKd = 80 µM. That means, affinity 
would be fairly weak if there was some in the first place. The same result is observed at 
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pH 7.4 with all tested lipid mixtures (POPC, POPG and POPC/POPG mixtures) (data not 
shown). 
Doing the same sequence of injections into the cell pre-loaded with liposomes of 
POPC/POPG 1:1 (Figure V-10A, blue dots), we obtain a complex curve with a quasi-
sigmoidal, exothermic behavior followed by a local, endothermic maximum. This shape 
has been discussed before for the binding of a self-associating drug, doxorubicin, to 
polymeric nanoparticles [40]. In the beginning, the peptide oligomers dissociate like in the 
blank, but there are fewer monomers accumulating in solution since most of the injected 
peptide molecules bind to the liposomes. We will find below that the contribution from 
this “primary” binding of peptide monomers to the membrane is approximately 
represented by the blue, simulated curve. Hence, the heats in the beginning of the 
titration are simply up-shifted from the black, primary binding curve by about 7 kJ/mol, 
the “blank” heat of dissociating injected oligomers (Figure V-9). Primary binding saturates 
centered at 0.05 peptides per lipid, implying the existence of defined “binding sites” for 
the peptide on the membrane. In the current example, the average number of lipid 
molecules per site is 1/0.05 = 20. Note that this does not mean that all these lipids really 
take part in peptide binding. Beyond 0.05 peptide/lipid, it is not only that further 
exothermic, primary binding comes to a halt gradually and injected oligomers keep on 
dissociating. The endothermic offset increases to values larger than the blank and the 
liposomes start to grow gradually while maintaining a PDI < 0.2 (see Figure V-10B). These 
phenomena can be assigned to a secondary, super-saturating binding of peptide to the 
liposomes.  At even higher peptide concentration of about 0.13 peptide/lipid, a dramatic 
increase in size and PDI implies aggregation of the peptide-supersaturated liposomes.  
Figure V-10C illustrates the reverse experiment, titrating liposomes into a 3 µM peptide 
solution. Up to 1/0.13  7 lipids/peptide, the peptide to lipid ratio is in the secondary 
binding range but the absolute liposome concentrations are considerably lower than in 
Figure V-10A. As a result, aggregation is quite limited but there is an endothermic 
deviation from the blue, primary binding curve (identical parameters as the one in Figure 
V-10A). Continuing the titration beyond 7 lipids/peptide, possible small aggregates may 
be disintegrated and peptide oligomers in solution are dissociated (endothermic) as more 
and more peptide is adsorbed by added liposomes. At about 15 lipids/peptide, these 
processes seem to be finished. The only significant process left is the binding of the 
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peptide monomers remaining in solution to primary sites on the injected liposomes. These 
data define the blue, primary binding curves in Figure V-10C and, re-calculated, Figure 
V-10A, according to the law of mass action for the generalized reaction: 
𝑃 + 𝑛𝐿 ⇄  𝑃𝐿𝑛 (V-6) 
 yielding a dissociation constant, Kd: 
𝐾𝑑 =  
(𝑛𝑐𝐿
0 − 𝑐𝑃
𝑏)(𝑐𝑃
0 − 𝑐𝑃
𝑏)
𝑐𝑃
𝑏  (V-7) 
where cL0 stands for the total lipid concentration and cP0 for the total peptide. cPb denotes 
the concentration of membrane bound peptide and, in other words, the concentration of 
occupied sites, and ncL0 represents the total concentration of membrane binding sites 
with the average number of lipids per binding site, n. The binding site is a pre-assembled 
membrane patch (so, n does not appear in the exponent) and n may include contributions 
from inactive lipids, e.g. in an inaccessible interior of the liposome, or of a non-binding 
lipid species. 
Fit and simulation were done using Malvern-MicroCal software for ITC. It should be 
emphasized that the approach to exclude the beginning of the experiment, where 
secondary binding occurs, from the fit means that the fit parameters obtained here should 
refer to primary binding only. 
Qualitatively similar curves and consistent fits were obtained repeating the lipid-into-
exenatide titrations at different exenatide concentrations (not shown in detail). For the 
other lipid systems studied, the respective results are compiled in Table V-4 on page 154. 
Summarizing this section, we find no binding of exenatide to POPC in the lower µM 
concentration range. In the presence of POPG, we find rather strong primary binding 
saturating at about 9 -26 lipids per peptide depending on the specific PC-PG ratio. Upon 
saturation of the primary sites, further, secondary binding proceeds as an endothermic 
process. We have not been able to obtain a quantitative description of this secondary 
binding from ITC data. 
V.2.2.2  Isothermal steady state fluorescence 
The sensitivity of the initial tryptophan fluorescence of exenatide to exenatide-liposome 
interactions seen in the MST system (see section V.1.4.4  ), motivated a more detailed 
inspection in a fluorescence spectrometer [43]. Contact of tryptophan and many other 
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fluorophores with water causes fluorescence quenching and dipolar relaxation 
phenomena to lower energies, indicated by a red shift of the spectrum. Hence, binding 
processes shielding previously superficial tryptophan residues from water and rendering 
their environment less polar can be detected in terms of an increase in intensity as well 
as a spectral shift to lower wavelengths [43]–[47].  
 A significant shift of the fluorescence spectral maximum of exenatide to smaller 
wavelengths (blue-shift) was, indeed, observed in the presence of liposomes composed 
of POPC/POPG mixtures or liposomes composed of 100% POPG at pH 4.5 (see Figure 
V-11A). The fluorescence maximum shifts from approximately 347 nm to 334 nm after the 
addition of POPG liposomes to a 5 μM exenatide solution at pH 4.5.  
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Figure V-11: Normalized fluorescence spectra of the titration of exenatide (5 μM) with A) POPG-liposomes (0.5 mM - 
1.5 x 10-5 mM) and B) POPC-liposomes (0.5 mM - 1.5 x 10-5 mM). 
No changes in fluorescence maximum were observed for the addition of liposomes 
composed of 100% POPC (see Figure V-11B) and for all formulations at pH 7.4.  
To fit these data, we have assumed a two-state system with tryptophan showing the 
properties of the “free” or “bound” states. We may, then, write for the intensity, F, at a 
given wavelength, λ, as a function of the degree of binding, xb: 
( )( ) (1) 1 (0)b b bF x x F x F  = + −  (V-8) 
with xb defined as:  
0
b
P
b
P
c
x
c
=  (V-9) 
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and F(0) and F(1) representing the intensity expected if all peptide is free or all peptide is 
bound, respectively; these values should not depend on xb and be conserved in a binding 
experiment if the peptide concentration is held constant.  
To compute xb for a given parameter set, we have to calculate the concentration of bound 
peptide, cPb, by solving equation (V-7): 
𝑐𝑃
𝑏 =  
𝐾𝑑
2
∙ [
𝑛𝑐𝐿
0 + 𝑐𝑃
0
𝐾𝑑
+ 1 − √(
𝑛𝑐𝐿
0 − 𝑐𝑃
0
𝐾𝑑
)
2
+ 2 ∙
𝑛𝑐𝐿
0 + 𝑐𝑃
0
𝐾𝑑
+ 1] (V-10) 
Equation (V-8) with (V-9) and (V-10) was used to fit Kd and n along with F330(0), F330(1), 
F350(0), and F350(1) to the intensity changes at both 330 and 350 nm simultaneously as a 
function of lipid concentration (see Figure V-12A). Data was fitted in Excel by nonlinear 
least-square fitting as shown by Kemmer et al. [48]. Our fit was fairly robust, which was 
tested by manually fixing Kd and n values to values slightly different from the optimal ones 
and observing how the sum of squared residuals is affected by changes of each of the 
parameters separately. 
Alternatively, we may fit the spectral shift, independently of intensity changes. Given that 
the maximum of the very broad spectrum is not well defined, we rather express spectral 
shifts in terms of the ratio 
350
350/330
330
F
R
F
=  (V-11) 
which decreases upon a blue-shift of the spectrum. Equation (V-8) applies to F330 and F350 
independently with shared xb. For R350/330, equations (V-8) and (V-11) yield: 
( )
( )
350 350
350/330
330 330
(1) 1 (0)
( )
(1) 1 (0)
b b
b
b b
x F x F
R x
x F x F
+ −
=
+ −
 (V-12) 
In contrast to Fλ, R350/330, is not simply an xb-weighted average of the values for all-free 
and all-bound peptide but additionally spectral shifts are taken into account. This fit is 
illustrated by Figure V-12B. The parameters, also included in Table V-4, agree with those 
from the intensity fit within experimental error. 
Again, both F and R350/3390 of exenatide are found unaffected by the addition of POPC 
liposomes at pH 4.5 as well as any lipid tested at pH 7.4. 
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Figure V-12: A) Raw fluorescence curves at 330nm and 350nm of titrations of 5µM exenatide with liposomes 
composed of POPC/POPG 7:3 along with fit curves of a global fit representing Kd = 1.4 µM, n = 9.2 µM, F330(0) = 38, 
F330(1) = 730, F350(0) = 57, F350(1) = 650 according to eq. (V-8) with (V-9) and (V-10).  B) Ratio 350 nm/330 nm of the 
data presented in panel A, along with a solid curve calculated on the basis of the fit parameters (Kd and n) obtained 
in panel A and a dashed curve fitted to the data shown here according to eq. (V-12), yielding Kd = 1.2 µM and n = 9.2. 
For a compilation of these parameters and those for the other lipid mixtures (fits not shown), see Table V-4, 
“Fluorescence” section. 
V.2.2.3  Comparison of binding events detected by ITC, fluorescence 
measurements and MST 
In order to compare all of the above described methods used to study binding between 
exenatide and phospholipids, data obtained from MST had to be re-evaluated with the 
same fit-function (law of mass action with open stoichiometry n, equation (V-7)) used for 
ITC and fluorescence data. By taking into account the possibility of several phospholipids 
binding to one exenatide molecule (n = L/P), new binding parameters were obtained (see 
Table V-4). 
The system at hand is much more complex than a simple ligand-to-receptor binding in 
solution. In line with the finding of a significant self-association of the peptide in the low 
micromolar concentration range (Figure V-10B), we have found that also membrane 
binding proceeds from a primary binding of the peptide to a number of lipids to the 
subsequent, secondary binding of peptide to pre-bound peptide layers. As different 
methods focus on different aspects of this complex behaviour, they may yield apparently 
contradictory results unless their different readouts are put into proper perspective. 
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Table V-4: Summary of Kd-values [μM] and Stoichiometry (n = lipid per peptide) derived from the different methods 
with which interactions were evaluated.  Additionally, for ITC-experiments the reaction enthalpy ΔH [kcal/mol] is 
shown. All experiments were performed at pH 4.5 in 50 mM sodium acetate buffer. 
Lipid 
composition 
ITC 
(primary binding only) 
MST Fluorescence 
Initial 
fluorescence 
MST-signal 
Fluorescence 
intensity 
Ratio 350/330 
Kd 
[μM] 
n 
(L/P) 
ΔH 
[kcal/
mol] 
Kd 
[μM] 
n 
(L/P) 
Kd 
[μM] 
n 
(L/P) 
Kd 
[μM] 
n 
(L/P) 
Kd 
[μM] 
n 
(L/P) 
POPC No interaction detected 
POPC/POPG 
7:3 
5.8 26 -0.57 1.7 6.7 2.3 2.9 1.4 9.2 1.2 9.2 
POPC/POPG 
1:1 
2.9 19 -0.77 0.5 5.0 2.4 3.1 0.3 4.4 4.2 4.4 
POPG 0.6 8.9 -1.18 2.1 5.5 0.9 27 0.3 2.5 1.2 2.5 
ITC seems uniquely suited to distinguish primary and secondary effects given that both 
types of binding contribute to liposome mass equally, to changes in water accessibility of 
Trp in the peptide similarly, but to the ITC signal with different signs. Both, strongly 
exothermic primary binding and weakly endothermic, secondary binding can be detected 
by ITC and primary binding can, to a good approximation, be fitted separately. The 
average number of lipids per primary binding site is 9, 20, and 26 lipids per site for 
membranes with 100%, 50%, and 30% POPG, respectively. Expressed per POPG only, 
which would be responsible for electrostatic binding, we obtain a common average of 9.5 
± 0.5 POPG molecules per site. Given that ITC detects binding within a few minutes after 
injection only, it is very likely that it includes little or no binding to the inner membrane 
surface, so that half of the lipid is inaccessible and the “contact site” would involve only 
patches of 4.8 POPG, along with 0 – 8 POPC molecules. Taking into account that a 
compact, spherical protein of 5 kDa would have a cross sectional area of about 6 lipid 
molecules and an alpha helix that of 2-3 lipids, it seems that a pure POPG membrane is 
virtually completely covered by peptide upon primary saturation. In membranes of lower 
POPG concentration, surface coverage could be weaker, with each peptide still clustering 
about 4 -5 PG molecules to its site so that the capacity is not significantly increased.  
Secondary binding is qualitatively detected by ITC but it was not attempted to quantify it 
this way. A much more straightforward method to determine complete, i.e., primary and 
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secondary, binding is MST, which reports on size or mass changes of the liposome 
including all bound peptide molecules equally. MST of POPC/POPG mixtures suggested n 
values of about 3 lipids per site, which corresponds to 0.9 – 1.5 POPG for inside and 
outside and 0.4 – 0.8 POPG per site for outside only binding. These values provide further 
support to the secondary binding mechanism, given that they seem to require more than 
one layer of bound peptide covering the membrane surface. This is a rather clear result 
but the scatter of the fit parameters obtained by MST is somewhat larger.  
A third method of characterizing binding is based on Trp fluorescence responding in 
intensity and wavelength to the polarity and water accessibility of the molecular 
environment of the Trp residue.  Intensities were measured in the MST system and, at 
two wavelengths, in a fluorescence spectrometer. Intensities and spectral shapes were 
fitted separately, yielding consistent fits within experimental error (see Table V-4). Binding 
sites obtained by the two types of fits to the spectrometer data require 2.4 ± 0.4 POPG 
plus 0 – 6 POPC for full lipid accessibility or half as much for outside only binding to the 
liposomes. A priori, it is not clear whether primarily and secondarily bound peptides show 
virtually identical fluorescence properties. However, the fact that we obtained quite good 
fits of all intensities at 330 and 350 nm by a two-state model and the general consistence 
of the parameters with those obtained by MST suggests that this is essentially the case. 
Overall, the fit parameters should give a good idea of primary and secondary binding 
together.  
The scheme (Figure V-13) illustrates the concentration ranges covered by the different 
experiments and the resulting ranges where primary and secondary binding proceed. 
Interestingly, MST is found primarily sensitive to secondary binding. Secondary binding 
may have a particularly strong effect on the hydrodynamic size due to surface roughness 
and/ or beginning, transient liposome association phenomena (see DLS data in Figure 
V-10), it also involves considerably more peptide molecules than primary binding.  
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Figure V-13: Scheme describing the concentration ranges covered by the different experiments and the transition 
ranges revealed by them. Triangles indicate the approximate beginning and completion of transition ranges (blue: 
ITC; orange: MST; green: Trp fluorescence) and vertical bars are separators between secondary and primary (at lower 
lipid) and primary only (at higher lipid) binding. Grey grid lines illustrate specific total mole ratios of lipid-to-peptide. 
Concentration ranges covered by different experiments are illustrated by colored areas. 
All dissociation constants are, within error, of the order 1 µM.  The fact that ITC reports 
primary and secondary binding as sequential effects implies that primary binding shows a 
higher affinity but this difference seems to be rather weak and could not be resolved. A 
possible decrease of Kd with increasing POPG concentration could be explained, for 
example, by the entropic “costs” of clustering POPG from a mixed membrane. A detailed 
and rigorous discussion of these subtle differences is, however, not warranted and outside 
the scope of this study. 
 Binding to zwitterionic POPC is at least 2 orders of magnitude weaker. Such a Kd may still 
suffice for binding all peptide in a lipid gel with its far higher concentration but the weaker 
binding energy would still allow for a faster off rate and, hence, release kinetics from the 
surface to the bulk solution. 
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V.2.2.4  Insertion of exenatide into phospholipid monolayers  
The interactions between the phospholipid and the encapsulated exenatide as 
determined by MST, ITC and fluorescence measurements, could not explain the 
differences in release behavior as described in section V.1.4.2   for the differently 
composed VPGs. Thus, we wanted to investigate if the permeation behavior of exenatide 
through the phospholipid layers in the VPGs may explain the differences in release 
behavior.  
In order to assess if exenatide permeates through the phospholipid layers, insertion of 
exenatide into lipid monolayers was investigated using a Langmuir trough. It is expected 
that after some time (few days of the release studies) pH of the inner phase of the VPG 
aligns to the pH of the release medium (20 mM PBS pH 7.4). Hence, experiments were 
performed at the more relevant pH of 7.4 only. 
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Figure V-14: Stability of phospholipid monolayers on 20 mM PBS pH 7.4. (A) Compression isotherms of lipid 
monolayers. (B) Collapse pressure obtained from compression isotherms. 
By carefully dropping lipid-solutions on the surface of aqueous buffers, extremely thin 
lipid monolayers are formed [49]. First, the stability of the different lipid monolayers was 
tested by isothermal compression tests. Representative compression isotherms of the 
phospholipids are shown in Figure V-14A. All phospholipids and mixtures thereof form 
stable lipid monolayers at the surface. Collapse pressure (π ≈ 40-45 mN/m) and the 
correlating area per molecule are similar for all tested phospholipids (Figure V-14B) and 
both are in the range of previous observed values for phospholipid monolayers [50]. 
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With the aim to understand interactions of exenatide with lipid monolayers formed on a 
buffer subphase, the propensity of exenatide to localize at the air/water interface was 
determined by measuring the surface pressure with increasing exenatide concentration. 
The ability of α-helical peptides like exenatide to interact with membranes is usually 
associated with high surface activity [51]. This surface activity can be evaluated by 
observing the behavior of peptides at an air/water interface. The adsorption of exenatide 
to the surface results in a maximum surface pressure of πmax = 15.5 mN/m ± 1.6 mN/m. 
From this value the exenatide sub-phase concentration for the insertion studies of 
exenatide into the phospholipid monolayers is calculated. The obtained concentration 
(2.5 µM) is a constant which represents the drug concentration at 0.5 πmax [50]. 
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Figure V-15: Insertion of exenatide into phospholipid monolayers. A) Time course of surface pressure after injection 
of buffer in the subphase (20 mM PBS pH 7.4). B) Time course of surface pressure after injection of exenatide beneath 
the monolayer at a subphase concentration of 2.5 µM. Monolayers were formed from POPC, POPG and mixtures of 
both lipids (7:3 and 1:1). Arrow indicates the time of injection. 
To characterize the peptide-lipid interactions between exenatide and the different 
phospholipids, a constant area approach was chosen. Exenatide was injected underneath 
a phospholipid monolayer with a surface pressure of 30 mN/m at a constant area. Then 
changes in surface pressure were monitored over 60 minutes. Peptide molecules, 
interacting only with the lipid head groups induce minimal surface pressure changes of 
less than 3 mN/m, while surface pressure changes of up to 10 mN/m are generally a result 
of the insertion of the peptide into the monolayer [51].  
When exenatide is injected underneath phospholipid monolayers (Figure V-15B), no 
substantial changes in surface pressure in comparison to the “blank” injection of buffer 
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(Figure V-15A) was observed over 60 minutes, independently of the type of phospholipids 
in the monolayer. 
In general, different mechanisms for the binding of water-soluble substrates like 
exenatide are thinkable. Non-charged and partially hydrophobic molecules intercalate 
into the hydrophobic regions of the fatty acyl chains of the lipid monolayer as a result of 
hydrophobic interactions, while charged molecules remain on the outside and may 
interact electrostatically with the polar head groups of the lipids [37]. Exenatide is 
negatively charged at pH 7.4 (as shown in section V.1.4.1  ). Hence, an insertion of the 
peptide into the lipid monolayer is very unlikely. The monolayer experiments in the 
presence of exenatide demonstrate that exenatide rather interacts with the polar head 
groups of the phospholipids (changes of π ≤ 3 mN/m), than intercalates between the fatty 
acyl chains. This result is paralleled by the binding studies described above, which showed 
electrostatically interactions of the peptide at pH 4.5. 
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V.3  Conclusion 
The release behavior of protein and peptide drugs from vesicular phospholipid gels is 
difficult to describe. A complex mixture of mechanisms affects the release behavior from 
VPGs and results in characteristic release curves depending on the type of phospholipids, 
phospholipid concentration, encapsulated protein, pH-value and buffer composition. In 
this chapter, the effect of protein-phospholipid interactions on the release from VPGs was 
investigated. 
In vitro release tests of exenatide from VPGs with different phospholipid composition 
showed differences in the release kinetics of the peptide. While slow release was 
observed for VPGs composed of POPC, faster release was recorded when POPG was 
present in the formulation. At the same time an increase in viscosity was observed when 
the lipid mixture contained POPG. These observations are inconsistent with the 
expectation that VPGs with high viscosity show a slow release of the encapsulated drug. 
In order to show if the release rates were in fact an effect of interactions between the 
phospholipids and the encapsulated peptide, different methods (MST, ITC, fluorescence 
measurements) were chosen to investigate the binding of the two molecules. 
For VPGs containing POPG the release of exenatide showed half-lifes of several days in 
comparison to several weeks from VPGs composed of POPC. These differences were 
obviously a result of the erosion of the phospholipid matrix. MST, ITC and fluorescence 
measurements showed a strong binding of exenatide to POPG containing vesicles with 
high affinity at pH 4.5, while binding was not detectable at pH 7.4 with all methods. The 
fact that both gels (encapsulation pH 4.5 and 7.4) showed similar release rates, may be 
explained by a rapid alignment of the pH in the VPG to the surrounding buffer phase 
(pH 7.4). All obtained binding parameters (Kd ≈ 1 µM) are comparable between the three 
techniques after fitting the data to the law of mass action with an open stoichiometry. 
However, different binding events, which are not registered by all methods with the same 
sensitivity, have to be distinguished. A significant self-association of the peptide occurs at 
low concentrations. Further, membrane binding of exenatide involves primary binding of 
the peptide to the phospholipids and secondary binding to pre-bound exenatide. While 
ITC seems to distinguish between primary and secondary effects, MST and fluorescence 
measurements are able to determine complete binding (primary and secondary binding). 
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VPGs composed of POPC showed much slower half-lifes of several weeks, which could 
neither be attributed to the erosion of the VPG nor to interactions between the peptide 
and phospholipids. Thus, other mechanisms like stability and permeability of phospholipid 
membranes for drug compounds may be responsible for the sustained release from VPGs. 
In order to assess the permeability of exenatide through the phospholipid bilayers 
composed of POPC, POPG and mixtures of both, monolayer experiments at the air/water 
interface were conducted. Surface pressure measurements at a starting value of 30 mN/m 
and a constant area showed, that exenatide did not intercalate into the phospholipid 
monolayer, independently of the lipid composition. These findings suggest a very weak 
permeability of exenatide across the lipid membranes in the VPG.  
In conclusion, interactions between the encapsulated protein and the phospholipid occur 
and are measurable with the commonly used techniques for the investigation of binding. 
However, binding is not the major or at least not the strongest factor influencing release 
behavior of proteins from VPGs. Depending on the lipid type and the encapsulated 
protein, erosion of the lipid matrix and permeability of the protein through the lipid layers 
are suggested to be the most powerful parameters controlling the release from VPGs in 
vitro. Though, it has to be taken into account, that erosion is expected to be different in 
vivo compared to the in vitro situation. In the present study, it was shown that VPGs 
composed of POPG or phospholipid mixtures containing POPG disintegrate faster in 
comparison to VPGs composed of POPC only. Since, for exenatide release from VPGs 
membrane permeability was found to be a minor factor, erosion of the VPGs is rate 
limiting for release kinetics in this specific case. However, it has to be kept in mind, that 
membrane permeability strongly depends on the encapsulated protein or peptide and the 
lipid composition. Further, encapsulation of proteins may also influence the erosion 
behavior of the VPGs, which has to be considered for each VPG formulation individually. 
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Chapter VI  
APPLICATION OF VESICULAR PHOSPHOLIPID 
GELS AS DEPOT SYSTEM FOR SMALL 
HYDROPHOBIC DRUGS 
Parts of this chapter have been published in the following original research papers: 
• G. Balsevich, A.S. Häusl, C.W. Meyer, S. Karamihalev, X. Feng, M.L. Pöhlmann, C. 
Dournes, A. Uribe-Marino, S. Santarelli, C. Labermaier, K. Hafner, T. Mao, M. 
Breitsamer, M. Theodoropoulou, C. Namendorf, M. Uhr, M. Paez-Pereda, G. Winter, 
F. Hausch, A. Chen, M.H. Tschöp, T. Rein, N.C. Gassen, M.V. Schmidt, Stress-responsive 
FKBP51 regulates AKT2-AS160 signaling and metabolic function, Nat. Commun. 8:1725 
(2017). (section VI.4.1  ) 
• M. Maiarù, O.B. Morgan, T. Mao, M. Breitsamer, H. Bamber, M. Pöhlmann, M. V. 
Schmidt, G. Winter, F. Hausch, S.M. Géranton, The Stress Regulator Fkbp51: A Novel 
and Promising Druggable Target for the Treatment of Persistent Pain States Across 
Sexes, Pain. 159, 1224-1234 (2018). (section VI.4.2  ) 
• M.L. Pöhlmann, A.S. Häusl, D. Harbich, G. Balsevich, C. Engelhardt, X. Feng, M. 
Breitsamer, F. Hausch, G. Winter, M. V. Schmidt, Pharmacological Modulation of the 
Psychiatric Risk Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs, 
Front. Behav. Neurosci. 12:262 (2018). (section VI.4.3  ) 
This work was conducted in close cooperation with the Max-Planck-Institute of Psychiatry 
in Munich and the University College of London. The personal contribution covers the 
development of SAFit2-VPG and #41-VPG and characterization of the in vitro release 
behavior as well as the preparation of SAFit2-VPG and #41-VPG for all in vivo studies. The 
in vitro release behavior of SAFit2-VPG was studied together with Weiwei Liu. 
Pharmacokinetic calculations were done by Weiwei Liu (LMU, Munich), Dr. Jilong Wang 
and Prof. XiaoJiao Du (Institutes for Life Sciences and School of Medicine, South China 
University of Technology, Guangzhou, China). 
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VI.1  Introduction 
Within the last years, sustained release of small molecular weight drugs (MW < 1000 Da), 
as well as proteins and peptides from VPGs has received more and more attention. To 
date, several pharmaceutically relevant substances like cetrorelix, thymopentin, 
cytarabine and exenatide have been successfully encapsulated in VPGs and sustained 
release from the depot matrix was demonstrated [1]–[5]. Since all of these molecules 
were soluble in aqueous buffers, direct entrapment was easily feasible by DAC, HPH or 
magnetic stirring. To this end, phospholipids and the aqueous drug solution were weighed 
accurately and homogenized with the method of choice. Other molecules like vincristine 
and gemcitabine have been encapsulated by passive loading [6]–[8]. 
The encapsulation of lipophilic compounds, which are insoluble in water, has been 
described in theory before [9], [10]. Within the present work, a depot formulation for two 
lipophilic drug candidates (SAFit2 and #41) was developed, using a direct incorporation 
method for lipophilic compounds. Furthermore, in vitro release behavior of the newly 
developed VPG formulations was investigated and correlated to in vivo plasma 
concentrations. Additionally, the performance of the depot was tested in vivo in different 
applications which will be summarized in the following [11]–[13]. 
VI.1.1  SAFit2 
SAFit2 is a novel selective antagonist of FK506 binding protein 51 (FKBP51) by induced fit 
[14]. FKBP51 is best known as a regulator of the responsiveness of steroid hormone 
receptors, due to its classification as a co-chaperone for heat shock protein 90 (Hsp90) 
[15]. Thus, FKBP51 is a regulator of the hypothalamic-pituitary-adrenal axis (HPA-axis) and 
thereby a common target in recent research. However, it is structurally closely related to 
FKBP52, which antagonizes its effect. More specifically, while FKBP52 enhances 
glucocorticoid receptor (GR) activity, FKBP51 inhibits GR activity [14], [16]. Hence, 
selective inhibitors are needed  to avoid FKBP52 inhibition which may be associated with 
severe side-effects [14]. 
The mechanism of action of SAFit2 is illustrated schematically in Figure VI-1. Stressful 
stimuli, corticotropin-releasing hormone (CRH) is released from the hypothalamus, which 
induces the release of adrenocorticotropic hormone (ACTH) from the pituitary gland, 
 
 
APPLICATION OF VESICULAR PHOSPHOLIPID GELS AS DEPOT SYSTEM FOR SMALL HYDROPHOBIC DRUGS 
169 
which in turn promotes the release of glucocorticoids (cortisol) from the adrenal glands. 
Subsequently, glucocorticoids activate the GR, which is chaperoned by Hsp90 and FKBP51. 
Upon glucocorticoid binding the GR-Hsp90 complex exchanges FKBP51 for FKBP52, which 
is able to interact with dynein and induces internalization of the receptor into the cell 
core. Subsequent FKBP5 gene transcription leads to secretion of new FKBP51. FKBP51 
inhibits the negative feedback of glucocorticoids on the HPA-axis und hence leads to a 
hyperactivity of the HPA-axis [17]. 
It is known that single nucleotide polymorphisms (SNPs) in the FKBP5 gene (coding for 
FKBP51), which are associated with increased FKBP5 expression and thus increased 
FKBP51 levels, have a hand in stress-related and psychiatric disorders [11], [18]. In this 
context, SAFit2 antagonizes the effect of FKBP51 on the HPA-axis and hence has an impact 
on stress-related pathophysiologies.  
 
Figure VI-1: Schematic mechanism of action of SAFit2. SAFit2 inhibits the effect of FKBP51 and hence promotes the 
negative feedback of cortisol on the HPA-axis. 
Thus, SAFit2 is a potential drug candidate in the treatment of several diseases like 
depression, cancer and diseases related to the energy metabolism [15].  
Yet, the applicability of this new drug candidate is limited, due to its poor solubility in 
aqueous buffers and short plasma half-life [14]. A novel drug formulation with prolonged 
release kinetics is needed to facilitate its versatile application. 
 
 
CHAPTER VI 
170 
VI.1.2  Novel drug candidate #41 
#41 is a novel drug candidate for psychiatric disorders. So far, little is known about #41 as 
a new drug candidate and the exact mechanism of action is not resolved yet. However, 
first tests in vivo show promising results. Yet, the applicability of the #41 is limited, due to 
its short plasma half-life (1.5 h) and poor solubility in aqueous buffers. As for SAFit2, a 
drug formulation is needed, which prolongs plasma half-life for #41 substantially. 
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VI.2  Material and Methods 
VI.2.1  Material 
Egg lecithin (Lipoid E80), containing at least 80% (m/m) phosphatidylcholine (PC), was 
purchased from Lipoid GmbH (Ludwigshafen a. Rhein, Germany). SAFit2 was obtained 
from the Max-Planck-Institute for Psychiatry (Munich, Germany). Tween 80 and 
propylene glycol were purchased from Sigma Aldrich GmbH (Steinheim, Germany) and 
PEG 400 was obtained from Merck KGaA (Darmstadt, Germany). Bovine serum albumin 
(BSA) was acquired by VWR International GmbH (Darmstadt, Germany). #41 was supplied 
by Lead Discovery Center (Dortmund, Germany) and Max-Planck-Institute of Psychiatry 
(Munich, Germany). 
VI.2.2  Methods 
VI.2.2.1  Preparation of VPG encapsulating SAFit2 or #41 
Both substances were encapsulated into the VPG following the protocol by Brandl  for the 
incorporation of drugs which are poorly soluble in aqueous medium [9].  
To this end, Lipoid E80 was accurately weighed and solved in ethanol (conc. 500 mg/ml). 
Stock solutions with a final drug-concentration of 20 mg/ml of the two substances were 
prepared in ethanol (SAFit2) or acetone (#41). Then, the desired amount of the respective 
stock solution was added to the desired amount of the phospholipid solution and mixed 
by repeated pipetting or gentle shaking. To obtain a solid mixture of the two components, 
the organic solvent was subsequently evaporated in a vacuum drying oven at a 
temperature of 25 °C and a pressure of 10 mbar for at least 72 hours. After that, the 
phospholipid-drug-mixture was hydrated with 20 mM PBS pH 7.4 and homogenized with 
a SpeedmixerTM DAC 150FVZ (Hauschild GmbH & Co KG, Hamm, Germany) for 45 minutes 
at 3500 rpm. Using this procedure SAFit2-VPG with 30 or 50% (m/m) Lipoid E80 and a 
drug-load of 10 mg/g and #41-VPG with 50% (m/m) Lipoid E80 and a drug-load of 10 mg/g 
or 20 mg/g was prepared. Additionally, #41-VPG with 50% (m/m) Lipoid E80 and a drug-
load of 10 mg/g was prepared by TSC extrusion using a ZE-5 Mini-Extruder (ThreeTec 
GmbH & Co KG, Seon, Switzerland). 
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VI.2.2.2  Preparation of a SAFit2-solution as control for in vivo study 
A nonretarded SAFit2 solution in 40% (m/m) propylene glycol, 20% (m/m) ethanol, 5% 
(m/m) Tween 80 and 5% (m/m) polyethylene glycol 400 in 0.9% (m/m) saline was 
prepared by solving SAFit2 in ethanol and carefully adding the other components to the 
solution. The final concentration of SAFit2 in the solution was 10 mg/ml. Using this 
solution, a comparison of the application of SAFit2-VPG to the injection of a nonretarded 
solution with the exact same dose and injection volume was possible. 
VI.2.2.3  In vitro release studies 
In vitro release behavior of SAFit2 or #41 from VPG was characterized using flow-through 
cells (FTC) as previously described by Tardi et al. [19]. To this end, approximately 0.5 g 
VPG was accurately weighed into the donor compartment of the custom-made release 
cells. As acceptor medium 20 mM PBS pH 7.4 or 20 mM PBS pH 7.4 containing 4% (m/v) 
bovine serum albumin (BSA) was used. Release buffer was supplied by a syringe pump 
(LA-160, Landgraf Laborsysteme HLL GmbH, Langenhagen, Germany) with a flow rate of 
0.5 ml/h. Released fractions were collected at predetermined time points. 
VI.2.2.3.1  Quantification of SAFit2 by RP-HPLC 
SAFit2 concentration in the released fractions were quantified by RP-HPLC. Samples were 
prepared by dilution with ethanol (1:2), subsequent mixing using a vortexer and 
centrifugation for 10 minutes at 4 °C and 10 000 rpm. The clear supernatant was taken for 
analysis. By this extraction method an extraction efficiency of 100.2 ± 1.6% was achieved.  
A YMC-Triart C18 3 µm column (YMC Europe GmbH, Dinslaken, Germany) was used in 
combination with a UltiMateTM 3000 system (Thermo Fisher Scientific, Waltham, MA, 
USA) equipped with a UltiMateTM FLD 3100 fluorescence detector. Mobile phase A was 
composed of 0.1% (m/m) TFA and 10% (m/m) acetonitrile in HPW, while mobile phase B 
was composed of 0.1% (m/m) TFA in acetonitrile and a multi-step gradient (0-15 min: 20-
100% mobile phase B; 15-17 min: 100% mobile phase B; 17-18 min: 100-20% mobile 
phase B; 18-21 min: 20% mobile phase B) with a flow of 0.5 ml/min was used for 
quantification. SAFit2 was detected at λem = 310 nm (λex = 280nm) with a retention time 
of approximately 14 min. The method was qualified using samples with known 
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concentrations of SAFit2, BSA, phospholipids or mixtures of them after using the 
extraction protocol described above. 
VI.2.2.3.2  Quantification of #41 
Released fractions were quantified using LC-MS/MS. Quantification of the released 
samples was conducted by the Max-Planck-Institute of Psychiatry in Munich or by the 
Lead Discovery Center in Dortmund. 
VI.2.2.3.3  Quantification of phosphatidylcholine 
PC in the released fractions was quantified using a phospholipid assay (LabAssayTM 
Phospholipid, FUJIFILM Wako Chemicals Europe GmbH, Neuss, Germany) as described in 
section IV.2.5.3  .  
VI.2.2.4  In vivo release studies 
The in vivo study was performed in accordance with the European Communities’ Council 
Directive 2010/63/EU by the Max-Planck-Institute of Psychiatry, Munich, Germany. 
8 to 12-week-old male mice (C57BL/6N) were used for this experiment. Testing was 
carried out in the animal facilities of the Max-Planck-Institute of Psychiatry. Animal 
housing and conditions are described in detail by Pöhlmann et al. [12]. 
VI.2.2.4.1  SAFit2-VPG 
SAFit2-VPG (30 and 50% (m/m) phospholipid concentration) and SAFit2-solution, as 
control for a fast releasing formulation, was tested in vivo after a single s.c. injection of 
the formulation in C57BIL/6-mice (number of parallels = 6-7).  All formulations were 
injected subcutaneously with a dose of 10 mg/kg body weight. Blood samples were taken 
at predetermined time-points and plasma concentration was analyzed by LC-MS/MS by 
the Max-Planck-Institute of Psychiatry (Munich, Germany) as described in detail by Gaali 
et al. [14]. 
VI.2.2.4.2  #41-VPG 
#41-VPG with a phospholipid concentration of 50% (m/m) and a drug-load of 10 mg/g or 
20 mg/g, prepared by different techniques (DAC or TSC extrusion) was tested in vivo after 
a single s.c. injection of the formulation (80 mg/kg or 160 mg/kg) in C57BIL/6-mice 
(number of parallels = 5). Blood samples were taken at predetermined time-points and 
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plasma concentrations was determined by LC-MS/MS by the Max-Planck-Institute of 
Psychiatry (Munich, Germany) or the Lead Discovery Center (Dortmund, Germany). 
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VI.3  Development of SAFit2-VPG 
SAFit2 is a hydrophobic drug candidate with a relatively short plasma half-life of only 9.7 
hours after intra peritoneal injection [14]. Due to its application as an antidepressant drug 
or against chronic pain states, repeated application is needed to maintain therapeutic 
drug plasma levels for a longer period of time. Subsequently, for further development of 
the drug candidate, a depot formulation is needed to facilitate clinical applications. 
By a simple direct incorporation method similar to the one described by Brandl, it was 
possible to encapsulate SAFit2 into VPGs [10]. The release behavior of SAFit2 from the 
obtained VPG was characterized in vitro and in vivo. SAFit2-VPG was tolerated well by the 
animals after s.c. injection. 
VI.3.1.1  In vitro release behavior of SAFit2 from VPG 
A sustained release profile was observed for SAFit2-VPG containing 30% (m/m) or 50% 
(m/m) of Lipoid E80 (see Figure VI-2). While SAFit2-VPG 30% (m/m) releases the drug 
substance continuously with a low release rate, a biphasic behavior was observed for 
SAFit2-VPG 50% (m/m). Release is very slow during the first 7 days, then release rate 
increases significantly.  
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Figure VI-2: In vitro release behavior of SAFit2 from VPG. Left axis and black curves show cumulative release of SAFit2 
in %, while right axis and grey curves show cumulative release of PC in %.  
In both cases, release behavior for SAFit2 can be correlated to release of PC and thus 
erosion of the phospholipid matrix of the VPG. This close correlation was to be expected 
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due to the high hydrophobicity of SAFit2 and its insolubility in aqueous solution. Hence, 
simultaneous release of SAFit2 and PC is a result of the erosion of the VPG, releasing 
SAFit2 mainly in phospholipid vesicles or particles. Only a very low concentration of SAFit2 
may be released as free drug by diffusion through the VPG. 
VI.3.1.2  Pharmacokinetic study of SAFit2-VPG 
Next to the in vitro characterization of SAFit2-VPG, both VPG formulations were also 
tested in vivo. Additionally, an aqueous SAFit2-solution was developed to be able to 
compare the s.c. VPG applications, with a s.c. application of nonretarded SAFit2 with the 
same injection volume and dose as used in VPG applications.  
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Figure VI-3: Blood plasma concentration of SAFit2 after a single s.c. injection of SAFit2-VPG 30% (m/m) (filled 
squares), SAFit2-VPG 50% (m/m) (open circles) and SAFit2-solution (grey triangles). 
Both VPG formulations show sustained release of SAFit2, while the SAFit2-solution shows 
fast release with a burst phase in the first few hours. Pharmacokinetic parameters (see 
Table VI-1) were estimated from the plasma concentration curves, which are shown in 
Figure VI-3. Calculations were done by Weiwei Liu (Pharm. Technology and 
Biopharmaceutics, LMU, Munich), Dr. Jilong Wang and Prof. XiaoJiao Du (Institutes for Life 
Sciences and School of Medicine, South China University of Technology, Guangzhou, 
China) using a non-compartmental model. 
As expected SAFit2 concentration reaches its maximum concentration (cmax) only few 
hours after s.c. injection of the solution. This result is in good accordance with the values 
found by Gaali et al. for i.p. administration [14]. The encapsulation of SAFit2 in VPG as a 
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depot, results in lower cmax-values and increased tmax. Pharmacokinetic behavior during 
the first few days after application, strongly depends on the phospholipid concentration 
of the formulation. While SAFit2-VPG 30% (m/m) leads to a tmax of approximately 6 hours, 
SAFit2-VPG 50% (m/m) results in an increased tmax 36 hours after administration. Hence, 
the encapsulation of SAFit2 into VPGs as drug delivery device, leads to a prolonged release 
over several days. 
Table VI-1: Summary of PK parameters for SAFit2-VPG. (Non-compartmental model, calculated by Dr. Jilong Wang 
and Prof. XiaoJiao Du) 
 SAFit2- solution SAFit2-VPG 30% SAFit2-VPG 50% 
t1/2 [h] 30.73 215.72 146.17 
tmax [h] 2.3 6 36 
cmax [µg/ml]  5692.32 1520.11 1473.34 
AUC0-t [h*µg/ml]  135857.40 264254.83 327500.32 
AUCt-∞ [h*µg/ml]  164585.26 406632.98 431084.84 
Cl/F [l/h/kg]  0.067 0.027 0.025 
Both, in vitro and in vivo data showed that SAFit2-VPGs achieved sustained release of the 
drug candidate for several days without significant initial burst release. However, in vitro 
and in vivo release profiles show differences, which may be a result of the release model 
and drug used in this study. Different release models (e.g. dialysis bag model by Zhang et 
al., micro-centrifugation tube model by Even) have been described in literature amongst 
which the FTC model is the most investigated in vitro [3], [19], [20]. However, all current 
models do have drawbacks and none of them has been properly correlated to in vivo data 
since most of the in vivo studies concentrate on the pharmacodynamic effect of the 
encapsulated drug after release from VPG.  
Additionally to the in vitro release model, drug properties, which may have an influence 
on the release behavior, have to be taken into account. A drug with high hydrophobicity, 
like in the case of SAFit2, limits the choice of release models to those, which not only show 
diffusion-controlled release as it is the case in the dialysis bag model mentioned above. A 
high partition coefficient and hence high hydrophobicity of a drug result in slower 
diffusion. Thus, release from VPG is rather erosion controlled since the drug is released in 
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lipid vesicles or particles rather than as free drug and the release model should take this 
into account.  
In a similar way in vitro release is influenced by the acceptor medium, which is in our case 
an aqueous salt solution (20mM PBS pH 7.4) with albumin (BSA). For a good in vitro-in 
vivo correlation it is important to simulate the physiological conditions as good as 
possible. Thus, BSA was added to the acceptor medium as it was described before [21].  
Improved in vitro release models for semisolid drug formulations like VPGs and more in 
vivo data on different drug compounds are needed to find a good in vitro-in vivo 
correlation. 
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VI.4  In vivo applications of SAFit2-VPG 
In the last years, SAFit2-VPG has been used for different applications in vivo. Since a 
complete reproduction of this data is beyond the scope of this work, focus was set on 
formulation relevant data. Thus, in this section the relevant data from publications, which 
we have contributed to in the course of this thesis, is summarized shortly. 
VI.4.1  Balsevich et al., Stress-responsive FKBP51 regulates 
AKT2-AS160 signaling and metabolic function, Nature 
Communications (2017) 
High-fat diet (HFD) or other exposure to nutrient overload, is known to be a stress factor 
and leads to increases in the FKBP51 levels [22], [23]. Nevertheless, the role of FKBP51 in 
whole body glucose metabolism has not been elucidated so far. In this study, Balsevich et 
al. investigated the role of FKBP51 in energy and glucose homeostasis.  
 
Figure VI-4: Metabolic effects of SAFit2 treatment. A) High SAFit2 plasma levels were observed for 72 hours after a 
single s.c. injection of SAFit2. B) Body weight under control diet conditions. C) Glucose tolerance under control diet 
conditions. SAFit2 has no effect on glucose tolerance. D) Glucose tolerance under HFD conditions. SAFit2 significantly 
improves glucose tolerance. E) Effect of SAFit2 was not present in 51KO-mice under HFD conditions. F) Body weight 
under HFD conditions. (Figure was adapted from Balsevich et al. [11].) 
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In the course of the presented work, SAFit2 was used to antagonize the effect of FKBP51 
as a possible treatment for metabolic stress-related disorders like type 2 diabetes. To this 
end, SAFit2 was encapsulated into VPG to achieve high plasma concentrations for a 
prolonged time. It was shown that a single injection of SAFit2 resulted in elevated plasma 
levels of the drug for 72 hours post-injection (Figure VI-4A). Although, SAFit2-VPG did not 
show any effect in chow fed mice 48 hours after injection (Figure VI-4B and Figure VI-4C), 
glucose tolerance was significantly improved in HFD-fed mice (Figure VI-4D). This effect 
was found to be specific to FKBP51 inhibition, since no effect on 51KO-mice was observed 
(Figure VI-4E). Further, body weight was not affected by the SAFit2 treatment (Figure 
VI-4F). 
The encapsulation of SAFit2 in VPG facilitated its application in this study and prolonged 
SAFit2 effect to over 3 days after application. The pharmacological antagonization of 
FKBP51 by SAFit2 improves glucose tolerance and thus may be a treatment opportunity 
for type 2 diabetes. 
VI.4.2  Maiarù et al., The stress regulator FKBP51: a novel 
and promising druggable target for the treatment of 
persistent pain states across sexes, Pain (2018) 
Traumatic events are powerful stress-factors, which induce HPA-axis activation. Recently 
it was demonstrated that FKBP51 plays a key role in the development and maintenance 
of chronic joint inflammatory pain [24], [25]. In this context, Maiarù et al. explored the 
potential of FKBP51 as a new pharmacological target for the treatment of chronic pain 
across the sexes. 
 A single i.p. injection of a nonretarded SAFit2 solution (solution A: in 4% (m/m) ethanol, 
5% (m/m) PEG 400 and 5% (m/m) Tween 80 in 0.9% (m/m) saline, conc.: 2 mg/ml) was 
able to reduce the injury-induced mechanical hypersensitivity after full development of 
the pain state i.e. 3 days after complete Freund’s adjuvant (CFA) injection in the ankle 
joint (Figure VI-5A) or 5 days after spared nerve injury (SNI) surgery (Figure VI-5B). 
However, the effect of this single i.p. injection lasted no longer than 8 hours in both 
models. Repeated injection (twice daily over 4 days) resulted in a significant reduction of 
the injury-induced hypersensitivity for up to 4 days in both pain models (Figure VI-5C and 
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Figure VI-5D). Finally, to improve animal stress and the efficacy of the drug treatment, 
VPGs were used as a sustained drug delivery device for SAFit2. A single s.c. injection of 
SAFit2-VPG 5 days after SNI surgery reduced injury-induced hypersensitivity for at least 7 
days after injection (Figure VI-5E).  
 
Figure VI-5: Pharmacological blockade of FKBP51 reduces the mechanical hypersensitivity seen in long-term pain 
states across sexes. A) Single i.p. injection of SAFit2-solution A 3 days after CFA injection. B) Single i.p. injection of 
SAFit2-solution A 5 days after SNI surgery. C) Repeated i.p. injection of SAFit2-solution A 3 days after CFA injection. 
D) Repeated i.p. injection of SAFit2-solution A 5 days after SNI surgery. E) Single s.c. injection of SAFit2-VPG 5 days 
after SNI surgery. F) Single s.c. injection of SAFit2-solution B 5 days after SNI surgery. G) SAFit2-VPG had no effect in 
naïve mice. H) SAFit2-VPG had no effect in CFA-injected FKBP5 KO mice. I) Single s.c. injection of SAFit2-VPG, 12 days 
after the first PTX injection. J) Delayed (12 days) and repeated administration of SAFit2-VPG after SNI surgery. (Figure 
was adapted from Maiarù et al. [13]) 
The depot effect of the VPG was confirmed by the injection of a SAFit2-solution (solution 
B: in 20% (m/m) ethanol, 40% (m/m) propylene glycol, 5% (m/m) PEG 400 and 5% (m/m) 
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Tween 80 in 0.9% (m/m) saline, conc.: 10 mg/ml) with the same dose (100 mg/kg) and 
injection volume as used for the VPG (Figure VI-5F). Further, the effect of SAFit2 on 
paclitaxel (PTX) treatment was investigated. As expected, SAFit2-VPG was able to reduce 
the mechanical hypersensitivity for at least 5 days after injection (12 days after the first 
PTX injection) (Figure VI-5I). Additionally, it was shown, that SAFit2-VPG could improve 
long-term pain states that have been established for at least one week and repeated 
SAFit2-VPG administration (7 days after the first application) maintains the improvement 
of the pain state (Figure VI-5J). 
Altogether, the presented data suggests, that FKBP51 is a promising target for the 
treatment of chronic-pain and SAFit2 is a potent antagonist of FKBP51. The administration 
of SAFit2 encapsulated in VPG, resulted in an effect of the drug candidate over at least 5 
days after a single injection and 10 days after repeated injection. Hence, SAFit2-VPG has 
a high potential for chronic treatment of injury-induced mechanical hypersensitivity. 
VI.4.3  Pöhlmann et al., Pharmacological Modulation of the 
Psychiatric Risk Factor FKBP51 Alters Efficiency of 
Common Antidepressant Drugs, Frontiers in Behavioral 
Neurosciences (2018) 
Since pharmacological treatment of mental disorders (i.e. depression of anxiety disorders) 
with a single drug is often rather ineffective, co-medication with functional diverse 
antidepressants are often needed. For further development of SAFit2 as a new drug 
candidate, it is important to know if FKBP51 inhibition interferes with the effect of other 
antidepressants and anxiolytics. In this work, Pöhlmann et al. investigated the 
combination of SAFit2 with the commonly prescribed selective serotonin reuptake 
inhibitor (SSRI) escitalopram.  
The focus of this study was on the pharmacological effects only, while VPG was only used 
as a drug delivery vehicle. Although the depot effect of VPGs was not addressed, for the 
sake of completeness a short description of the results obtained with SAFit2-VPG is given 
in the following. 
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SAFit2-VPG already showed beneficial release behavior and efficacy of SAFit2 treatment 
during both above described in vivo studies. Thus, VPG was used in the current study as a 
drug delivery device for SAFit2, while escitalopram was injected as aqueous solution. 
 
Figure VI-6: Treatment with SAFit2 and escitalopram (Esc) affected behavior in open field test (anxiety-test). A) 
Distance traveled during the test. B) When splitting the test in three time-bins of 5 min each, no differences were 
observed between the two escitalopram groups in the first five minutes but significant differences in time-bin 2 and 
3. C) Exploration time of the inner zone. (Figure was adapted from Pöhlmann et al. [12]) 
Interestingly, escitalopram efficacy in anxiety-related tests was lowered by combining it 
with SAFit2 (Figure VI-6), while stress coping behavior was improved by the combination 
of both drugs (Figure VI-7).  
The study shows, that combination of SAFit2 with SSRIs could be beneficial in anxiety 
disorders and depression, more prone to stress.  
 
Figure VI-7: Treatment with SAFit2 and escitalopram (Esc) affected behavior in forced swim test (stress-coping test). 
A) Struggling time was significantly increased by combination of SAFit2 with escitalopram. B) Time course of the 
forced swim test shows that animals with SAFit2 treatment struggle significantly more in the last 3 minutes. (Figure 
was adapted from Pöhlmann et al. [12]) 
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VI.5  Development of a VPG formulation for the 
delivery of #41 
#41 is a highly hydrophobic molecule and thus shows poor solubility in aqueous buffers. 
To encapsulate such molecules in relevant concentrations in VPG, a homogenous mixture 
of the substance and the phospholipids is needed. To this end, the drug substance and 
the phospholipids are brought into solution by organic solvents and mixed in the desired 
quantities in solution. Then the organic solvent is removed, the mixture is re-hydrated 
with aqueous buffer and homogenized with one of the before mentioned methods. 
Hence, solubility of #41 in different solvents was tested and data is summarized in Table 
VI-2. 
Table VI-2: Summary of the solubility study for #41. 
Solvent Concentration [mg/ml] 
Ethanol not soluble 
2-Propanol not soluble 
Acetone 28.0 
Methanol 50.0 
Even though the organic solvent is evaporated in a vacuum drying oven for several hours, 
the presence of residual solvent is likely and cannot be ruled out. ICH guideline ICH 
Q3C(R5) defines the toxicological acceptable limits for residual solvents and classifies 
organic solvents according to their toxicity [26]. Following this guideline, the use of 
methanol as a solvent should be limited (class 2 solvent) in pharmaceutical products. Thus, 
despite of the superior solubility of #41 in methanol, acetone (class 3 solvent = solvent 
with low toxic potential) was preferred for the preparation of #41-VPG. 
By solving #41 in acetone and subsequent mixing with a phospholipid solution in ethanol, 
a homogenous mixture was achieved. After evaporation of the solvent mixture, the 
mixture was re-hydrated with 20 mM PBS pH 7.4 and VPGs were prepared either by DAC 
or by TSC extrusion. In both cases, a macroscopically homogenous VPG was obtained. 
Residual acetone or ethanol in the VPG was not determined in this first, basic study and 
#41-VPG was tolerated well by the animals during the in vivo study. However, residual 
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solvent concentrations should be determined during further development of the 
preparation process of #41-VPGs. 
VI.5.1  In vitro release behavior of #41 from VPG 
As shown in Figure VI-8, #41 is released (acceptor medium: 20mM PBS pH 7.4) from VPG 
slowly with an almost linear release profile over more than 18 days. Differences between 
the formulations and preparation techniques are observable. First, release is slower (0.7% 
per day) when the VPG is prepared by TSC extrusion. In comparison to that, VPG prepared 
by DAC releases #41 with a release rate of 1.8% per day. Furthermore, an increase of the 
drug-load from 1% (10 mg/g) to 2% (20 mg/g) does not result in significant changes in the 
release rate. 
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Figure VI-8: In vitro release characterization for #41-VPG. Black curves show cumulative release of #41 from VPG 
prepared by DAC or TSC-extrusion with different drug load (20 mg/g). Red curves show simultaneous PC release. 
When looking at the erosion behavior of the phospholipid matrix, differences were 
observable for the different preparation methods. VPG prepared by extrusion 
disintegrates more slowly in comparison to VPG prepared by DAC. Additionally, erosion of 
the lipid matrix and release of #41 are in good accordance, which is an expected 
consequence of the high hydrophobicity of the drug candidate.  
Overall, #41 is released in vitro over more than 18 days since release curves show an 
incomplete, still increasing cumulative concentration at the end of the testing period. 
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VI.5.2  In vivo performance of #41-VPG 
Results of the first in vivo study are inconclusive and thus not shown here. So far, only few 
things can be concluded from the first study. 
Plasma concentrations of #41 after administration of the drug candidate in VPGs show 
sustained release of the substance over several hours. First, rough estimations of the 
plasma half-life show that encapsulation of #41 into VPGs prolongs the plasma half-life to 
25 – 45 hours, in comparison to 1 - 2 hours after a single i.p. injection of #41-solution in 
DMSO/PEG 400/PBS (20/40/40).  
After sacrificing the animals at 120 or 168 hours, the VPG is still visible at the injection 
site. Thus, in contrast to a mainly erosion driven process in vitro release kinetics in vivo 
may be influenced by other factors as well. 
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VI.6  Conclusion 
Within this chapter, VPGs were applied as depot drug delivery system for two small 
molecular weight, hydrophobic drugs. 
Both drug candidates were encapsulated successfully into VPGs by a direct incorporation 
process. A similar encapsulation process has been described in theory before by Brandl et 
al. and was modulated to fit the special requirements (i.e. solubility in specific solvents) 
of the two substances.  
In vitro release studies showed a sustained release of SAFit2 from VPG composed of 30% 
(m/m) or 50% (m/m) egg lecithin over several days, which was dominated by the erosion 
of the phospholipid matrix. A pharmacokinetic study in vivo showed faster release in 
comparison to in vitro, but still a significant prolongation of plasma half-life in comparison 
to a non-retarded formulation. 
The pharmacological effect of SAFit2 was shown after application of the substance 
encapsulated in VPGs. SAFit2 improves glucose tolerance in mice, reduces injury-induced 
mechanical hypersensitivity in chronic pain treatment and shows promising results in 
combination with SSRIs in anxiety disorders and depression. Hence, the encapsulation of 
SAFit2 into VPGs prolongs the duration of the pharmacological effect in vivo up to 5 days 
(or 10 days after repeated administration) and facilitates the versatile application of the 
novel drug candidate. Additionally, all in vivo studies showed that VPGs were tolerated 
well, since no adverse reactions were observed at the injection site. 
Next to the application of VPGs for SAFit2, #41 was encapsulated into VPGs. #41-VPG 
showed sustained release in vitro, which was obviously controlled by erosion of the VPG. 
Release rates were different, when different manufacturing techniques were chosen for 
#41-VPG. Slow release was achieved when #41-VPG was prepared by extrusion using a 
TSC extruder, while faster release rates occurred after preparation of the #41-VPG by DAC. 
It is hypothesized that larger vesicles, which are obtained after preparation of the VPGs 
by extrusion result in a slower erosion process in vitro and thus also slower release of the 
hydrophobic drug.  
In vivo a substantial prolongation of plasma half-life was observed, when #41 was 
encapsulated into VPGs. However, due to the inconclusiveness of the in vivo data, further 
studies are needed to characterize depot effect of VPGs for #41. 
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In conclusion, our study confirms the excellent biocompatibility of VPGs in general and 
demonstrates their application as drug delivery device for hydrophobic substances. The 
preparation of VPGs by extrusion does not only lead to superior sustained release 
behavior, but may also facilitate the direct entrapment of hydrophobic substances by co-
extrusion with the phospholipids, rendering the use of organic solvents unnecessary. 
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Chapter VII  
SUMMARY AND OUTLOOK 
 
Parenteral depot systems for the sustained release of drugs were intensively researched 
over the last years. Amongst a variety of different starting materials for depot 
formulations, lipids have proven to be versatile due to their biodegradability and 
biocompatibility. Besides solid lipid nanoparticles (SLNs), solid lipid implants (SLIs), 
liposomes for sustained delivery and other systems, vesicular phospholipid gels (VPGs) 
were successfully investigated for their potential as drug delivery system with sustained 
release kinetics for macromolecules, such as proteins, and small molecular weight 
substances. 
 
The work presented in this thesis focused on the optimization of different aspects of VPGs 
as depot formulation: their manufacturing, administration and application. Moreover, 
interactions between the encapsulated protein and the phospholipids were investigated 
in an attempt to understand the release mechanisms of proteins and peptides from these 
systems. 
 
Chapter I contains the general introduction of the thesis. The state of the art of VPGs with 
special focus on the delivery of proteins and peptides is reviewed. Manufacturing 
techniques, which have developed over the years, as well as different encapsulation 
procedures are discussed. Furthermore, in vitro models for release testing of substances 
from VPGs are introduced and theories on the release mechanism are explained. 
Additionally, different applications of VPGs in the last years, as storage form for liposomes 
or depot formulation for different types of molecules are summarized.  
 
In Chapter II the aims of the thesis are explained. 
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The administration of highly viscous drug formulations is a challenge for drug formulation 
development, especially for semisolid systems like VPGs. Formulations with high viscosity 
cannot be administered conventionally by using needle and syringe. In this context, 
Chapter III focuses on the optimization of the administration process, by using needle-
free injection (NFI) technology. Establishing and qualifying a simple and more elegant 
administration technique, compared to injection with needle and syringe or alternatively 
implantation during surgery, is demonstrated. By using the (FDA approved) Biojector 2000 
it was possible to inject VPGs with a phospholipid concentration of up to 50% (m/m) into 
pig skin post mortem with two types of single-use syringes with different orifice diameter. 
Beyond that, the limits of injectability were tested and post mortem injections were 
supported by measurements of the pressure of the ejected jet stream. It was shown that 
NFI is very robust against changes in phospholipid concentration, temperature and 
injection volume. However, NFI of VPGs is limited at an injection volume of 1 ml since the 
pressure of the jet stream drops below a critical value of 8 MPa at this volume and wet 
shots occur more often.  
NFI opens the possibility for further development and clinical applications of VPGs, since 
it facilitates pain-free administration of the system. 
 
Besides challenges in the administration of the semisolid VPGs, manufacturing of these 
systems e.g. by dual asymmetric centrifugation (DAC) or high-pressure homogenization 
(HPH) underlies several drawbacks. In Chapter IV twin-screw (TSC) extrusion is suggested 
as continuous manufacturing method for the preparation of VPGs. This chapter focuses 
on the optimization of the manufacturing process by TSC extrusion with regards to process 
parameters and how changing these parameters resulted in changes in viscosity and 
vesicle size.  
In vitro release behavior was characterized with FITC-Dextran and a monoclonal antibody 
(mAb) and similar or even superior release kinetics were found for VPGs prepared by 
extrusion in comparison to the established DAC method. The differences in release 
behavior were explained to some extent by differences in vesicle size. VPGs composed of 
larger vesicles (e.g. after preparation by TSC) erode slower in comparison to VPGs with 
very small vesicles (e.g. prepared by DAC). Viscosity of the formulation is only a minor 
indicator for release behavior. 
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Moreover, the stability of proteins (mAb and EPO) during encapsulation into VPGs by 
extrusion was demonstrated. After 3 months of storage both proteins were stable in the 
formulation and no aggregation or degradation was observed. Besides the stability of the 
encapsulated proteins or peptides, the physical stability of the VPG was tested over a 
storage time of three months at 2 - 4 °C and 25 °C. Stable VPG were achieved, using the 
HAAKE MiniLab® Micro Rheology Compounder and ZE-5 Mini- Extruder.  
A first attempt at up-scaling the process to a larger Leistritz Micro 27 GL-28D extruder, 
resulted in VPG with decreased mixing quality and stability and revealed room for future 
process optimization. Longer residence time of the phospholipid buffer mixture, in 
combination with a different screw design and die size, may achieve a compromise 
between an easy process, good up-scalability and a sufficient VPG stability, as well as 
preferred sustained release kinetics.  
TSC extrusion is the first method described for continuous and fast production of VPG with 
easy controllability of temperature and shearing forces. The parameters during extrusion 
and procedure itself are flexible and, in theory, may also facilitate the direct entrapment 
of lipophilic substances by co-extrusion with the phospholipids.  
However, more effort has to be put into process optimization with different extruders to 
achieve robust, stable products. Furthermore, chemical stability of the phospholipids 
during extrusion has to be evaluated, since metal abrasion from the moving parts of the 
extruder may make the lipids more vulnerable to chemical degradation. Different 
strategies, like the addition of antioxidants or chelators, as well as coated extruders or 
extruders made from ceramic are proposed to overcome these challenges in the future. 
 
Release from VPG is a result of a complex mixture of mechanisms like erosion, diffusion, 
membrane permeability and interactions. Additionally, composition and physical 
parameters of the VPG, like viscosity of the formulation, influence release kinetics. 
Chapter V deals with interactions between encapsulated protein and phospholipids and 
their effect on release behavior from VPG. High affinity (Kd ≈ 1 µM) of exenatide to 
liposomes composed of POPG (anionic phospholipid) at pH 4.5, where exenatide is slightly 
positively charged, was shown by MST, ITC and fluorescence measurements, while no 
interactions were measurable for liposomes containing POPC, a globally neutral 
phospholipid or at pH 7.4, where the peptide is negatively charged. Two different binding 
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events, which are not registered by all three methods, were distinguished. Primary 
binding of exenatide to the phospholipids and secondary binding of the peptide to pre-
bound peptide are involved in the complete membrane binding process of exenatide. 
While ITC is able to distinguish both processes, MST and fluorescence measurements only 
determine complete binding.  
After all, the faster release from POPG-containing VPGs, with half-lifes of several days in 
comparison to several weeks from VPGs composed of 100% POPC, could not be correlated 
with interactions. It was demonstrated that release from VPGs containing POPG is rather 
erosion controlled. A mechanism based on poor membrane permeability of exenatide is 
proposed for VPGs composed of POPC only. Investigations of exenatide interactions with 
lipid monolayers (composed of POPC, POPG, and mixtures of both) at the air/water 
interface showed no intercalation of the peptide into the membrane, independently of 
the phospholipid composition. Since these findings suggest a very weak permeability of 
exenatide across the phospholipid membranes, erosion is proposed to be the rate limiting 
factor for exenatide release from VPG. 
These results highlight that release from VPGs is a multifactorial process. Erosion of the 
VPG and barrier permeability contribute majorly to release behavior and depend on the 
composition of the VPG as well as on the encapsulated protein, while interactions 
between the encapsulated protein and the phospholipid only have a minor impact to 
overall release. Still, the transferability of this study to other proteins and peptides, as 
well as other phospholipids is limited. Stronger interactions between the protein and 
phospholipid may result in a stronger effect on the release behavior. Even if this study 
brought deeper insight into the mechanism behind the release of proteins and peptides 
from VPGs, the contribution of interactions to the release kinetics has to be assessed in 
case to case studies taking into account the encapsulated drug, the phospholipid as well 
as surrounding conditions. 
 
In the past, VPGs have been mainly used for the encapsulation and sustained release of 
hydrophilic drugs. Within Chapter VI two hydrophobic drug candidates, SAFit2 and #41, 
were encapsulated into VPGs and used for different applications. Both substances were 
successfully encapsulated by a direct incorporation process, using ethanol or acetone as 
organic solvents. In vitro release studies demonstrated sustained release of SAFit2 and 
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#41 and a correlation between erosion of the VPG matrix and release of the drug 
candidates was observed. Pharmacokinetic studies in vivo showed a substantial increase 
in plasma half-life after release from VPGs for both substances. For SAFit2-VPG 50% (m/m) 
a plasma half-life of 36 hours was determined, in comparison to only two hours after 
administration of a non-retarded SAFit2 solution. In vivo data for #41 was inconclusive, 
allowing only a rough estimation of plasma half-lifes. Nevertheless, again a up to ten-fold 
prolongation of plasma half-life was achieved by encapsulation of the drug into VPGs. 
Besides the described in vitro and in vivo characterization of the VPG formulations, three 
in vivo studies on pharmacological effect of SAFit2 after release from VPGs were 
successfully conducted. Due to encapsulation of SAFit2 into VPGs, pharmacologic effect 
was successfully prolonged to 5 to 10 days after administration. Additionally, SAFit2 
showed beneficial effects in the treatment of chronic pain states, metabolic disorders and 
mental disorders like anxiety and depression. 
Based of the very promising results of the in vivo studies, VPGs encapsulating SAFit2 and 
#41 should be developed further in the future. First steps into this direction have already 
been taken in this work, showing a slower in vitro release of #41 and erosion of the 
phospholipid matrix after preparation of the VPG by TSC. On the basis of this the 
development of a direct encapsulation technique for #41, as well as for SAFit2, in a one-
step, solvent-free process by co-extrusion is thinkable. By that, release kinetics could be 
further improved and manufacturing process could be simplified significantly. 
 
In the course of this thesis it was possible to improve, optimize and overcome some of the 
challenges arising from VPGs as novel drug delivery systems. A step towards an 
explanation of the release behavior was taken and possibilities for further applications 
were evaluated. In general, further research on this topic should focus on the 
development of more sophisticated in vitro release models for VPGs and the construction 
of a reliable in vitro – in vivo correlation.  
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ACTH adrenocorticotropic hormone 
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cmax maximum plasma concentration 
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DAOS N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt 
DC dual centrifugation 
DLS dynamic light scattering 
DNA deoxyribonucleic acid 
E80 Lipoid E80, egg lecithin 
EDTA ethylenediaminetetraacetic acid 
EPO erythropoietin 
Esc escitalopram 
FDA food and drug administration 
FF-TEM freeze fracture transmission electron microscopy 
FITC fluorescein isothiocyanate 
FKBP5 FK506 binding protein 5 
FTC flow-through cell 
FT-IR Fourier-transform infrared spectroscopy 
G’ storage modulus 
G’’  loss modulus 
G-CSF granulocyte-colony stimulating factor 
GR glucocorticoid receptor 
HE HAAKE MiniLab® Micro Rheology Compounder 
HFD high fat diet 
HME hot melt extrusion 
HPA-axis hypothalamic-pituitary-adrenal-axis 
HPH high pressure homogenization 
HPLC high performance liquid chromatography 
HPW highly purified water 
Hsp90 heat shock protein 90 
i.m. intra muscular 
i.p. intra peritoneal 
i.v. intra venous 
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IgG immunoglobulin G 
ITC isothermal titration calorimetry 
LC-MS/MS liquid chromatography–mass spectrometry 
LEI Leistritz Micro 27GL-28D 
LVE-region linear viscoelastic region 
mAb monoclonal antibody 
MAG magnetic stirring 
MB methylene blue 
MCT medium chain triglyceride 
MES 2-(N-morpholino) ethanesulfonic acid 
MLV multilamellar vesicles 
MSD mean square distance 
MST microscale thermophoresis 
MVL multivesicular liposomes 
MW molecular weight 
MWCO molecular weight cut off 
NFI needle-free injection 
OD optical density 
OVA ovalbumin 
PAMPA parallel artificial membrane permeability assay 
PBS phosphate buffered saline 
PC phosphatidylcholine 
PDI polydispersity index 
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PK pharmacokinetic 
PLA polylactide 
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SAFit2 selective antagonist of FKBP51 by induced fit 2 
SD standard deviation 
SDS sodium dodecyl sulfate 
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SLN solid lipid nanoparticle 
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TTE ThreeTec ZE-5 Mini-Extruder 
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